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Abbreviations 
 
1D  One-dimensional 
1H  Hydrogen-1 (proton) 
2D  Two-dimensional 
13C  Carbon-13 
31P  Phosphorus-31 
ADPKD Autosomal dominant polycystic kidney disease 
Acetyl-CoA Acetyl coenzyme A 
ANOVA Analysis of variance 
ATP  Adenosine triphosphate 
BHBA  Beta-hydroxybutyric acid 
°C  Degrees Celsius 
Ca  Calcium 
ck  Choline kinase 
CPMG  Carr, Purcell, Meiboom, Gill 
DIM  Days in milk 
EB  Energy balance 
EDTA  Ethylenediaminetetraacetic acid 
FDA  Food and Drug Administration 
FDR  False discovery rate 
FID  Free induction decay 
FPR  Fat-to-protein ratio 
g  Gravitational acceleration 
GC  Gas chromatography 
GC-MS Gas chromatography-mass spectrometry 
GPC  Glycerophosphocholine 
HF  Holstein-Friesian 
HFD  High-fat diet 
HMBC  Heteronuclear multiple bond correlation 
HSQC  Heteronuclear single quantum coherence 
Hz  Hertz 
IC  Independent component 
ICA  Independent component analysis 
kDa  Kilodalton 
kg  Kilogram 
LC  Liquid chromatography 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
LLOQ  Lower limit of quantification 
lpl  Lysophospholipase 
Mg  Magnesium 
mg  Milligram 
MHz  Megahertz 
MJ  Megajoule 
mL  Milliliter 
mmol/L Millimole per liter 
mol/L  Mole per liter 
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m/Q  Mass-to-charge ratio 
MUFA  Monounsaturated fatty acid 
MS  Mass spectrometry 
µL  Microliter 
µmol/L Micromole per liter 
n  Number 
NAC  N-acetyl-carbohydrates 
NAFLD Non-alcoholic fatty liver disease 
NASH  Non-alcoholic steatohepatitis 
NEL  Net energy content for lactation 
NIST  National Institute of Standards and Technology 
NMR  Nuclear magnetic resonance 
NOE  Nuclear Overhauser effect 
NOESY Nuclear Overhauser enhancement spectroscopy 
nte  Neuropathy target esterase 
OMS  Octamethylcyclotetrasiloxane 
p  Probability value 
PC  Phosphocholine 
PCA  Principal component analysis 
pH  Power of hydrogen 
pla/b/c/d Phospholipase A/B/C/D 
ppm  Parts per million 
PtC  Phosphatidylcholine 
PUFA  Polyunsaturated fatty acid 
PUI  Polyunsaturation Index 
R  Correlation coefficient 
RF  Radio frequency 
RSD  Relative standard deviation 
SCC  Somatic cell count 
SD  Standard deviation 
SI  Saturation index 
SIM  Selected ion monitoring 
S/N   Signal-to-noise ratio 
SRM  Standard reference material 
SVM  Support vector machine 
TE  Technical error 
TEG  Triethylene glycol 
TMA  Trimethylamine 
TMAO  Trimethylamine-N-oxide 
TMR  Total mixed ration 
TMS  Tetramethylsilane 
TSP  3-Trimethylsilyl-2,2,3,3-tetradeuteropropionate 
wt%  Weight percent 
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Glossary 
 
BALB/c 
A mouse strain commonly used in laboratory disease models. The name is derived from 
the name of its original breeder and reads Bagg’s albino.  
 
Biomarker 
A molecule whose concentration in a biological sample can provide information about the 
physiological status of the organism. 
 
C57/BL6  
A mouse strain commonly used for laboratory disease models. The name is derived from 
the ancestor of the mouse strain, female mouse number 57. The name is usually read as 
black six. 
 
Chemical Shift 
The resonance frequency of a nucleus in a nuclear magnetic resonance (NMR) spectrum. 
Chemical shifts are measured relative to a reference resonance signal from a standard 
molecule. They are calculated as the frequency difference between the nucleus of interest 
and the reference nucleus divided by the operating frequency of the spectrometer for a 
given nucleus, measured in Hertz [Hz]. As the resulting value is rather small, it is usually 
given in parts per million [ppm].  
 
Energy Balance 
The difference between energy from food uptake and energy needed for milk production 
and basal metabolism in lactating individuals. If the energy balance is negative, the 
individual uses more energy than it can take up with its nutrition. This status is somewhat 
comparable to starvation. 
 
Heteronuclear 
Involving atomic nuclei of different chemical elements, for example hydrogen-1 (1H) and 
carbon-13 (13C) nuclei. 
 
Lock 
Calibration of the NMR spectrometer frequency by matching it to a given reference, for 
example the signal of deuterium oxide contained in the sample. 
 
Metabolic Fingerprinting 
The discriminatory analysis of samples based on comprehensive measurements. Instead 
of using concentration levels of predefined compounds, whole spectra are used. Usually, 
a metabolite identification step is performed after a fingerprinting analysis to identify the 
discriminatory spectrum features. The exact definition of this term and the delimitation to 
targeted profiling are subject to discussion (Nielsen & Jewett 2007; Lindon & Nicholson 
2008). 
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Metabolite 
A small molecule that is part of metabolic pathways, for example amino acids and other 
organic acids. 
 
Metabolome 
The entirety of all metabolites associated to an organism (Nielsen & Jewett 2007). 
 
Metabolomics 
The comprehensive study of metabolites in an organism in order to gain insight into 
metabolic status or disease progression (Lindon & Nicholson 2008). 
 
Probe Head 
A device containing a sample tube, coils for sending and receiving radio frequency (RF) 
signals, shim coils and gradient coils. The NMR probe head is mounted at the place of the 
strongest magnetic field in the magnet. 
 
Shim 
The magnetic field homogeneity of an NMR spectrometer at the place of the sample. The 
homogeneity can be raised by using coils incorporated in the probe head (shimming). 
Inhomogeneous magnetic fields cause bad line shapes in NMR spectra. 
 
Targeted Profiling 
The discriminatory analysis of concentration levels of selected compounds in a sample. A 
prerequisite for this method is the beforehand choice of the analyzed compounds, in 
contrast to metabolic fingerprinting approaches. The exact definition of this term and the 
delimitation to metabolic fingerprinting are subject to discussion (Nielsen & Jewett 2007; 
Lindon & Nicholson 2008). 
 
Tuning and Matching 
The sending and receiving coil of an NMR spectrometer work as resonant circuits. The act 
of changing the circuit’s resonance frequency to the resonance frequency of the observed 
sample is called tuning. Tuning is necessary to get the maximum signal intensity from the 
receiver coil. Matching means adjusting the impedance of the circuit to the impedance of 
the respective transmission line. This is necessary to get a maximum energy transmission 
from the sending coil to the sample. As tuning and matching affect each other, both have 
to be performed iteratively. 
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Abstract 
 
In this thesis, metabolism profiles of different diseases were measured in body fluids and 
tissues using high-resolution one-dimensional (1D) and two-dimensional (2D) proton (1H) 
and carbon-13 (13C) nuclear magnetic resonance (NMR) spectroscopy at natural 13C 
abundance. Protocols for measuring and quantifying low-molecular weight organic 
molecules in urine, milk, plasma, serum and tissue extracts were established and 
validated by comparison with established analytical techniques such as gas 
chromatography-mass spectrometry (GC-MS), liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and routine methods from clinical chemistry. It was shown 
that NMR allowed the quantification of small molecules in complex biofluids. A software 
named QUANTIFY was developed to enable accurate and reliable quantification from 
NMR spectra by using spectral integrals and additional information on the respective 
molecules. For 2D spectra and a recording time of 55 minutes, the lower limits of 
quantification (LLOQ’s) were between 78 and 350 micromole per liter [µmol/L]. For  1D 
spectra and a recording time of 15 minutes, LLOQ’s as low as 3 µmol/L were observed, 
although 1D quantification is not applicable to all metabolites due to signal overlap. 
 
Among others, urine specimens obtained from patients with autosomal dominant 
polycystic kidney disease (ADPKD), and urine and liver samples from mice with non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) were 
investigated. Additionally, milk and plasma specimens from dairy cows suffering from 
production diseases such as ketosis were analyzed. The focus of the latter analyses lay on 
metabolic traits connected to lipid synthesis and breakdown. The analyses were 
performed both in a targeted manner, with selected molecules quantified and compared 
between diseased and healthy individuals, and in fingerprinting approaches, where 
whole spectra were used to identify unknown biomarkers for different diseases. 
 
Results show that NMR spectra of biofluids or tissue extracts may be used for the 
diagnosis of disorders such as NASH and ADPKD, and the prognosis of ketosis in dairy 
cows. Urinary compounds that distinguish NASH from NAFLD were found to be, among 
others, citric acid, creatinine, leucine, phenylalanine, phosphocreatine, taurine and 
trimethylamine-N-oxide (TMAO). For ADPKD, the most striking result was a raised 
urinary methanol level in the ADPKD patient group. In dairy cows, a high ratio of milk 
glycerophosphocholine (GPC) to phosphocholine (PC) was found to be associated with a 
low incidence of ketosis. A hypothesis about the biochemical backgrounds of these 
compounds in disease progression was created and validated by additional NMR 
measurements of blood plasma. 
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Zusammenfassung 
 
In dieser Doktorarbeit wurden eindimensionale (1D) und zweidimensionale (2D) 
Protonen- (1H) und Kohlenstoff-13 (13C)-Kernspinresonanz (NMR) verwendet, um 
Stoffwechselprofile verschiedener Krankheiten in Körperflüssigkeiten und Geweben zu 
erstellen. Es wurden Protokolle für die Messung und die Quantifizierung von kleinen 
organischen Molekülen in Urin, Milch, Plasma, Serum und Gewebeextrakten entwickelt. 
Die Resultate wurden durch Vergleiche mit etablierten Analysemethoden wie 
Gaschromatographie-Massenspektrometrie (GC-MS), Flüssigkeitschromatographie-
Tandemmassenspektrometrie (LC-MS/MS) und Routinemethoden der klinischen Chemie 
validiert. Es wurde gezeigt, dass NMR die Quantifizierung kleiner Moleküle in 
komplexen Mischungen wie Urin, Plasma, Serum, Milch und Gewebeextrakten 
ermöglicht. Für diesen Zweck wurde eine Software namens QUANTIFY entwickelt, die 
mit Hilfe spektraler Intensitäten und zusätzlicher Informationen über das betreffende 
Molekül eine genaue und zuverlässige Quantifizierung ermöglicht. Für 2D-Spektren mit 
einer Aufnahmezeit von 55 Minuten wurden untere Quantifizierungsgrenzen (LLOQ’s) 
zwischen 78 und 350 Mikromol pro Liter [µmol/L] beobachtet. Für 1D-Spektren mit 
Aufnahmezeiten von 15 Minuten wurden LLOQ’s bis zu 3 µmol/L beobachtet, wobei 
allerdings wegen Signalüberlagerungen eine Quantifizierung aus 1D-Spektren nicht für 
alle Metaboliten möglich ist. 
 
Diese neu entwickelten Methoden wurden auf verschiedene Krankheiten angewendet,  
untersucht wurden unter anderem Urin von Patienten mit autosomal-dominanter 
polyzystischer Nierenerkrankung (ADPKD) sowie Urin und Leberproben von Mäusen 
mit nichtalkoholischer Fettlebererkrankung (NAFLD) und nichtalkoholischer 
Steatohepatitis (NASH). Zusätzlich wurden Milch und Plasma von Milchkühen mit 
Produktionskrankheiten wie Ketose analysiert. Schwerpunkt dieser Untersuchungen 
waren Stoffwechselprodukte aus der Synthese und dem Abbau von Lipiden. 
Durchgeführt wurden sowohl gezielte Untersuchungen, bei denen die Konzentrationen 
von ausgewählten Stoffen bestimmt wurden, um Unterschiede zwischen gesunden und 
kranken Individuen zu finden, als auch „Fingerprinting“-Untersuchungen, bei denen 
komplette Spektren genutzt wurden um bisher unbekannte Biomarker für verschiedene 
Krankheiten zu identifizieren. 
 
Die Ergebnisse zeigen dass mit NMR-Spektren von Körperflüssigkeiten und 
Gewebeextrakten die Diagnose von Krankheiten wie NASH und NAFLD sowie die 
Vorhersage von Ketose in Milchkühen möglich sind. Für NASH und NAFLD wurden im 
Urin differenzierende Biomarker gefunden, unter anderem Zitronensäure, Creatinin, 
Leucin, Phenylalanin, Phosphocreatin, Taurin und Trimethylamin-N-Oxid (TMAO). Bei 
der Untersuchung von ADPKD war ein unerwartetes Resultat ein erhöhter 
Methanolspiegel im Urin von ADPKD-Patienten. In Milchkühen war ein hohes Verhältnis 
der Konzentrationen von Glycerophosphocholin (GPC) zu Phosphocholin (PC) mit einem 
geringen Ketoserisiko verbunden. Es wurde eine Hypothese zu den biochemischen 
Mechanismen dieser beiden Stoffe bei der Krankheitsentstehung aufgestellt und durch 
zusätzliche NMR-Messungen von Plasma bestätigt. 
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1 Introduction 
 
1.1  Background 
 
Nuclear magnetic resonance (NMR) spectroscopy has become a widely used tool for 
chemical and biological analyses during the last decades. Originally and mainly used for 
protein structure determination, it is now increasingly applied to metabolomics. 
Metabolomics aims at providing a comprehensive overview of all small organic molecules 
(metabolites) of a biologic sample to gain insight into the metabolic status of an organism. 
This quite new field is part of the so-called -omics research family that includes genomics 
and proteomics (Pearson 2007). Starting from gene variations and gene expression, gene 
transcription leads to protein synthesis, with the proteins in turn affecting metabolite 
levels. The combination of these different fields shall give an almost complete insight into 
the various processes of an organism.  
 
In the following paragraph, some important metabolic processes of an organism will be 
briefly described according to (Alberts et al. 2001). The energy metabolism includes the 
metabolic pathways leading to the formation of the energy-carrying molecule adenosine 
triphosphate (ATP). Most of the ATP is created within the mitochondria, with acetyl 
coenzyme A (acetyl-CoA) as a starting point for the citric acid cycle. Acetyl-CoA may be 
derived either from carbohydrates via glycolysis, from fatty acids via beta-oxidation or 
from amino acids from protein breakdown. Acetyl-CoA, on the other hand, is also the 
starting product for fatty acids synthesis in the cytosol. Amino acids are synthesized in 
the cytosol by amination of α-keto acids stemming from glycolysis or the citric acid cycle, 
for example by glutamic acid. Nucleotide synthesis is a quite complex process taking 
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place in the cytosol with partial mitochondrial involvement. Here, amino acids, sugars 
and organic acids are involved. 
 
Techniques used for metabolomic analyses include many varieties of chromatography 
and mass spectrometry (MS) methods. Generally, these “classical” metabolomics methods 
have a high sensitivity, which means their lower limits of quantification (LLOQ’s) are 
lower than those of NMR. For gas chromatography-quadrupole mass spectrometry (GC-
MS) in selected ion monitoring (SIM) mode, LLOQ’s have been found in the range of 0.3 -
 30 micromole per liter (µmol/L) for free amino acids (Kaspar et al. 2008). On the other 
hand, derivatization and column selection narrow the nature of compounds amenable to 
analysis. Unknown or unexpected biomarkers may therefore be missed. Here, NMR can 
provide a more comprehensive picture as only little sample pretreatment is required and 
the whole range of organic molecules is accessible within one measurement (Lindon et al. 
2006; Lindon & Nicholson 2008; Wishart 2008). Additionally, it has been shown that when 
analyzing the same sample set using MS and NMR, only little overlap between the 
metabolites identified with both methods occurs (Wishart et al. 2008). Hence, NMR is an 
important tool as it will show other aspects of a sample than other techniques (Blow 2008). 
An additional advantage of NMR is that the sample is not destroyed during the 
measurement, and thus can be further analyzed using other methods after the NMR 
measurement.   
 
The simple sample preparation for NMR measurements, in combination with automated 
measuring and data processing routines, paves the way for high-throughput analyses, 
where hundreds or even thousands of samples can be analyzed, giving a broad base for 
statistical analyses. 
 
 
1.2 Motivation and Specific Aims 
 
Several questions are posed in this thesis. These are described in the following in terms of 
specific aims. 
 
The first specific aim is to elucidate whether reliable quantification can be performed 
using NMR spectra of complex biofluids. Quantification in one-dimensional (1D) spectra 
is hampered by the large number of signals present in a typical spectrum, leading to 
overlapped signals. Intensity values from two-dimensional (2D) spectra have the 
drawback that different signals show different intensities even when equal concentrations 
are observed. This aim shall be pursued using a test set of urine and milk samples that 
shall be measured in parallel by established methods to allow for a comparison. 
 
The second specific aim is to identify whether the metabolic status of an individual gives 
rise to a distinct change in its body fluid composition, and if this change is within the 
scope of the used measurement techniques. This could be used for diagnostic purposes. 
This question shall be first elucidated using mice as a model organism for non-alcoholic 
steatohepatitis (NASH), and later on extended by using urine specimens obtained from 
human autosomal dominant polycystic kidney disease (ADPKD) patients. 
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The third specific aim is whether biofluid samples allow the prediction of diseases in 
dairy cattle. To answer this question, time series of samples and complete medical records 
in the follow-up after sample collection are needed. For this reason, time series of milk, 
plasma and urine specimens were collected for more than 300 dairy cows. 
 
This thesis has in parts already been published (Gronwald et al. 2008; Gronwald et al. 
2011; Klein 2007; Klein et al. 2010; Klein et al. 2011a; Klein et al. 2011b; Kohl et al. 2011) 
and was funded by the Bavarian Genome Network BayGene of the Bavarian State 
Ministry of Sciences, Research and the Arts (Munich, Germany), the Fugato-plus MeGA-
M program of the German Federal Ministry of Education and Research (Berlin, Germany) 
and the intramural ReForM program of the Regensburg School of Medicine (Regensburg, 
Germany). All persons named in the thesis are with the Institute of Functional Genomics 
of the University of Regensburg (Regensburg, Germany) unless stated otherwise. 
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2 Method Development 
 
2.1 Basics of Nuclear Magnetic Resonance 
 
Nuclear magnetic resonance (NMR) is a spectroscopic method able to give a 
comprehensive overview of the most abundant organic compounds in a sample 
employing one measurement (Nicholson & Lindon 2008). It is based on the magnetic 
moment caused by the spin of atomic nuclei. A spin is a concept from quantum mechanics 
that can be described using similar equations as an angular momentum. For a better 
understanding, one might think of the atomic nucleus as a sphere that is rotating around 
an axis that goes through its center of gravity. This rotation is called spin. Far from all 
atomic nuclei possess a spin, atoms with nuclear spins include hydrogen-1 (1H), 
deuterium, carbon-13 (13C), nitrogen-14, nitrogen-15 and phosphorus-31 (31P), amongst 
others. 
A rotating electrically charged particle creates a magnetic field along its rotation axis, and 
the particle gets a magnetic dipole moment µ. In an outer magnetic field B0, the particle 
then has the energy 
0µ BE
rr
⋅−=  
 
To reach their lowest energy, all particles should align along the outer field, comparable 
to a compass needle that aligns with the earth’s magnetic field. 
When coming to particles on atomic scales, one observes a different picture. In an outer 
magnetic field, measuring the spin orientation along the magnetic field lines will show 
that all particles are aligned either parallel or anti-parallel along the magnetic field, as 
seen in Figure 1 (Klein 2007). 
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The reason for this behavior is called energy quantization. This idea from quantum 
mechanics assumes that not all energy states are possible, rather that only a few defined 
energy states are allowed. 
All elementary particles have a property called spin (s) that can take the values 0, ½, 1, 3/2, 
2, 5/2 and so on. Depending on its spin, a particle can have different spin quantum 
numbers sz. Possible values for sz are -s, -s+1, ... , s-1, s. A particle with spin s = ½, such as a 
proton, can therefore be only in one of two states: Either sz = -½ or sz = ½. This property 
can be visualized as a clockwise or an anti-clockwise rotation, as shown in Figure 1 (Klein 
2007). The two possible states of a spin explain the alignment pattern observed in an outer 
magnetic field. The two states are usually called spin down and spin up. 
 
 
 
 
 
Figure 1. Atomic nuclei with spin ½ in an outer magnetic field B0 (blue lines).  
A: Clockwise rotation is called spin down; B: Anti-clockwise rotation is called spin up. 
 Shown is the projection to the axis of the outer magnetic field. Adapted from (Klein 2007).  
 
 
Without an outer magnetic field, the two spin states have the same energy, this is called 
degeneration. As the states have the same energy, none of them will be preferred, so the 
two states will be observed equally often. When placed in a magnetic field, the two spin 
orientations will have different energies, as seen in Figure 2 (Klein 2007). 
 
 
 
 
Figure 2. An energy difference occurs between the two spin states when placed in an outer 
magnetic field B0. Abbreviation: E: Energy, ∆E: Energy difference.  
Adapted from (Klein 2007).  
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In this case, the state with lower energy is preferred, and under ideal conditions all 
particles will be in the lower energy state. In reality, both states are populated due to 
thermodynamic effects as described by the Boltzmann equation: 
 
Tk
E
l
h Be
n
n
∆
−
=  
 
where nh is the number of particles in the higher state, nl is the number of particles in the 
lower state, ∆E is the energy difference, T is the temperature and kB is the Boltzmann 
constant. The energy provided by thermal motion may be sufficient to raise particles into 
their higher state, depending on the temperature and the energy difference. For atomic 
nuclei, the energy difference between the different states is very low compared to the 
thermal energy. Therefore the occupation number of the two states is almost identical 
under equilibrium conditions. Depending on the magnitude of the outer magnetic field 
B0, temperature and energy difference, the number of particles in the two states differ only 
by a ratio of approximately 10-5 for protons at room temperature. Therefore, NMR 
experiments always have a problem of relatively low sensitivity compared to other 
spectroscopic methods, as only this small fraction of all nuclei can be detected. The excess 
of protons in the lower spin state results in a bulk magnetic field in the sample parallel to 
the outer magnetic field. The bulk magnetic field is called magnetization.  
 
To raise a particle into the other spin state, one has to transfer the matching amount of 
energy; this can be done using electromagnetic waves (Purcell et al. 1946). This effect is 
called absorption and is shown in Figure 3A (Klein 2007). 
 
 
 
 
Figure 3. Possible state transitions in a two-state spin system.  
A: Absorption; B: Induced emission; C: Spontaneous emission. Abbreviation: E: Energy 
Adapted from (Klein 2007). 
 
 
The energy difference between the states of a proton can be described as 
 
0Nµ gBE =∆  
 
where ∆E is the energy difference, µN is the nuclear magneton, g is the Landé factor of the 
proton and B0 is the magnitude of the outer magnetic field.  
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The matching frequency of the electromagnetic wave and the energy difference are 
connected in the equation 
 
hfE =∆  
 
where ∆E is the energy difference, f is the frequency of the electromagnetic wave and h is 
the Planck constant.  
 
Pulse Fourier Transformation NMR 
To measure the spectra, NMR instruments use the so-called pulse Fourier transformation 
technique. A short, high-power radio frequency (RF) pulse containing many frequencies is 
applied. The magnetic field of the RF pulse is called the B1 field. The B1 field causes the 
spins to rotate by a certain angle (Figure 4B). For maximal effect a rotation by 90 ° is 
preferable. After the RF pulse, the bulk magnetization is no longer aligned with the outer 
magnetic field B0 and the magnetization vector starts a precession movement around the 
magnetic field direction (Figure 4C).  
 
 
 
 
Figure 4. Scheme of a pulsed NMR experiment. 
A: Bulk magnetization of all spins in the sample in thermal equilibrium is parallel to the outer 
magnetic field B0 along the z-axis.  
B: An on-resonance RF pulse rotates the magnetization vector around the y-axis. 
C: The magnetization vector precesses around the outer magnetic field vector B0 along the z-axis. 
 
 
The magnetization precession movement induces a voltage in the receiver coil of the 
spectrometer (Bloch 1946). This time-dependent signal called free induction decay (FID) is 
recorded and turned into a frequency-dependent spectrum by a Fourier transformation.  
 
Simultaneously with the precession movement, the spins want to return into the 
equilibrium state described by the Boltzmann equation above, and start moving toward 
the z-axis. This process is called relaxation and is usually catalyzed by interactions with 
other electromagnetic fields in the surrounding. Different mechanisms may lead to 
relaxation. One mechanism is called T1 relaxation and is caused by interactions between 
the spin and the surrounding lattice. T1 relaxation causes the magnetization vector to 
grow in the z-axis. The second important relaxation process is called T2 relaxation and is 
caused by interactions between neighboring spins. T2 relaxation causes the magnetization 
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vector to diminish in the x-y-plane. In the end, the vector is completely aligned along the 
z-axis. As only a precession around the z-axis can induce measurable voltages in the 
receiving coil, this effect reduces the NMR signal drastically. Usually the T2 relaxation is 
faster than the T1 relaxation. A third relaxation mechanism is relaxation due to magnetic 
field inhomogeneities (T2* relaxation).  
 
During the return to the equilibrium magnetization, radiation may be emitted in two 
different ways. The first way is spontaneous emission (Figure 3C). This is a stochastic 
process and can be described with a half-life period. Spontaneous emission, however, is 
an unlikely process concerning the energy differences present in NMR. The far more 
common way of emitting radiation is induced emission (Figure 3B). This is triggered by 
the irradiation with waves matching the energy difference. The fluctuating magnetic field 
of the matrix, e.g. caused by water molecules, is a common source for induced emission. 
When a radio signal is applied to a sample, spins will get raised into the upper energy 
state by absorption. As the number of spins in the upper state rises, more and more 
induced emission will occur, moving the spins to the lower energy state. Using long 
irradiation times, at some point equilibrium between absorption and induced emission is 
reached, this is called saturation. In saturation, no signal from the spins can be measured. 
 
Please note that although the explanations for NMR effects given above are widely 
adopted and seem reasonable at first sight, they fail to explain all effects observed in NMR 
experiments. Instead of thinking of absorption and emission of real photons, NMR effects 
have been shown to be consistent with effects of zero energy virtual photons in the near 
field of the sample (Hoult & Ginsberg 2001). This concept goes too far into quantum 
electro dynamics to be presented in the scope of this thesis, though. 
 
Chemical Shift 
The energy difference between two spin states is proportional to the magnetic field at the 
nucleus. Therefore, local changes of the outer field cause shifts in the resonance frequency 
of the nucleus. These local magnetic field aberrations can be caused by nearby electrons 
and are thus specific for the molecule in which the nucleus is located. This effect is shown 
in Figure 5 for a one-dimensional (1D) spectrum. The resulting resonance frequency of a 
nucleus is called chemical shift. 
 
 
 
 
Figure 5. Shifting of the signal due to local magnetic field distortions. 
Abbreviations: f: Frequency; I: Intensity 
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Coupling 
When a nucleus with a spin is located near another nucleus carrying a spin, it may 
interact or couple with this spin. One important way of coupling is the indirect dipole-
dipole coupling, also called J-coupling. J-coupling is mediated by the electron bonds 
connecting the two nuclei.  
Consider two spins, spin A and spin B, who are neighbors in a molecule. When measuring 
the resonance frequency of spin A, spin B can be either in state spin up or in state spin 
down. Spin B has a small magnetic field due to its electric charge. This small field adds to 
the (stronger) outer magnetic field. Depending on the direction of spin B, the magnetic 
field at the location of spin A is either strengthened or weakened. The resonance 
frequency of spin A is proportional to the strength of the outer magnetic field. Therefore 
spin A may either have an increased or a decreased resonance frequency, depending on 
the direction of spin B. In a real sample, the considered molecule will be present many 
times, in each of which spin B will have either direction, on average at almost the same 
rate. Therefore, both the increased and the decreased resonance frequency of spin A will 
show up in the NMR spectrum. This results in a splitting of the signal of spin A into two 
signals, each having a lower intensity than the original signal (Figure 6). The same 
considerations are true for spin B, so the signal of spin B will be split in the same manner. 
 
 
 
 
Figure 6. Splitting of a signal due to coupling to spins in the nuclear surrounding of the particle. 
Abbreviations: f: Frequency; I: Intensity 
 
 
J-coupling is scalar, which means it is not dependent on the spatial orientation of the two 
neighboring spins. The coupling constant J is the distance between the two signals 
measured in Hertz (Hz). 
 
The second important coupling mechanism is dipolar coupling that couples two spins 
directly without mediating electrons. Dipolar coupling depends on the orientation of the 
vector connecting the two nuclei. In freely moving molecules, the dipolar coupling is 
averaged out as every orientation has the same likelihood. Dipolar coupling is not visible 
in the NMR spectrum in this case, but still acts as a relaxation mechanism. In case where 
the movement or rotation of the molecules is restricted, the dipolar coupling may be 
visible in the spectrum. 
 
Signal splitting due to coupling may occur simultaneously and repeatedly for each 
nucleus. Coupling mechanisms may lead to different coupling patterns. A signal that is 
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not coupled will show a single, sharp line called singlet, a signal showing a two-peak 
pattern is called a doublet, a signal with three peaks is called a triplet and so on. Signals 
with a large number of peaks are called multiplets. 
 
Most organic molecules will have several protons, each of which will undergo shifting 
and coupling. This creates a characteristic NMR spectrum for each molecule. This fact 
renders NMR a valuable tool for analytic purposes and for molecular structure 
determination. Please note that NMR signals of an acid and its salt usually cannot be 
distinguished. 
 
Multidimensional Experiments 
The use of RF pulses allows the combination of several pulses in one experiment. Usually, 
a program of several pulses is repeated several times with different increments of the 
delay time between two of the pulses. This yields a matrix of data points in the time 
domain. These are transformed to the frequency domain by a double Fourier 
transformation (one for each dimension axis).  
 
Magnetization can be transferred from one nucleus to a neighboring nucleus. This can be 
used for measuring nuclei with a low sensitivity indirectly by measuring the 
magnetization transferred to a more sensitive nucleus. An example for this sensitivity 
gain is the indirect measurement of 13C spectra using more sensitive 1H spectra. 
Magnetization transfer also allows the elucidation of molecule structure, as the intra-
molecular distance between different nuclei can be estimated. Two-dimensional (2D) 
NMR spectra are usually displayed in a map-like style, where lines mark areas of equal 
intensity. As in a geographic map, narrow lines indicate steep signal increases, whereas 
large distances between the lines indicate only low intensity changes. In the following 
paragraphs, some standard multidimensional experiments are briefly explained. 
 
NOESY 
The nuclear Overhauser enhancement spectroscopy (NOESY) experiment, which is 
measured mostly in a multidimensional fashion, is based on the nuclear Overhauser effect 
(NOE). It is caused by dipolar couplings. These are interactions between neighboring 
spins that are mediated through space, and not through electron bonds. The NOE 
describes the fact that spins are raised into the upper energy state through cross-
relaxation when a neighboring spin is saturated (Overhauser 1953). This may be utilized 
to enhance the sensitivity of the measurement of one proton by saturating the neighboring 
proton. Another application of NOESY makes use of the through-space nature of the NOE 
to gain information about the spatial conformation of a molecule (Berger & Braun 1998). 
In addition, the first increment of a 2D NOESY sequence is often used for the 
measurement of 1D spectra, because it offers enhanced suppression of unwanted 
resonances such as the strong water signal (Nicholson et al. 1995).  
 
CPMG 
The Carr-Purcell-Meiboom-Gill (CPMG) experiment is used to measure 1D spectra 
without disturbing signals from macromolecules such as proteins. The experiment is 
named after its developers. CPMG experiments utilize the fact that large molecules have 
faster spin relaxation than small molecules due to the higher number of neighboring spins 
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enabling spin-spin interactions. To reduce the contribution of macromolecules to the 
recorded FID, the start of the recording is delayed by a filtering period. After the filtering 
period, the RF signals from macromolecules have decayed, while signals from small 
molecules are still present at noteworthy intensities, leaving a spectrum of small 
molecules. The length of the filtering period is defined by the number of waiting loops.  
 
HSQC 
In a heteronuclear single quantum coherence (HSQC) experiment, magnetization is 
transferred from the excited nucleus to a neighboring nucleus of another chemical 
element that is connected by an electron bond. This nucleus is called the indirect nucleus. 
After a waiting period, the magnetization is transferred back to the original (direct) 
nucleus. Variations in the time before the retransfer are used to create a second dimension 
axis. In these spectra, the frequency of the directly excited nucleus is connected to the 
frequency of the indirect nucleus by a cross peak (Berger & Braun 1998).  
 
HMBC 
The heteronuclear multiple bond correlation (HMBC) experiment is quite similar to the 
HSQC experiment, apart from the magnetization being transferred to the indirect nucleus 
over more than one electron bond. In a HMBC spectrum, the frequency of the direct 
nucleus is connected to the frequency of the indirect nuclei that have a distance of two or 
more electron bonds (Berger & Braun 1998). This fact can be used as complementary 
information for molecule structure elucidation. 
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The Used Spectrometer 
The instrument used in this thesis is an Avance III spectrometer (Bruker BioSpin, 
Rheinstetten, Germany) and is shown in Figure 7. The spectrometer has an operating 
frequency for protons of 600 megahertz (MHz), corresponding to a magnetic field 
strength of 14.1 Tesla.  
 
 
 
 
Figure 7. The 600 MHz Avance III cryo probe spectrometer with a cooled automatic sample 
changer was used for all NMR measurements in this thesis. 
 
The magnetic field is created by a superconducting magnet cooled by liquid helium, the 
helium Dewar in itself is cooled by liquid nitrogen to reduce helium evaporation loss. The 
magnet is surrounded by a magnet of inverse polarization to reduce (shield) the magnetic 
field outside of the instrument. The probe head is a so-called triple-resonance head and 
contains emitter/receiver coils for the frequencies of three different nuclei: 1H, 13C and 31P. 
These coils are cryogenic, this means they are superconducting and are cooled by a flow 
of cooled helium gas. The use of superconducting coils can lower electronic noise 
tremendously and enables faster measurements at the same signal-to-noise (S/N) ratio. 
Additionally, the probe head has a coil for the deuterium resonance frequency for 
frequency calibration (so-called locking) purposes. A coil to produce magnet field 
gradients along the z-axis is implemented. It can be used for de-phasing and, thus, 
reducing the disturbing solvent signal. The probe head has a bore for 5-millimeter 
diameter glass tubes that are held at 298 Kelvin (25 degrees Celsius (°C)) by a flow of 
heated compressed air. The spectrometer is equipped with a sample changer for around 
500 sample tubes to enable automated measurements of large sample quantities. The 
samples are cooled to 4 °C as long as they are in the sample changer to minimize sample 
degradation. 
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2.2 Alternative Methods 
 
To confirm the results obtained by NMR, selected samples were measured by other 
common metabolomics techniques for comparison reasons. These techniques are briefly 
described in the following paragraphs. 
 
Mass Spectrometry 
Mass spectrometry (MS) uses the fact that charged particles change their velocity and/or 
direction when they are placed in an electric field. The magnitude of this effect depends 
on the charge and the mass of particle and can thus be used to calculate the mass-to-
charge ratio (m/Q) of this particle. Technically, the particles are vaporized and ionized 
and then led into an electric field. Many organic molecules have identical m/Q values, 
though. Therefore, in metabolomics, MS spectrometers are usually coupled to some sort 
of separation apparatus like liquid chromatography (LC) or gas chromatography (GC) to 
reduce the number of simultaneously analyzed substances (Grob & Barry 2004).  
 
Tandem Mass Spectrometry 
In tandem mass spectrometry, two mass spectrometry measurements are combined in one 
experiment. This can be done using two separate yet coupled mass spectrometers or using 
one mass spectrometer to perform two measurements that are separated in time. Usually, 
the first MS run separates the molecules based on their m/Q ratios, then the molecules are 
fragmented by chemical or physical means, and then the fragments are separated in the 
second MS run. As fragmentation follows specific chemical rules, the fragments can give 
more detailed information about the molecule they originate from (Grob & Barry 2004). 
Also tandem mass spectrometry may be combined with additional separation methods. 
 
Liquid Chromatography 
LC is a commonly used separation method. It is based on the fact that different molecules 
will travel through a substrate at different speeds, depending on adhesion effects of the 
substrate. The analyzed liquid is therefore led through a column that has an inner coating 
or a packing with the desired adhesion properties. At the end of the column, the different 
molecules of the mixture will elute at different time points, this can be used for 
identification of the molecules (Cammann 2000). A tandem mass spectrometry system 
may be coupled to the end of the column to further analyze the eluting molecules. This is 
called liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
 
Gas Chromatography 
GC is a separation method that has much in common with LC. It does not operate with 
molecules in the liquid or aqueous phase though, but needs to evaporate the molecules to 
the gas phase. This is done by heating the sample using a predefined temperature 
program, commonly including periods of rising temperature and periods of constant 
temperature. The evaporated molecules are transported through a column with an 
adhesive inner coating by a carrier gas, usually helium. Commonly used column lengths 
are around 15 meters, with diameters of 0.25 millimeters (Kaspar et al. 2008). As not all 
molecules can be evaporated, a derivatization step is performed before the analysis. In 
this step the molecules are adapted in a way to enable evaporation (Grob & Barry 2004). 
To allow further separation, for example of enantiomers, two columns with different 
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properties can be coupled (Waldhier et al. 2011). GC may also be used in connection with 
MS analyses of the eluting fractions, this technique is called gas chromatography-mass 
spectrometry (GC-MS). GC-MS allows hundreds of metabolites to be identified and 
quantified in a single run (Almstetter et al. 2009). 
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2.3 Data Analysis 
 
Technical Errors 
To assess the measurement precision, NMR experiments were performed in duplicate and 
the technical errors (TE’s) were calculated according to the following equation: 
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where n is the number of samples that were measured in duplicate, and xi,1 and xi,2 are the 
first and second measurement of a specific sample, respectively. 
  
Bland-Altman Plots 
A Bland-Altman plot (Bland & Altman 1986) is a graphical model, also known as Tukey 
mean difference plot that is used to analyze the agreement between two experimental 
methods. The difference yn between the value x0 obtained by method #1 and the value y0 
obtained by method #2 
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is plotted for each sample against the average xn of the two methods  
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to allow a visual inspection of the differences between the methods. 
 
P-Values, T-Tests and ANOVA 
To assess whether two or more groups of individuals differ in their properties, different 
analysis methods may be used. If concentration values are known for the compounds of 
interest in a targeted profiling approach, or bin integral values are known in a 
fingerprinting approach, one of the most common approaches is calculating p-values. A 
p-value is a probability value that measures how likely it is that the observed groups have 
the same properties on average. The hypothesis that the groups have the same properties 
is called the null hypothesis. Groups stemming from the same overall distribution will 
have slightly different properties due to statistical fluctuations, and due to the limited 
number of observed group members. A p-value may take all values between zero and 
one. Low p-values indicate that it is unlikely that the groups share the same medium 
properties. This means that the null hypothesis may be rejected. 
To decide whether a calculated p-value indicates differences between the observed 
groups, significance levels may be defined. This can be based on arbitrarily chosen levels, 
such as the commonly used levels p ≤ 0.05 (so-called significant differences) and p ≤ 0.001 
(so-called highly significant differences). 
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P-values may be calculated by different approaches having different prerequisites 
concerning the kind of distributions observed (Gaussian or non-Gaussian), means, 
standard deviations, number of observed groups, and so on. The choice of the approach 
depends on the observed problem. 
The most common way to compare two groups is Student’s t-test. This test compares 
means and standard deviations of the groups. The test has as prerequisites that only two 
groups may be compared and that the observed variable is normally distributed. The test 
was calculated as a two-sided test, which means that it was tested both whether group 
one has a higher or a lower mean than group two. Unequal standard deviations for the 
two groups were assumed. 
 
In case more than two groups shall be compared, an analysis of variance (ANOVA) test 
may be used. ANOVA tests whether all groups share the same mean and variance, or 
whether one or more groups differ from the others. Anyway, ANOVA does not tell which 
group or groups differ from the rest. Thus, a significant ANOVA result has to be further 
analyzed to identify the group or groups differing from the other groups. This might be 
done by pairwise comparing all groups using Student’s t-tests. In this thesis, single factor 
or one-way ANOVA was used. In this test, the groups may be described by a single factor 
or variable, for example one individual may either be in group #1, #2 or #3, resulting in 
the value of the variable being one, two or three. In this setting, an individual can never 
be in group #1 and group #3 at the same time. An example for this case would be an 
individual suffering from two distinct diseases at the same time. 
 
False Discovery Rate 
Low p-values do not guarantee actual differences between groups, as they can also result 
from random fluctuations. This is a cause of error especially when p-values are calculated 
for many different variables of the same data set. This is called the problem of multiple 
testing. Although these “false” significances cannot be avoided, it is possible to estimate 
the number of “true” and “false” significant results. One way to do this is the false 
discovery rate (FDR) according to (Benjamini & Hochberg 1995). 
This method is based on the distribution of p-values calculated from one data set. In case 
of randomly chosen groups, p-values should be equally spread over the whole range from 
zero to one. In case real differences exist between the groups, more p-values will be 
observed in the low range than in the mid and high range. This is used to estimate the 
number of erroneously classified significant differences within a selected range of p-
values. For example, when using all p-values below 0.05, this may correspond to an FDR 
of 13 %, depending on the data set, indicating that 13 % of the variables with p-values 
below 0.05 are not significantly different in fact. Another possibility is to set the FDR to a 
desired value, for example 5 %, and to calculate the p-value below which this FDR is 
fulfilled. 
 
Odds Ratios 
Odds ratios can be used to investigate whether two groups of individuals differ in their 
rates of developing certain diseases (Cornfield 1951). The odds ratio takes values between 
0 and infinity. Values larger than one indicate that the first group has a higher disease 
risk, values smaller than one indicate a lower disease risk for the first group and a value 
of one indicates equal disease risks. The odds ratio was calculated as  
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where n1 is the number of diseased individuals in the first group, n2 is the number of 
diseased individuals in the second group, n3 is the number of healthy individuals in the 
first group and n4 is the number of healthy individuals in the second group.  
 
Normal Distributions 
To test whether a distribution is a normal (Gaussian) distribution, the Lilliefors-
Kolmogorov-Smirnov-test may be used (Lilliefors 1967). This test has as a result the p-
value for the null hypothesis that the underlying distribution is Gaussian. Gaussian 
distributions were fitted to distributions of real data using the mathematical software 
Origin (OriginLab, Northampton, MA, USA). 
 
Correlation Coefficients 
To gain information which metabolites are connected with each other in their synthesis or 
degradation, correlation analyses can give important information. A compound is said to 
be correlated with another compound, if their concentrations both show high respective 
low concentrations in the same samples. A common measure of correlations is the 
correlation coefficient (R). A correlation coefficient is a value in the range between -1 and 
1, with values close to -1 or 1 indicating a high correlation. 
The most common correlation coefficient is Pearson’s R (Köhler et al. 2002). It compares 
the covariance of the measured values of a variable. Although commonly used, it is prone 
to outliers as it uses the measured values directly. It is only able to detect linear 
correlations. The squared Pearson correlation coefficient R2 is often used to describe the 
proportionality of a set of paired variables. 
 
A more robust measure is Spearman’s R, named after its developer Charles Spearman 
(Spearman 1904). It is calculated as Pearson’s R with the exception that it uses the ranks 
instead of the absolute values. This makes it robust against outliers and enables to detect 
not only linear correlations, but also other monotonous dependencies, such as exponential 
correlations.  
Pearson and Spearman correlation coefficients were calculated using Excel 2007 
(Microsoft, Redmond, WA, USA). For each correlation coefficient, a matching p-value can 
be calculated based on the number of samples used. For large sample numbers, even 
small correlation coefficients may be significant, whereas in low sample numbers even 
very large correlation coefficients may not be a sign for a significant correlation. 
 
Partial Correlation Coefficients 
To check that high correlations are really due to direct correlations, and not due to a third 
variable that is correlated to both variables, partial correlation coefficients were calculated 
in an approach similar to that suggested by (de la Fuente et al. 2004). Partial correlation 
coefficients were calculated using the statistical programming language R and the 
function pcor.test available at http://www.yilab.gatech.edu/pcor.html. 
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For all pairs of significantly correlated variables, common variables showing significant 
correlations to both variables were searched. For each of these a first-order partial 
correlation coefficient and the corresponding p-value were calculated. If the p-value of a 
first-order partial correlation was above the significance level, this pair of variables was 
removed from the list of significantly correlated pairs. For all pairs of variables that were 
still marked as significant after all first-order-calculations, second-order calculations were 
performed for all possible pairs of common significant variables. If the p-value of a 
second-order partial correlation was above the significance threshold, this pair of 
variables was removed from the list of significantly correlated pairs. By using this 
approach, many high correlation coefficients were marked as non-significant. It shall be 
noted that this approach is rather conservative and will exclude many “true” correlations 
in order to reduce the number of false positive correlations. The R code for the calculation 
of partial correlations can be found in Appendix II. 
 
Metabolic Networks 
Correlations between metabolites are created when two metabolites are closely 
neighboring in the underlying metabolic network. Partial correlation coefficients are a 
first step into the deduction of the structure of the underlying metabolic networks, 
although to gain a real insight into the network, measurements of the undisturbed status 
are not sufficient, but an interventional step is necessary, for example the administration 
of labeled substances, to be able to analyze the induced change propagating through the 
metabolic network (Fan et al. 2009). 
 
Hierarchical Clustering and Heatmaps 
Hierarchical clustering is a method to divide samples into clusters in which the samples 
have similar properties. The clusters are created in a pairwise manner and then each of 
them is subdivided into a new pair of clusters and so on, until the “lowest” clusters 
contain one sample each. Hierarchical clustering is a so-called unsupervised algorithm. 
An unsupervised algorithm has no knowledge about the underlying groups, e.g. whether 
a sample comes from the healthy or the diseased group. If an unsupervised algorithm 
identifies the underlying groups within the sample set, this is an indication that strong 
differences exist between the groups. 
 
Heatmaps are a visualization method for complex data and may be integrally combined 
with hierarchical clustering methods. Heatmaps show the observed data in a matrix style, 
with samples as rows and features or metabolites as columns. The intensities or 
concentrations are represented by a color-code to enable a quick manual inspection. 
Usually the color coding uses a three-color scheme, with colors for low, medium and high 
values. This allows for a good visualization of binary distributions.  
 
Heatmaps with hierarchical clustering were generated using the R-package compdiagTools. 
All bin intensities were centered and scaled to unit variance for a better visualization in 
the heatmap. All R code used for this thesis is attached in Appendix II.  
 
Principal Component Analysis 
Principal component analysis (PCA) is another commonly used unsupervised algorithm  
(Pearson 1901). A PCA defines new axes in the subspace spanned by the measured 
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variables (metabolite concentrations). The axes are chosen in a way that the first axis lies 
along the maximal variance observed in the data. The next axis is added orthogonally to 
the first axis in a way to lie along the highest remaining variance (Abdi & Williams 2010). 
This process is usually repeated until a convergence criterion is reached, e.g. until 95 % of 
the variance present in the data are explained by the new axes. As the amount of variance 
gets lower and lower for each added axis, usually the first few axes are sufficient to 
explain the structures underlying the data set. The result of a PCA is a set of vectors that 
define the axes of the calculated principal components. Each vector contains a set of 
weight factors called loadings. For each spectral bin an individual loading is obtained, 
which is a measure of the contribution of a specific bin to a given principal component. 
Plotting the new found axes, group separations may be observed between the groups 
present in the data set. In this case, identifying the compounds having high loadings will 
reveal the chemical basis of differences between the observed groups. 
 
Since many compounds have several distinct peaks in an NMR spectrum, they will show 
up in more than one bin. In turn, a single NMR peak can contain signals from several 
compounds, which may impede the unambiguous identification of discriminatory 
compounds. 
 
Independent Component Analysis 
Independent component analysis (ICA) is a method similar to PCA. As in PCA, new axes 
are defined for the subspace spanned by the measured variables. These axes are chosen in 
way that the variance of the new-defined axes is maximized. Additionally, the 
independence of the axes is optimized to gain components that are independent of each 
other. The data have to fulfill some prerequisites, one of these is that the data has to be 
non-normally distributed. However, the actual distribution does not have to be known. 
The new axes do not need to be orthogonal to each other as in PCA (Hyvärinen & Oja 
2000). Analyses of ICA results are similar to the analysis of PCA results explained above. 
 
It has been shown (Scholz et al. 2004) that ICA often gives more meaningful results than 
PCA in biological data sets. Anyway, ICA has some drawbacks such as the lack of 
determining the variance explained by single independent components (IC’s), as it is 
possible in PCA (Hyvärinen & Oja 2000). ICA was performed using the JADE (Joint 
Approximate Diagonalization of Eigen-matrices) algorithm (Cardoso & Souloumiac 1993) 
available at http://cran.r-project.org/.  
 
Support Vector Machines 
A support vector machine (SVM) is a so-called supervised algorithm. Supervised 
algorithms use knowledge about the group membership of the analyzed samples to 
identify significant differences between groups. As these algorithms always will find 
group differences, even between randomly chosen groups, cross-validation of the results 
with an independent set of samples is highly recommended. 
 
An SVM defines a plane that separates the given groups in the multidimensional space 
spanned by the values of the observed bins, with each bin equaling one dimension. This 
separating plane is optimized in a manner that it lies in the middle between the nearest 
points of each group, i.e. that the distances to the nearest point of each group are equal. 
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The plane’s parameters are calculated on a training set of samples. Afterward, 
unclassified samples can be classified according to their location left or right of the plane. 
To assess the accuracy of the classification, the original data set is divided into a training 
set and the remaining samples are used as test samples. The test samples are classified 
and the amount of correctly and incorrectly classified test samples is saved. This method 
may be repeated with different combinations of training and test samples, thus allowing 
the calculation of a mean accuracy. 
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2.4 Quantitative Measurements  
 
As a first step in the analysis of biofluids, protocols for sample preparation and 
measurements had to be established. Milk is quite complex in its composition, being an 
emulsion of aqueous and lipophilic parts and containing microscopic structures such as 
lipid droplets and casein micelles (Töpel 2004). As a more straight-forward way of getting 
started, protocols were set-up for easier-to-handle urine samples. The suitability of NMR 
for the analysis of urine has been demonstrated previously (Waters et al. 2002). Parts of 
this chapter have already been published (Gronwald et al. 2008). 
 
Issues in Quantifying from NMR Spectra 
Biofluids may be very complex in composition containing hundreds to thousands of 
different compounds even in healthy individuals (Holmes et al. 1997). This in turn leads 
to an even larger number of signals in the corresponding NMR spectra that results in 
considerable signal overlap especially when only 1D 1H spectra are acquired. As a 
consequence, the high signal number hampers accurate metabolite identification and 
quantification considerably. A mathematical solution to this problem is to fit overlapped 
experimental signals to signals modeled from pure compound spectra (Weljie et al. 2006). 
Experimentally, spreading the signals over two or more dimensions will also reduce 
overlap. The advantages of multidimensional NMR have been recognized in several 
metabolomic studies (Holmes et al. 1997; Adosraku et al. 1994; Tang et al. 2004; Zheng 
et al. 2007). However, in most instances, multidimensional spectra have been acquired 
solely for metabolite identification and not for quantification. Only recently, the superior 
resolution of 2D spectra has been utilized for the quantification of metabolites (Hu et al. 
2007; Lewis et al. 2007; Shanaiah et al. 2007). The long acquisition times required in the 
past for 2D spectra had rendered them impractical for high-throughput metabolomic 
studies. Further, 2D cross-peak intensities depend on a larger number of different factors, 
such as structure-dependent coupling values and relaxation times, mixing times, 
evolution times, and uneven excitation profiles, which must be taken into account when 
they are used for quantification.  
 
2D 1H-13C HSQC spectra offer the advantage of large signal dispersion in the indirect 13C 
dimension. Quantification results for standard metabolite mixtures obtained from 2D 1H-
13C HSQC spectra were found to be quite accurate, while using 1D spectra underestimated 
the actual metabolite concentrations (Lewis et al. 2007). The large signal dispersion can be 
used to reduce signal overlap, as seen in Figure 8.  
 
In a 1D spectrum, a single peak may contain one or more metabolite signals (Figure 8A). 
In case several signals are present in one peak, reliable quantification is impossible. In a 
2D spectrum, these peaks may be separated in the additional frequency axis (Figure 8B). 
This should allow a more reliable compound identification. 
 
NMR Measurements 
For each sample, the probe was automatically locked, tuned, matched and shimmed using 
Topspin (Bruker BioSpin, Rheinstetten, Germany). For shimming, the topshim command 
was used. After a three-dimensional shim run on a urine sample and investigation of the 
observed line shapes, a shim file containing the obtained shim values was saved. This 
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standard shim file was used as a starting point for the automated shimming procedure of 
all other samples. To take magnet field variations that occur due to aging effects of the 
magnet, this shim file was replaced by an up-to-date file periodically. Each sample was 
allowed to equilibrate for 300 seconds in the magnet before measurement. The 
temperature unit was calibrated using a deuterated methanol sample. 1D 1H and 2D 1H-
13C HSQC spectra of each sample were automatically collected using the automated 
acquisition suite ICON-NMR (Bruker BioSpin, Rheinstetten, Germany). All spectra were 
acquired without spinning. 
 
 
 
 
Figure 8. Overlap reduction by using multidimensional spectroscopy.  
A: A single peak in a 1D spectrum may contain one or more metabolite signals. 
B: In a 2D spectrum overlapping peaks can be separated due to their different f1 frequencies. 
Abbreviations: f: Frequency; I: Intensity; f1, f2: Frequency 1, 2 
 
 
For each sample, a 1D 1H NOESY experiment was recorded. For the 1D spectra, a total of 
128 scans was collected into 65536 data points using the pulse program noesygppr1d 
(Bruker BioSpin, Rheinstetten, Germany) with presaturation during relaxation and mixing 
time for water suppression and additional spoil gradients. A relaxation delay of four 
seconds, an acquisition time of 2.66 seconds and a mixing time of 0.01 seconds were used. 
The spectral width was set to 20 parts per million (ppm) for each 1D spectrum and four 
dummy scans were applied prior to each measurement. These scans were discarded to 
avoid using data measured before the sample had reached equilibrium conditions. 
Spectra were automatically Fourier transformed and phase corrected, applying a line 
broadening of 0.3 Hz and zero filling to 131072 points. A flat baseline was obtained by 
using the baseopt option of Topspin, which performs a correction of the first points of the 
FID.  
 
It has been shown that metabolite signals are far more separated in the 13C frequency than 
in the 1H frequency and, thus, using an experiment that employs 13C-frequencies allows 
more reliable metabolite identification (Xia et al. 2008). Therefore, a 2D 1H-13C HSQC 
spectrum was recorded for each sample. For the HSQC spectra, 2048x128 data points were 
collected with the pulse program r_hsqcetgppr (Bruker BioSpin, Rheinstetten, Germany) 
using eight scans per increment, a relaxation delay of three seconds, an acquisition time of 
0.14 seconds and 16 dummy scans. This resulted in a total acquisition time of 56 minutes 
per spectrum. The spectral widths were set to 12 and 165 ppm in the proton and carbon 
dimensions, respectively. Water suppression was achieved using presaturation during the 
relaxation delay.  
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For all sample types, additional high-resolution 2D 1H-13C HSQC and HMBC spectra were 
recorded for representative control samples. The HSQC spectra were collected with 
2048x512 data points and 64 scans per increment. For the HMBC spectra, 2048x512 data 
points and 72 scans were acquired. The total acquisition times for these HSQC and HMBC 
spectra, which were recorded only once for each sample type, were 15 hours and 25 
minutes and 17 hours and 42 minutes, respectively. 
 
Frequency Adjustment for Water Suppression 
For effective water signal suppression it is necessary to adjust the presaturation RF signal, 
the so-called O1 frequency, to exactly match the resonance frequency of water at around 
4.8 ppm. As the change of O1 also causes spectrum baseline distortions, these had to be 
compensated by adjusting the sixth-order shim coil, the so-called z6 shim. As the z6 shim 
also affects the water resonance signal, these adjustments had to be performed iteratively. 
For this, first O1 was adjusted to match the maximum position of the water signal of a 
urine sample. Then, the symmetry of the residual water signal was checked. Depending 
on the kind of deviation (higher signals left or right of the O1 frequency), the z6 shim had 
to be raised or lowered. After this, O1 had to be readjusted. This procedure was repeated 
until a symmetric residual water signal was observed. While the O1 frequency is part of 
the acquisition parameters and is stored in the experiment files, the z6 is stored in the shim 
file. The O1 frequency had to be readjusted due to magnetic field changes in the magnet 
on average once a year. 
 
Spectrum Processing 
To transform the time-dependent FID into a frequency-dependent spectrum, Fourier 
transformation was performed using Topspin. In Fourier transformation, the intensities 
and phases of the corresponding frequencies are calculated. Due to reasons such as the 
delay between the RF pulse and the start of the measurement, the phase usually cannot be 
calculated in the right way and has to be corrected. For 1D spectra, Topspin offers 
automated phase correction algorithms. These spectra were inspected by eye for correct 
phase correction. In a few cases with strongly diluted samples, the automatic routine had 
problems with phase correction, possibly due to the fact that negative artifacts of the 
suppressed water signal dominated these spectra. Usually, a phase error of 180 ° was 
observed in these cases. These samples were phase corrected manually. Software scripts 
were developed in the programming language Python to facilitate additional processing of 
the raw data. These scripts can be found in Appendix II. All 1D samples were baseline 
corrected using a third-order polynomial. 2D spectra were semiautomatically processed 
employing a 90 ° shifted squared sine-bell window function in both dimensions. For 
increased resolution in the indirect carbon dimension, the number of data points was 
doubled prior to Fourier transform using complex forward linear prediction. Due to 
difficulties in peak picking, caused by residual J-couplings that lead to signal splits, the 
resolution of the 1H-frequency was reduced to 50 %, yielding 1024 data points, in the 
processing parameters. All 1D and 2D spectra were chemical shift referenced relative to 
the reference substance signal. As Topspin failed to set the 13C-frequency of the reference 
signal to zero in many cases, the 13C-frequency was corrected using the 1H-frequency of 
the reference signal to calculate the matching 13C-frequency. All 2D spectra were manually 
phase corrected in both dimensions and a fifth-order polynomial baseline correction was 
applied excluding the region around the water artifact. 
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2.5 Measurement of Urine Specimens 
 
Sample Preparation 
100 milliliter (mL) of 0.1 mole per liter (mol/L) potassium phosphate buffer (pH 7.4) was 
prepared by adding 8.02 mL of 1 mol/L of aqueous potassium hydrogen phosphate 
solution to 1.98 mL of 1 mol/L of aqueous potassium dihydrogen phosphate solution and 
filling up to 100 mL with pure water. Finally, 30 milligram (mg) of boric acid was added 
to prevent bacterial growth.  
400 microliter (µL) of urine were mixed with 200 µL of potassium phosphate buffer. As 
urine is more acidic, this yielded final pH values of around 7.0. To allow spectrometer 
frequency locking, 50 µL of deuterium oxide containing 29.02 millimole per liter (mmol/L) 
3-trimethylsilyl-2,2,3,3-tetradeuteropropionate (TSP) as internal standard were added 
(Beckonert et al. 2007). 
 
Identification of Urine Compounds 
For initial assignment of the metabolites, the high-resolution 2D 1H-13C HSQC and HMBC 
spectra of a representative urine specimen were used. First, a manual metabolite 
assignment was performed on the high-resolution 2D 1H-13C HSQC spectrum aided by the 
corresponding 1D 1H spectra. Amix 3.8.1 (Bruker BioSpin, Rheinstetten, Germany) was 
used starting with manual picking of peaks in the high-resolution HSQC spectrum. An 
NMR peak search was performed using the Biological Magnetic Resonance Data Bank 
(available at http://www.bmrb.wisc.edu/) (Seavey et al. 1991), and the Human 
Metabolome Database (available at http://www.hmdb.ca/). To assign the signals, the 
spectrum was manually overlaid with reference spectra of pure compounds. The 
reference spectra were taken from the commercially available reference compound 
database Bbiorefcode 2-0-3 (Bruker BioSpin, Rheinstetten, Germany) that contains 
reference 1D 1H, 2D 1H-13C HSQC and 1H-13C HMBC spectra of metabolite standards 
measured under a variety of different experimental conditions (e.g. pH values and 
solvents). As an example, a creatinine reference spectrum was overlaid with a 1D urine 
spectrum in Figure 9.  
 
 
 
Figure 9. Overlay of a urine spectrum (blue) and the reference spectrum of creatinine (red). The 
two peaks of creatinine fit quite well considering frequency and intensity ratios, but a closer 
inspection seen in the inset shows frequency shifts. 
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In the figure, the two creatinine peaks at 3.05 ppm and 4.07 ppm agree quite well with the 
peaks observed in the urine spectrum considering frequency and intensity ratios. Taking a 
closer look, frequency differences are visible, though. These might be due to differences in 
experimental conditions, such as pH value, between the reference spectrum and the urine 
spectrum. To assure that the peaks in question really stem from the supposed metabolite, 
the pure metabolite was purchased, solved in pure water and measured under the same 
conditions as the urine sample to validate the exact peak positions. Additionally, spike-in 
experiments can be used to assure a peak assignment. In these experiments, a small 
amount of the pure substance is added to the sample. Comparing the spectra recorded 
before and after spiking, the peaks belonging to this substance can be identified. 
 
Initial assignments were further validated by long-range proton-carbon couplings 
obtained from the high-resolution 2D 1H-13C HMBC spectrum. HSQC spectra show a peak 
at the 1H and 13C frequencies of nuclei connected with one electron bond. HMBC spectra 
show peaks at the 1H and 13C frequencies of nuclei connected with two electron bonds.  
 
This can be used to validate that several peaks stem from the same molecule. Consider 
having identified two peaks (peak a and peak b) in a HSQC spectrum that supposedly 
arise from the same molecule. In case the two 13C atoms of peak a and peak b are directly 
connected by one electron bond in the molecule, the HMBC spectrum should show a peak 
c at the 13C frequency of peak a and the 1H frequency of peak b. In case no peak is visible at 
this position, peak a and peak b most probably do not stem from the same molecule, or are 
not directly neighboring in this molecule. This is exemplarily shown for the creatinine 
signals of a urine sample in Figure 10.  
 
 
 
 
 
Figure 10. Validation of peak assignments using high-resolution HSQC (A) and HMBC (B) spectra. 
Peaks a and b in the HSQC spectrum are supposedly from the same molecule. The existence of a 
peak c at the intersection of the corresponding 1H and 13C frequencies in the HMBC spectrum 
supports this idea. The peaks stem from creatinine in this example. 
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Additionally, literature research provided hints about highly abundant urinary 
metabolites that are expected to be visible in the spectra. A summary of the identified 
urinary compounds including chemical shift data is provided in Tables 1 and 2 in 
Appendix I. A high-resolution 2D urine spectrum where typical urinary compounds have 
been marked is shown in Figure 11.  
 
 
 
 
Figure 11. 2D 1H-13C HSQC spectrum and 1D 1H spectrum (left upper corner inset) of a healthy 
control urine specimen. Adapted from (Gronwald et al. 2011). 
Abbreviations: 1-Met-His: 1-methylhistidine; 3-Met-His: 3-methylhistidine; Ala: Alanine; Arg: Arginine;  
Gln: Glutamine; Gly: Glycine; His: Histidine; Leu: Leucine; Lys: Lysine; MeOH: Methanol; Phe: Phenylalanine; 
Thr: Threonine; TMAO: Trimethylamine-N-oxide; TSP:  3-Trimethylsilyl-2,2,3,3-tetradeuteropropionate;  
Trp: Tryptophan; Tyr: Tyrosine; Val: Valine 
 
 
Automated Integration of Metabolite Signals 
The obtained chemical shift information of each identified metabolite signal was used for 
automated integration of the spectral peaks using the Analytical Profiler module of Amix 
3.9.3 (Bruker BioSpin, Rheinstetten, Germany).  
Amix Analytical Profiler stores the chemical shift information and other data in a text file 
called knowledge base. To define the regions where the individual metabolite signals in a 
series of measured spectra are expected, individual chemical shift ranges were specified 
for each metabolite signal by manually analyzing inter-spectra chemical shift variations in 
a subset of the measured spectra. Depending on the analyzed type of spectrum, 
individually optimized chemical shift ranges were determined. In crowded regions of 2D 
spectra, it is especially important to choose very narrow search ranges to avoid 
integration of neighboring signals. It is not required that the whole peak is in the search 
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range - it is sufficient when just the peak maximum is in the search range. In addition to 
the search range, the knowledge base describes the individual signals of a compound in 
terms of multiplet patterns, couplings, relative intensities and masses. Coupling values 
with appropriate error bounds were obtained by analyzing the pure reference compound 
spectra together with the experimentally measured spectra of real samples. Note that 
multiplet patterns caused by J-couplings are in most cases only observable in the 1D 
spectra. In addition, the knowledge base allows the exclusion of overlapping signals 
located in crowded regions of the real urine spectra from the following quantification 
process. Overlapping signals were determined by manually analyzing a subset of the 
measured spectra. In Table 2 (see Appendix I), the metabolite signals used for 
quantification are listed.  
 
The next step of the analysis was the integration of the signals identified in the previous 
step. Integration was performed with the Analytical Profiler module of Amix 3.9.3. The 
1D 1H and 2D 1H-13C HSQC spectra corresponding to the series of measured urine 
samples were automatically peak-picked using an automated noise level calculation. For 
this purpose, regions that contained no signals in all spectra were manually defined. 
Using the information stored in the knowledge base, metabolite signals were identified 
and integrated. For 1D spectra, multiplet information stored in the knowledge base was 
used in the integration process to ensure that only the desired signals within the specified 
chemical shift ranges were integrated. For 2D spectra, multiplet information was not 
applicable. Here, information from the reference compound spectra database, such as the 
expected number of signals in a specific region, was used instead. 
Next, relative integrals with respect to the reference TSP signal were calculated for the 
individual metabolite signals. In this process, the number of atoms contributing to a signal 
was taken into account, i.e. each integral was divided by the number of protons giving 
rise to it. The use of relative integrals automatically corrects for machine-dependent 
sensitivity variations between experiments and has the additional advantage that 
calibration curves have to be determined only once.  
 
Dilution Series of Pure Compounds 
For the identified compounds, dilution series of the pure compound were prepared in 
order to calculate calibration curves and calibration factors for the different metabolites. 
 
For 1D 1H spectra, calibration curves for all compounds and their respective signals 
should be very similar provided that a sufficiently long relaxation delay had been 
applied. To verify this expectation, calibration curves were generated for all non-
overlapping signals of all quantified metabolites at multiple concentration values. 
 
A 10 millimole per liter (mmol/L) standard stock solution of each compound was serially 
diluted to yield final concentrations of 10000, 5000, 2500, 1250, 625, 312.5, 156.2, 78.1, 39 
and 19.5 micromole per liter (µmol/L), respectively, and the corresponding spectra were 
acquired. For creatinine, the concentration range was extended to 15 mmol/L. For lowly 
abundant metabolites quantified from 1D spectra, serial dilution was continued for the 
concentration values of 9.8, 4.9, 2.5 and 1.2 µmol/L. Table 2 (see Appendix I) shows the 
signals that were used for compound quantification. Due to overlap of signals even in the 
2D spectra, only a subset of all signals could be used for quantification. 
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For the lowest concentration values of the dilution series, poor water suppression was 
observed. When only very low concentrations of solved compounds are present, the water 
signal shifts slightly. The water presaturation frequency then does no longer match the 
exact water resonance frequency, resulting in a larger residual water signal. This may 
cause receiver overflows, leading to decreased spectral quality. One solution for this 
problem is lowering the receiver gain for these samples, the other solution is adding other 
compounds to the dilution series in constant amounts. Therefore, 40 µL of 10 mmol/L 
compound mix were added to 360 µL of the dilution series sample, resulting in 
concentrations of 1 mmol/L of a standard compound mix present in each sample. This 
prevented the above described problems. 
 
A typical example for a calibration curve obtained from 1D 1H spectra is shown for 
creatinine in Figure 12A. The peak integrals (relative to the TSP integral) were plotted 
against the weighed-out concentrations. The curves were measured for the two signals 
corresponding to the creatinine methylene (H2A/H2B) and methyl group 
(H6A/H6B/H6C), respectively. As can be seen, both curves are almost identical and show 
a linear behavior with R2 values of 0.999 when fitted to a straight line. 
 
 
 
 
Figure 12. 1D (A) and 2D (B) calibration curves for creatinine generated from the signals H2A/H2B 
and H6A/H6B/H6C, respectively. The used atom numbering scheme for creatinine is shown as an 
inset (A). On the x-axis, the concentration values employed are shown [µmol/L] and on the y-axis 
the corresponding relative integrals are given with respect to the TSP signal.  
Adapted from (Gronwald et al. 2008). 
 
 
In the case of 2D spectra, multidimensional peak intensities are influenced by a number of 
factors such as non uniform relaxation, different transfer efficiencies of the insensitive 
nuclei enhanced by polarization transfer (INEPT) steps of the HSQC spectra and uneven 
excitation profiles. This results in calibration curves of markedly different slopes for the 
two signals of creatinine (Figure 12B). Linear regression lines were added. The R2 values 
near 1 show that signal volumes scale linearly with concentration also for the 2D spectra, 
but with different slopes for each peak. 
Similar results were obtained for most other metabolites. Consequently, if 2D spectra are 
used for quantification, it is necessary to calibrate each signal individually to obtain a 
reliable and accurate quantification of a compound. The slope of the regression line can be 
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used as a calibration factor: Dividing a peak integral by this value will result in the 
absolute compound concentration. 
 
For calculating the lower limits of detection (LLOQ’s), the lowest three points of each 
calibration curve were measured in triplicate and the corresponding relative standard 
deviations (RSD’s) were determined. Following the recommendation of the Food and 
Drug Administration (FDA, White Oak, MD, USA) guide for Bioanalytical Method 
Validation (FDA 2001), the LLOQ was defined as the lowest concentration value that 
could be determined with an RSD < 20 %. The LLOQ values are shown in Table 2 (see 
Appendix I). The lowest values of LLOQ were obtained again for compounds with 
multiple methyl groups, the protons of which give rise in most instances to one sharp 
singlet signal. The LLOQ’s obtained are a function of the NMR acquisition time. 
Therefore, lower values may be obtained by increasing the acquisition time.  
 
Analysis of Citric Acid 
In contrast to NMR spectra of a citric acid standard, two sets of signals for citric acid were 
present in some urine spectra. It was confirmed that both signal sets belonged to citric 
acid by addition of exogenous citric acid that resulted in corresponding increases in signal 
intensities for both sets of signals. The two signal sets of citric acid were separated by 
1.61 ppm in the carbon dimension, while only a minor split was observed in the proton 
dimension. A full description of the measured chemical shift can be found in Table 2 (see 
Appendix I). For the urine specimens with this “double” citric acid signal, a wide 
variation of relative intensities was observed between the two forms. There was no clear 
concentration dependent trend for the intensity ratios obtained. The observed signal 
splitting agrees with an earlier NMR observation that urinary citric acid is involved in 
complexation reactions with calcium ions (Ca2+) and magnesium ions (Mg2+) (Neild et al. 
1997). As expected, addition of ethylenediaminetetraacetic acid (EDTA) resulted in the 
presence of a single citric acid state. The possibility of complexation reactions is further 
supported by the average Ca2+ and Mg2+ concentrations of 4.37 and 3.97 mmol/L, 
respectively, found in the human urine (Ciba-Geigy 1983). Another possible explanation 
for the observed signal duplication is the use of boric acid as a preservative at the time of 
urine collection. High concentrations of boric acid lead to citric acid-borate complex 
formation with distinctive signal duplication (Smith et al. 2009). To elucidate whether 
addition of EDTA also would render single citrate signals in a citric acid-borate complex, 
3 mmol/L boric acid were added to a solution of 1 mmol/L citric acid. This yielded the 
expected duplication of the citric acid signal. Addition of EDTA in concentrations up to 
19 mmol/L yielded no change in the duplication of the citric acid signal. This is another 
hint that the observed signal duplication is due to Ca2+ and Mg2+ ions rather than borate. 
Consequently, volume integrals for the corresponding citric acid signals were summed for 
the determination of urinary levels of citric acid in case signal splitting was observed. 
 
Mouse and Rat Urine 
Mouse and rat urine are highly concentrated. Their measurement according to the above 
protocol led to several spectral distortions. Firstly, the high salt concentration led to a high 
absorption of the RF signal, making very long RF pulses necessary. This may be harmful 
to the spectrometer due to overstressing of the sensible sending coils and causing 
extensive heating of the sample. Secondly, the added buffer could no longer achieve a full 
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pH adjustment, leading to uncontrolled signal shifts. Therefore, mouse and rat urine of 
30-100 µL was diluted to 400 µL with pure water, and then prepared as described for 
urine above. In these diluted samples, the buffer was able to adjust the pH value 
sufficiently. 
It was tested whether an exact pH adjustment gives superior results compared to just 
adding potassium phosphate buffer. 18 mouse urine samples were pH adjusted by adding 
small amounts in the low µL range of hydrochloric acid or sodium hydroxide. Although 
the group clustering result of a subsequent ICA was somewhat improved, this difference 
was not large. Taking into account the time and work needed for adjustment of larger 
sample numbers, the protocol using simple buffer addition was chosen for all analyses. 
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2.6 QUANTIFY: A Tool for Accurate Quantification 
 
In the study on urine, strong signal overlap was observed for many metabolites. As urine 
may vary strongly in its composition, signals from unexpected molecules may overlap 
with signals used for quantification of expected metabolites. This may lead to strong over-
quantification if not corrected. One possible way to reduce this problem is manual 
inspection of each peak. An automatic routine would be a more convenient way, as it 
would not be dependent on the skill and experience of the researcher inspecting the 
spectra. Additionally, an automated routine would save time especially when quantifying 
large sample sets. Therefore, an automatic approach using several peaks for each 
compound was developed. 
 
A software named QUANTIFY was developed using Matlab 2007b (The Mathworks, 
Natick, MA, USA) to automate these analyses. The manual for QUANTIFY 1.0 is shown in 
Appendix III. Matlab code and executable files of QUANTIFY 1.0 are attached in 
Appendix II. The current version can be found in the software section of the Internet page 
of the Institute of Functional Genomics of the University of Regensburg (Regensburg, 
Germany): http://genomics.uni-regensburg.de/. 
 
A screenshot of the main screen of QUANTIFY is shown in Figure 13.  
 
 
 
 
Figure 13. Main screen of QUANTIFY. For a detailed description of all items see the manual in 
Appendix III. 
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Originally, QUANTIFY was intended only for the analysis of 2D HSQC data, but has 
proven to provide reliable results also for 1D spectra. It may also easily be used for data 
from other one- or multidimensional NMR experiments. 
 
To visualize the inputs and outputs of QUANTIFY, a data flow diagram was created. The 
diagram is shown in Figure 14. 
 
 
 
 
 
 
Figure 14. Data flow diagram of QUANTIFY. Functions are shown as circles, user inputs as boxes, 
data storage files as two horizontal lines and data flows as arrows with the transferred data shown 
on top of the arrows (DeMarco 1979). Optional parameters and files are marked in green. 
 
 
The program takes as input a file containing the peak integrals of the investigated 
spectrum. This might either be an Amix Analytic Profiler output file, an Excel file or a text 
file. The latter two file types were implemented to be able to use QUANTIFY 
independently of the employed spectrometer software.  
 
In addition to the signal intensities, information about the individual peaks of a 
metabolite such as calibration factors and number of protons may be provided as an Excel 
or text file. LLOQ’s for each metabolite may be provided in an Excel or text file. 
 
In case individual calibration factors are provided, each peak integral is multiplied by its 
individual calibration factor, as shown to be necessary for 2D spectra in Section 2.5. As 
this may not be needed in all cases this function is optional.  
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Outlier Detection 
The main benefit of QUANTIFY is its ability to identify and to exclude overlapped peaks 
and outliers. For this, several algorithms were developed. These algorithms raise the 
reliability of the results of NMR quantification, especially in complex biofluids.  
 
When inspecting several peaks belonging to one compound, single peaks may be 
overlapped with disturbing signals. Still, it is unlikely that all peaks of one compound are 
overlapped in the same manner. If single peaks deviate strongly from the other signals, 
they are therefore assumed to be overlapped. Peaks are excluded as outliers if their 
integrals differ by more than a chosen outlier threshold from the median of all peaks 
obtained for this compound. In practice, an outlier threshold of 40 % has proven 
meaningful. If only one peak is left after outlier removal, heavy overlap is assumed, and 
the median value of all peaks of this compound is chosen. For some metabolites, only two 
peaks may be available. In case these peaks show a deviation above the outlier threshold, 
the peak with the smaller concentration value is chosen, as peak overlap usually results in 
raised concentrations.  
 
For low-abundant compounds with many peaks, many or all of these peaks may not be 
visible above the noise level. At the same time, each of these peaks may be overlapped, 
thus giving rise to potentially false quantification results. To make the results for low-
abundance metabolites more reliable, only metabolites are quantified where the ratio of 
peaks left after outlier removal in comparison to all expected peaks is equal or higher than 
a so-called peak threshold. For the peak threshold, a value of 66 % has proven appropriate 
for the analysis of urine and milk. In case that fewer peaks are found, the quantification 
results are doubtful. In this case, a reliability check is performed based on the number of 
protons contributing to these peaks. This reliability check is based on the assumption that 
in case of low compound concentrations, peaks with more protons should be visible, 
while peaks with fewer protons will remain below the noise level. For all peaks left after 
outlier removal, the number of protons contributing to the peak is checked, and the 
largest number of protons is saved. For all peaks that were not found in this spectrum, the 
same procedure is applied. If the maximum number of protons of the found peaks is 
larger than the maximum number of protons of the peaks not found, the peak is 
considered to be reliable. Otherwise, the compound is marked as not detected. The peak 
reliability check of QUANTIFY is, to the best of my knowledge, a completely novel 
feature in NMR quantification. 
 
Single peaks of one compound may be marked as obligatory in QUANTIFY. In case this 
peak is not observed in the data set, all other peak integrals of this compound are 
discarded, and the compound is marked as not detected. This is useful for molecules with 
strong peaks that are often overlapped by other signals. By marking a weaker peak (with 
fewer protons) of the molecule as obligatory, this compound will only be quantified if the 
weaker peak is present. This will reduce the number of incorrect results. A similar routine 
using obligatory peaks has been previously implemented, yet only for compound 
identification and not for quantification (Xia et al. 2008). 
 
2 Method Development 2.6 QUANTIFY: A Tool for Accurate Quantification 
 
34 
Additional Features 
After these procedures, outliers and doubtful peaks have been removed, and the mean of 
the remaining peaks is calculated to yield the final concentration value. Optionally, the 
resulting value may be compared with the individual LLOQ of this compound. Values 
below the LLOQ will be discarded. 
 
For replicate samples, means and TE’s are calculated automatically. The tool optionally 
performs a concentration correction for diluted samples. Also, a correction for different 
reference substance concentrations may be performed. Concentrations may be normalized 
to a chosen compound, e.g. creatinine in urine samples.  
 
All parameters such as peak threshold and outlier threshold may be freely chosen. Finally, 
the calculated concentrations are saved to an output file. The values of identified outliers 
are stored in a separate spreadsheet for manual inspection. 
 
Documentation 
A change log listing all changes made between different versions of QUANTIFY can be 
found in the beginning of the source code file quantify.m that can be found in the 
attachment in Appendix II. Additionally, all previously released versions of QUANTIFY 
are available in the software section of the Internet page of the Institute of Functional 
Genomics of the University of Regensburg (Regensburg, Germany): http://genomics.uni-
regensburg.de/. 
For every QUANTIFY run, all parameters, file names, program versions, the user name 
and the computer name are automatically stored in a configuration spreadsheet in the 
results file. These data represent an accurate documentation of the quantification 
procedure. In combination with the change log and the archive of previous versions, the 
configuration data allow the exact reproduction of quantification procedures in case 
questions on the results arise at a later time point. Additionally, these configuration 
spreadsheets may serve as an information archive to facilitate performing similar 
experiments in the future and shall enable constantly reproducible results. 
 
All NMR quantifications in this thesis were performed using QUANTIFY.  
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2.7 Urine Test Samples 
 
In order to check the precision of the 2D NMR methods developed in the previous 
chapters, replicates of real biological samples were measured and quantified. To assess 
the accuracy of the methods, 2D NMR quantification results were compared to 
quantification results from 1D NMR and other established methods. Fifty human urine 
samples served as a test set. The values obtained by NMR were validated by 
measurements of the same samples using other commonly used quantification techniques. 
Bland-Altman analyses were performed by Wolfram Gronwald. This section has been 
published in part (Gronwald et al. 2008). 
 
Collection of Urine Samples  
Two sets of human urine samples were analyzed. Control urine was collected from 33 
volunteers. A set of 51 samples was prepared out of these 33 specimens, comprising six 
triplicates (18 samples), five duplicates (10 samples) and 22 single samples. In addition, 
one blank was included. Urine from patients with inborn errors of metabolism were 
provided by the Zentrum für Stoffwechseldiagnostik Reutlingen (Reutlingen, Germany). 
For the analysis of standard mixtures of known concentration, a certified mixture of 
amino acids was purchased from the National Institute of Standards and Technology 
(NIST, Gaithersburg, MD, USA). For the NMR measurements, 400 µL of the undiluted, 1:5 
and 1:10 dilutions of the NIST standard with water were prepared as the urine samples. 
The dilution was necessary as the samples were too acidic to be compensated by the used 
buffer and thus resulted in NMR signal shifts. 
 
Comparison of 1D and 2D NMR Urine Measurements 
Quantitative results from 1D and 2D NMR urinary spectra were compared to assess the 
degree of accordance. For a few highly abundant metabolites, such as creatinine, a very 
good agreement was found between 1D and 2D 1H-13C HSQC spectra with an R2 value of 
0.99 and a slope of 0.95 of the regression line (Figure 15A).  
 
 
 
 
Figure 15. Linear regression of the concentration [µmol/L] obtained for creatinine (A) and alanine 
(B) in 50 urine samples by 2D 1H-13C HSQC and 1D 1H  NMR. The insets show Bland-Altman plots. 
The centerline in the plots corresponds to the mean difference between 1D and 2D NMR, while the 
outer lines correspond to 1.96 standard deviations (SD’s). Adapted from (Gronwald et al. 2008). 
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However, for urinary metabolites, such as alanine, which are physiologically present at 
low µmol/L concentrations, 1D spectra gave higher concentrations as indicated by the 
slope of the regression curve of 1.13 and an offset of 135 µmol/L (Figure 15B). This is also 
demonstrated by the Bland-Altman plots (Bland & Altman 1986) shown as insets in 
Figure 15.  
For alanine, the obtained mean difference between 2D and 1D NMR measurements that is 
marked by the thick line in the corresponding Bland-Altman plot amounts to -161 µmol/L. 
The magnitude of this value is close to the 135 µmol/L offset of the regression analysis. 
When compared to the measurement range for alanine of 86 - 465 µmol/L, this mean 
difference amounts to a considerable relative error. A detailed investigation of the 
analyzed regions in the 1D spectra showed the presence of a high number of overlapping 
background signals, which stem most likely from urinary peptides and small proteins and 
cause an overestimation of concentration values. It should be noted that this is true for the 
alanine signals of the methine as well as the methyl group. It was also verified that the 
observed over-quantification could not be attributed to poor baseline correction or 
integral limits set too wide. As mentioned in Section 2.5, expected multiplet information 
was used in the integration process ensuring that only the desired signals present in the 
specified chemical shift ranges were integrated. However, this procedure will not correct 
for completely overlapping signals, as is the case here. In contrast, for the highly 
abundant creatinine, similar absolute differences in the urinary levels determined by 1D 
and 2D NMR spectra were observed in the regression analysis (285 µmol/L) and Bland-
Altman plot (71 µmol/L). However, when compared to the corresponding measurement 
range of 3069 - 13593 µmol/L, the relative error becomes quite small for creatinine. In 
general, correlation coefficients between results from 1D and 2D spectra also decrease 
with decreasing abundance of urinary metabolites. These data suggest that when 
analyzing complex biological matrixes, such as human urine, 1D NMR spectra are only 
suitable for the quantification of metabolites that are highly abundant or that possess 
signals in isolated areas of the spectra. Otherwise it is advantageous to use 2D spectra to 
reduce the amount of overlapping background signals. 
 
Reproducibility of 2D NMR Urine Measurements 
The six different triplicates included in the urine study were used for determining the 
reproducibility of the 2D NMR results. The observed data, which are summarized in 
Table 3 (see Appendix I), give the joint reproducibility of the sample preparation, NMR 
acquisition and data analysis. The calculated RSD’s vary between 2 and 21 % with an 
average of 11 %. RSD’s are typically inversely correlated with the abundances of urinary 
metabolites. 
 
Accuracy of NMR Urine and Standard Mixture Measurements 
For spike-in experiments, 0, 625, 1250 and 2500 µmol/L alanine, creatinine, ethanolamine, 
glutamine, glycine, hippurate and taurine, respectively, were added to a urine sample. 
Analysis of the 2D 1H-13C HSQC spectra recorded showed that on average 106 ± 2 % of the 
expected metabolite concentrations were recovered, as exemplified for creatinine, 
hippurate and glycine in Figure 16. One explanation for the slight over-quantification may 
be that the internal TSP standard interacts with urinary compounds. This interaction leads 
to a reduced TSP signal and, consequently, to increased relative integrals and 
concentration values for the urinary metabolites analyzed. As a consequence, all 
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concentration values measured in urine were multiplied with a global correction factor 
calculated as 100/106. Note that for the analysis of a certified standard solution no such 
correction was necessary, indicating that the observed over-quantification of urinary 
metabolites is indeed an effect of the biological matrix. 
 
 
 
 
Figure 16. Accuracy of quantification. Metabolites of known concentration were spiked into a urine 
sample. For creatinine, hippuric acid and glycine the correlations between added and observed 
concentrations [µmol/L] are given. The axis intercepts represent the metabolite concentrations 
present in the native urine sample. Adapted from (Gronwald et al. 2008). 
 
 
A certified amino acid standard obtained from NIST (Gaithersburg, MD, USA) was 
investigated by means of 2D NMR, to check the accuracy of the method. This standard 
reference material (SRM) is an aqueous mixture of 17 amino acids in 0.1 mol/L 
hydrochloric acid. Samples were prepared and analyzed as the urine samples. Of the 17 
amino acids, alanine, glycine, histidine, lysine and arginine were investigated, as they 
were part of the target set of urinary compounds. Table 4 (see Appendix I) shows the 
concentration values and standard deviations obtained by 2D NMR.  
 
Due to the low pH of the SRM, major chemical shift changes compared to the previously 
defined knowledge base values were observed in the undiluted sample for most amino 
acid signals. Therefore, Table 4 (see Appendix I) shows the 2D NMR values obtained for 
the 1:5 diluted samples with the exception of histidine, for which even at a dilution of 1:5 
significant chemical shift changes were observed. Hence, recovery of histidine was 
determined for the 1:10 diluted standard. Note that a pH correction of the NIST standard 
was not performed since this would lead to additional errors caused by the addition of 
small amounts of extra solvent. For comparison, the means and standard deviations were 
multiplied with the appropriate dilution factors. The NIST certified concentrations and 
their estimated uncertainties are based on in-house analysis at NIST and a round robin 
study that was conducted in cooperation with the Association of Biomolecular Research 
Facilities (Bethesda, MD, USA). The certified value is the equally weighted mean of the 
NIST average and the round robin average. Additionally, gravimetric values given by 
NIST are shown. The gravimetric value is based on the weighed amount of each amino 
acid used to prepare the solution. The last column of Table 4 (see Appendix I) shows the 
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recovery of the 2D NMR data in comparison with the NIST certified concentrations. As 
can be seen, the results obtained by 2D NMR agree well with the NIST certified 
concentrations. In all cases, the NIST certified concentrations are within the NMR error 
ranges. The best agreement between NMR data and NIST certified concentrations is 
observed for glycine with an absolute deviation of zero, while the largest deviation of 
0.31 mmol/L is observed for histidine. When analyzing the percentage of recovery given 
in the last column of Table 4 (see Appendix I), a range between 97 and 111 %, with an 
average of 102 %, is observed for the different amino acids. These data clearly indicate 
that 2D NMR allows the accurate determination of metabolite concentrations. It was also 
analyzed whether concentration-dependent effects can be observed. For that purpose, 
undiluted, 1:5 and 1:10 diluted SRM was used. As mentioned above, especially for the 
undiluted standard, major chemical shift changes were observed and a considerable 
number of the signals had to be reassigned and manually integrated. Additionally, for 
some amino acids such as arginine, the lowest concentration point was slightly below the 
LLOQ value of 312 µmol/L. Therefore, these data should be treated with some care. For 
three metabolites, namely, alanine, arginine and histidine, a linear regression analysis 
with the corresponding NIST certified concentrations plotted on the y-axis, was 
performed. Slopes of 1.06, 0.98 and 0.91 were observed for alanine, arginine and histidine, 
respectively, with corresponding y-axis intercepts in that order of -0.03, 0.02 and -0.06 
mmol/L. These data suggest the absence of pronounced concentration-dependent effects 
for 2D NMR based quantifications. In summary, one can say that 2D NMR allows the 
accurate quantification of metabolites in standard samples. 
 
Comparison of NMR and Colorimetric and Enzymatic Urine 
Measurements 
The creatinine content of the above set of 50 urine samples was also analyzed 
enzymatically with the enzymatic PAP method and the Jaffe alkaline picrate colorimetric 
method by Thomas Bertsch and Christine Aschenneller of the Institute of Clinical 
Chemistry, Laboratory Medicine and Transfusion Medicine of the Klinikum Nürnberg 
(Nürnberg, Germany). The comparison to 2D NMR values is shown in Figure 17. 
 
As can be seen in Figure 17, 2D NMR results for creatinine correlated well (R2 > 0.99) with 
those obtained for both the PAP method (Figure 17A) and the Jaffe method (Figure 17B). 
Further analysis showed that the colorimetric and enzymatic methods yielded on average 
somewhat higher concentrations as indicated by the positive axis intercepts of 273 and 
245 µmol/L, respectively. This is also demonstrated by the Bland-Altman plots shown as 
insets in Figure 17, showing a systematic concentration dependence of the obtained 
deviations between 2D NMR and both the Biomed PAP and the Olympus Jaffe method. 
Overall, the best agreement was obtained between 2D NMR and the Biomed PAP method. 
Note that the 2D NMR data were additionally validated by spike-in experiments 
(Figure 16). For serum samples, it is known from the literature (Peake & Whiting 2006) 
that interference effects with the biological matrix can lead to an overestimation of 
creatinine values by both enzymatic and colorimetric methods. It is likely that similar 
effects in urine account, at least in part, for the observed differences between 2D NMR 
and the other two methods. 
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Figure 17. Linear regression and Bland-Altman plot of 2D NMR versus enzymatic (A) and 
colorimetric (B) concentrations [µmol/L] for creatinine in 50 urine samples.  
Adapted from (Gronwald et al. 2008). 
 
 
 
Comparison of NMR and GC-MS and LC-MS/MS Urine Measurements 
The set of 50 urine samples was also analyzed by means of GC-MS by Hannelore Kaspar 
as described in (Kaspar et al. 2008) and by means of LC-MS/MS by Stephan Fagerer as 
described in (Gronwald et al. 2008). The results are shown in Table 5 in Appendix I. One 
important urinary metabolite amenable to both NMR and GC-MS is hippuric acid 
(Holmes et al. 2008). Figure 18 shows the comparison of the corresponding NMR and GC-
MS results. As indicated by the high R2 value of 0.99, both methods allowed the precise 
determination of hippuric acid and showed a linear correlation over the entire observed 
concentration range of 372 - 5392 µmol/L. The slope of the linear regression curve of 0.94 
and the positive y-axis intercept of 115 µmol/L confirmed good concordance between 
NMR and GC-MS data. The Bland-Altman plot in Figure 18A reveals an even smaller 
mean difference of 22 µmol/L between the 2D NMR and GC-MS measurements. The 
diagram also demonstrates that in the lower concentration range 2D NMR yielded slightly 
lower values than GC-MS, while for the higher concentration range somewhat larger 
values were measured with 2D-NMR. However, this was a minor trend only and in 
summary both methods agreed well.  
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Figure 18. Linear regression and Bland-Altman plot of 2D NMR (x-axis) versus GC-MS (y-axis) 
concentrations [µmol/L] for hippurate in 50 urine samples. 2D NMR values were obtained by 
averaging the volume integrals of three separate signals for hippurate that had been calculated 
using either (A) independent calibration curves for each signal or (B) a single calibration for all 
three signals. The used atom numbering scheme for hippurate is shown as an inset in B.  
Adapted from (Gronwald et al. 2008). 
 
 
Figure 18 also illustrates the importance of generating separate calibration curves for each 
signal of a compound used for quantification in 2D NMR. As evidenced by the slope of 
the regression line, a considerable decrease from 0.94 (Figure 18A) to 0.81 (Figure 18B) 
was observed, when instead of three independent only one calibration curve generated 
for the CH group in para position of the aromatic ring (C8/H8) was used to calculate the 
peak volume integrals of the three non-overlapping signals recorded for hippurate. In this 
case, the use of a single calibration curve led to a significant overestimation of the urinary 
level of hippuric acid by 2D NMR with the mean difference of measurements between 
NMR and GC-MS increasing from 22 µmol/L, when using separate calibration curves for 
the three signals, to 404 µmol/L. The degree of overestimation was the more pronounced 
the greater the concentration of urinary hippuric acid as indicated in the Bland-Altman 
plot, which is also reflected by the increase in standard deviation of the mean difference 
from 156 to 347 µmol/L. Similar observations were made for other metabolites such as 
lysine, for which multiple signals were available for quantification.  
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An important group of urinary metabolites are free amino acids, which are well-known 
markers for inborn errors of metabolism (Constantinou et al. 2005). Figure 19 shows linear 
regression and Bland-Altman plots for the comparative analysis of urinary glycine values 
obtained by means of 2D NMR, GC-MS and LC-MS/MS, respectively.  
 
 
 
 
 
Figure 19. Linear regression and Bland-Altman plots of 2D NMR (x-axis) versus GC-MS (A) and 
LC-MS/MS (B) concentrations [µmol/L] for glycine in 50 urine samples.  
Adapted from (Gronwald et al. 2008). 
 
 
Over the observed concentration range of 355 - 1976 µmol/L, GC-MS and NMR correlated 
well with an R2 value of 0.98 (Figure 19A). As described for hippurate, NMR yielded in 
general slightly higher concentrations. When comparing NMR and LC-MS/MS data for 
glycine (Figure 19B), a similar correlation with an R2 value of 0.97 was obtained. As 
reflected by the slopes of the regression curves of 0.87 for GC-MS and 0.90 for LC-MS/MS, 
both methods obtained slightly lower values for glycine in the higher concentration range 
than 2D NMR. This is further supported by the Bland-Altman plots, which revealed mean 
differences between 2D NMR and GC-MS and 2D NMR and LC-MS/MS, respectively, of 
48 and -13 µmol/L. In general, good agreement was observed between 2D NMR, on the 
one hand, and GC-MS and LC-MS/MS data, on the other hand, as evidenced in Table 5 
(see Appendix I).  
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However, one can also observe that the degree of correlation decreases when the 2D NMR 
concentrations of a metabolite are close to its LLOQ in all urine samples (Table 2 in 
Appendix I). For 3-aminoisobutyrate, in many cases heavy signal overlap of the methyl 
group was observed in the 2D spectra, and therefore, these measurements were excluded 
from further analysis. As a consequence, the comparisons with other methods are based 
on relatively few data points and should be treated with care. Also, the possibility of 
using the non-overlapped but much weaker signal of the CH group alone for 
quantification was investigated. However, in this case, an increase of the LLOQ from 312 
to 1250 µmol/L was observed, which rendered this approach impractical. Note that for the 
corresponding GC-MS measurements no isotope labeled internal standard was available, 
which somewhat compromised the reliability of the GC-MS data. 
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Analysis of Urine from Patients with Inborn Errors of Metabolism 
2D NMR was applied to the analysis of urine samples collected from patients with inborn 
errors of metabolism provided by Dr. Herbert Korall from the Zentrum für 
Stoffwechseldiagnostik Reutlingen (Reutlingen, Germany). A striking example, namely 
the 2D 1H-13C HSQC spectrum of a urine sample from a patient suffering from 
aminoaciduria (Malakauskas et al. 2007), is shown in Figure 20. Aminoaciduria is a 
condition characterized by high urinary amino acid excretion that might occur in 
disorders such as Hartnup disease, Dent’s disease and Fanconi syndrome. As expected, 
the spectrum showed considerably increased amino acid levels. This sample and other 
samples from patients with inborn errors of metabolism were analyzed by Wolfram 
Gronwald, a discussion of these samples can be found in (Gronwald et al. 2008). 
 
 
 
 
Figure 20. 2D 1H-13C HSQC spectrum of a urine sample from an aminoaciduria patient. 
Adapted from (Gronwald et al. 2008). Abbreviations: β-AIB: Beta-aminoisobutyate;   
TSP: 3-Trimethylsilyl-2,2,3,3-tetradeuteropropionate 
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2.8 Measurement of Bovine Milk 
 
After the successful application of NMR to the analysis of urine, a protocol for the 
analysis of bovine milk was established. Cow’s milk has a complex composition, 
including large amounts of lipids and proteins. These macromolecules give rise to 
unspecific, broad signals in NMR spectra and thus hamper identification and 
quantification of small molecules. In addition, complex formation between the used NMR 
reference compound and proteins was observed, which resulted in a considerably 
diminished reference signal. To remove the macromolecules, different sample 
pretreatments were compared. This chapter has in parts already been published (Klein 
et al. 2010). 
 
A commonly used method for protein removal is ethanol precipitation. A large amount of 
ethanol is added, leading to reduced solubility and denaturation of the proteins. Here, 
3.6 mL of ethanol were added to 400 µL of milk and incubated for three hours at -20 °C. 
After centrifugation for 30 minutes at 4000 gravitational accelerations (g) at 4 °C, the 
liquid phase was removed from the pellet. The pellet was washed with ethanol and the 
liquid phase removed. The liquid phases were pooled, dried in an evaporator and 
redissolved in 400 µL pure water. 
 
A second method for protein removal is ultrafiltration. The solution is placed in a tube 
with a membrane consisting of regenerated cellulose. The solution is then forced through 
the membrane using centrifugation, leaving macromolecules behind. Millipore Amicon 
Ultra-4 (Millipore, Billerica, MA, USA) filter devices with a molecular weight cutoff of 
5 kilodalton (kDa) were used. The filter was rinsed with water to remove filter-preserving 
substances of the filter such as glycerol and triethylene glycol (TEG). Three mL of water 
were transferred into the filter device and centrifuged at 4000 g at ambient temperature 
for 60 minutes. The contaminated filtered water was removed and 1 mL of milk was 
transferred into the device. The samples were centrifuged at 4000 g at ambient 
temperature for 60 minutes. 
 
After both protein removal methods, 400 µL of sample were prepared and measured as 
described in Sections 2.4 and 2.5 for urine, with the exception of a reduced receiver gain 
due to the strong lactose signals. 2D HSQC spectra for untreated milk, precipitated milk 
and filtered milk are shown in Figure 21. In precipitated milk several prominent signals 
including citric acid are missing. In the filtered milk sample, these signals are clearly 
visible, indicating less changing of the sample. 
 
As the filters with 5 kDa cutoff had been discontinued meanwhile, Millipore Amicon 
ultrafiltration devices with molecular weight cutoffs of 3 and 10 kDa were tested for best 
metabolite recoveries. The filter with 3 kDa cutoff showed a lower recovery for some 
metabolites. This indicates that the filter is clotted by the macromolecules. In the 10 kDa 
filters, this effect was not observed. 10 kDa filters were chosen for all further analyses. The 
peak areas of the preserving substances contained in the filters, glycerol and TEG, were 
excluded from further analyses. To ensure that no other pollutants were present in the 
filters, spectra of the rinsing water were recorded, showing that only glycerol and TEG 
were present at noteworthy concentrations. 
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Figure 21. 2D 1H-13C HSQC NMR spectra of raw (A), ethanol precipitated (B) and  
ultrafiltrated cow’s milk (C), respectively. Prominent signals are marked. 
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Milk metabolite identification and quantification was performed as described for urine in 
Section 2.5. A summary of the obtained chemical shift data is provided in Table 6 (see 
Appendix I)  
 
Overlapping signals located in crowded regions of the milk spectra were excluded from 
the quantification process. Especially in the region close to the intensive lactose signals, 
considerable overlap was present in both 1D and 2D spectra. To gain individual 
calibration curves, standard stock solutions were serially diluted to yield final 
concentrations of 9000, 4500, 2250, 1125, 562.5, 281.3, 140.6, 70.3, 35.2, 17.6 and 8.8 µmol/L, 
and the corresponding spectra were acquired. The concentration range was extended to 
166 mmol/L for lactose. Signal volumes scale linearly over the whole range of 
concentrations, i.e. over five orders of magnitude.  
 
The number of signals that were used for compound identification is presented in Table 6 
(see Appendix I) and equals the number of measured calibration curves.  
 
LLOQ’s and TE’s 
LLOQ’s for the 2D 1H-13C HSQC and 1D 1H spectra were calculated from calibration 
standards. The LLOQ values for the individual compounds are given in Table 6 (see 
Appendix I). The lowest LLOQ values were obtained for compounds with multiple 
methyl groups such as betaine, where the protons of the methyl group(s) gave rise to a 
single signal in the corresponding 2D NMR spectra, or for compounds that were 
identified from 1D spectra. The LLOQ values obtained for 2D spectra of pure compounds 
were generally higher than those obtained for 1D spectra. 1D spectra were used for 
quantification of low-abundant compounds such as acetone and beta-hydroxybutyric acid 
(BHBA); hence, considerably lower LLOQ’s were obtained. From the calibration curves, it 
was obvious that measurements remained linear up to concentrations as high as 
166 mmol/L for lactose without readjusting the receiver gain. 
 
Sixty milk specimens were measured as technical replicates to check the precision in 
terms of TE of measurement. For metabolites with simple peak shapes TE’s of around 3 % 
for alanine were obtained in the 1D spectra, whereas complex multiplet peaks resulted in 
higher TE’s of up to 8 % as seen for glutamic acid. This may be due to imperfections of the 
used peak fitting methods and increased noise contributions due to the presence of very 
broad multiplets. In 2D spectra TE’s were observed in the range from 0.7 % for lactose up 
to 14.7 % for galactose-1-phosphate. Obviously, the TE was the lower the higher the 
observed metabolite concentration was. On average, the TE for 2D measurements was 
7.0 %. 
 
Freezing and Thawing 
During the analyses it became clear that freezing and thawing is a crucial point in the 
preparation of milk samples. Freezing and thawing may unmix the sample (Mai 1912). 
This leads to drastically increased or decreased concentration values, depending on the 
pipette tip position in the sample tube. This is especially obvious for lactose 
concentrations, as these are strongly physiologically regulated and show only little 
variation. Therefore, it is indispensable not only to vortex the sample after thawing, but to 
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turn the sample upside down three to four times to achieve a complete mixing of the 
content.  
 
Dependence of the Citric Acid Signals on pH Value 
The position of citric acid signals is sensitive to changes in pH and salt concentration. It 
has been reported for mouse and rat urine samples that the citric acid shift is linearly 
correlated to sample pH (Miyataka et al. 2007). Therefore, it was assessed whether this 
was true for milk samples as well. An equation describing the correlation of pH and citric 
acid shift was derived from (Miyataka et al. 2007): 
 
42.163)48.59( +−∗≈ SCpH  
 
SC is the shift of the citric acid signal in ppm. This equation was derived from data 
between pH 6.0 and pH 9.0. The shift was calculated as the mean signal position of the 
four citric acid signals at around 2.61 ppm. 
Next, milk samples showing large citric acid shifts were chosen. For these, pH was 
measured using a thin pH electrode (Mettler Toledo, Greifensee, Switzerland) both for the 
filtered milk samples and the filtered and buffered milk samples. Assessment of pH 
values in whole milk was not possible using the pH electrode to avoid membrane 
contamination with milk fat. A pH test was performed using pH test strips (Macherey-
Nagel, Düren, Germany) for the pH range of 6.0 to 7.7, but the narrow range of pH values 
in milk rendered the test being too rough for this purpose. 
Measured pH values for the filtered milk were pH 6.80 ± 0.11 (mean ± SD) and ranged 
between pH 6.61 and pH 7.00. After buffering, the pH was 7.10 ± 0.05 and ranged between 
pH 7.02 and pH 7.18, indicating that the buffer effectively reduces pH variations. Only a 
weak correlation between the measured pH and the pH calculated from the citric acid 
shift could be observed, though. This could either depend on the more narrow range of 
pH values detected in milk, or on the fact that other factors such as salt concentration 
dominated the citric acid signal shifting in milk. 
 
Long Term Stability 
The stability of filtered milk was investigated. Three milk specimens were filtered and 
split into five aliquots each. Each aliquot was prepared as described above and then either 
stored for time periods of one, three, seven and 14 days, respectively, or measured 
directly after preparation. This experiment was performed both at room temperature and 
at 4 °C, the temperature of the sample changer. 
 
Over the two-week period, only few metabolites, including galactose-1-phosphate, 
glycerophosphocholine (GPC) and phosphocholine (PC), showed minor changes in 
concentration when stored at room temperature, while most compounds studied were 
subject to strong and fast changes in concentration. Lactate, acetone, alanine and glutamic 
acid stayed constant for one day, but decreased rapidly thereafter. Methanol and acetic 
acid increased, beginning at three days of storage. Some compounds like creatinine, N-
acetyl-carbohydrates and phosphocreatine stayed almost constant for three to seven days 
and increased slightly thereafter. Acetoacetic acid decreased slowly, starting at day seven. 
Citric acid concentrations decreased almost exponentially during the observed period 
with an average decay constant of -0.0546 ± 0.0131 per day (n = 3), representing a half-
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value period of 12.7 ± 3.06 days. Additionally, citric acid peaks shifted during the 
observed period. A closer examination showed that not only a signal shift had occurred 
during storage, but also the inter-peak distanced had changed, indicating changes in pH 
and in the overall salt concentration in the sample. As seen above, the correlation between 
citric acid signal shift and pH is not strong in milk. Anyway, the data indicated a slight 
drop in pH value of about 0.1 during storage. 
The lactose signal showed an unexpected behavior during storage: An increase in 
concentration was observed, showing the shape of a saturation curve, with saturation 
reached around day 14. Lactose increased by 9.7 ± 1.2 mmol/L during the first seven days. 
The values for α- and β-lactose behaved in the same way. This behavior could in part be 
explained by a solution effect due to the more and more acidic conditions during storage. 
Taking a closer look at the samples, a small residue of undissolved substances could be 
found in the NMR tubes. This residue falls out from the filtered milk when the buffer is 
added. When the conditions of the samples become more acidic during storage, more 
substances from the residue can be dissolved, thus raising the observed concentrations. To 
prove this assumption, the residue was carefully separated from the liquid of the sample 
and redissolved in water. While most concentrations were in the expected range, lactose 
showed raised levels in the residue on the first day of room temperature storage and 
dropped to normal values until storage day three. 
 
In the samples stored at 4 °C, only few changes were observed during the first week of 
storage. Two exceptions were acetic acid, whose levels increased by 10.7 ± 7.8 %, and citric 
acid, whose levels on average decreased by 10.3 ± 1.0 % during the first three days of 
storage, respectively. After 14 days, stronger changes in milk composition became visible. 
These changes were similar to the changes seen in the samples stored at room 
temperature. 
 
These results show that even filtered milk is relatively unstable at room temperature and 
that the use of a cooled sample changer is indispensable for measurements of large 
sample numbers. 
 
Comparison of NMR and GC-MS Milk Measurements 
Alanine, BHBA, glycine, and lactic acid were quantified in a set of 106 milk samples (for 
details on the milk samples see Section 3.2). These metabolites were additionally analyzed 
by GC-MS by Martin Almstetter as described in (Klein et al. 2010). A comparison of the 
corresponding NMR and GC-MS data for glycine is shown in Figure 22.  
 
The high R2-value of 0.92 indicates that both methods allowed the precise determination 
of glycine over the entire concentration range of 0.033 to 1.109 mmol/L. The slope of the 
linear regression curve of 0.93 and the positive y-axis intercept of 0.018 mmol/L confirmed 
good concordance between NMR and GC-MS data. The Bland-Altman plot shown as an 
insert in Figure 22 reveals an even smaller mean difference of 0.04 mmol/L between the 
2D NMR and the GC-MS measurements. Similar results were obtained for alanine 
(slope = 0.84, intercept = 0.22, R2 = 0.65), BHBA (slope = 0.79, intercept = 0.017, R2 = 0.86) 
and lactic acid (slope = 0.91, intercept = 0.021, R2 = 0.96). In summary, NMR quantification 
results on milk showed high concordance with GC-MS data on the same metabolites. 
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Figure 22. Linear regression and Bland-Altman plot of concentrations [mmol/L] of glycine in milk 
specimens measured by 2D NMR and GC-MS. Adapted from (Klein et al. 2010). 
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2.9 Measurement of Tissue Extracts 
 
Tissues and cell culture samples cannot be easily analyzed as they are, because the 
complex structure induces strong magnetic field distortions that severely hamper 
spectrum inspection. Due to the hindered mobility of molecules in intact tissue, dipolar 
couplings and contributions from chemical shift anisotropy do not average out, leading to 
very broad lines. Additionally, molecules in the rigid cell parts lead to fast signal 
relaxation, resulting in very broad background signals. Two often applied means to 
circumvent these issues are magic angle spinning where the sample is rotated at a high 
rate to average out anisotropic effects and the other is to use liquid tissue extracts. Here, 
tissue extraction was chosen for NMR analysis. The suitability of NMR for the analysis of 
liver extracts has been demonstrated previously (Waters et al. 2002). For analyses of these 
samples, several approaches are possible.  
 
A methanol/chloroform extraction was chosen as it has the advantage that both 
hydrophilic and lipophilic compounds are accessible for separate measurements. Samples 
of about 50 mg were cut into pieces and placed in 600 µL methanol at 0 °C for 15 minutes. 
After this, the samples were sonicated for 10 seconds using an ultrasound lance (Sonopuls 
Homogenisator HD2070, Bandelin Electronic, Berlin, Germany), and 600 µL pure water 
and 600 µL chloroform were added. After four hours at -20 °C, samples were centrifuged 
at 20000 g for 30 minutes at 4 °C to separate the hydrophilic from the lipophilic phase. 
Following evaporation, the aqueous phase was dissolved in 400 µL of pure water and 
treated as described for urine samples in Section 2.5. The chloroform phase was dissolved 
in 650 µL of deuterated chloroform containing tetramethylsilane (TMS, Merck, Darmstadt, 
Germany) or octamethylcyclotetrasiloxane (OMS, Sigma-Aldrich, Taufkirchen, Germany) 
as internal standard (Oostendorp et al. 2006). 
 
Lipid Analyses 
As lipids give rise to broad and quite unspecific signals, area integration of 1D spectra 
was chosen to assess the lipid concentrations. Signal areas for typical lipid functional 
groups were determined using measurements of standard samples of saturated fatty 
acids, unsaturated fatty acids, triacylglycerides, phosphatidylcholine (PtC), cholesterol 
and cholesterol ester. The identified functional groups and the respective signal 
frequencies and molecular masses are shown in Table 7 (see Appendix I). The signals 
were integrated either relative to the signal of the chloroform fraction contained in 
deuterated chloroform, or relative to the OMS signal. 
 
The molar concentration of unsaturated fatty acid bonds was measured using the signal of 
methylene groups not adjacent to double bonds. The concentration of polyunsaturated 
bonds was assessed using the signal of methylene groups adjacent to two double bonds 
(diallylic group). The molar lipid content was assessed by integrating the glycerol signal 
present in lipids such as triacylglycerides and phospholipids. The total lipid concentration 
in terms of weight percentage was estimated by summing up all lipid signals including 
the glycerol resonance and multiplying each by the molar mass of the associated 
functional group. 
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To assess the composition of lipids, several indices were derived from the lipid signals. A 
saturation index (SI), a polyunsaturation index (PUI) and a ratio of polyunsaturated fatty 
acids to monounsaturated fatty acids (PUFA/MUFA) were defined as: 
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where the I’s are the integrals of the corresponding lipid signals (Serkova et al. 2006; 
Johnson et al. 2008; Cobbold et al. 2009). For details on the used signals see Table 7 in 
Appendix I. 
 
Looking closely at the spectra, it became obvious that the methylene-to-carboxyl signals of 
free fatty acids differ slightly from those of fatty acids that are part of triacylglycerides 
and phospholipids. This difference is due to the glycerol that is attached to the carboxyl 
group in the latter lipid classes. 
 
Some lipophilic metabolites could be quantified exactly using sharp, specific signals, 
namely PtC, cholesterol and cholesterol ester. These were integrated as described for 
urine metabolites. The corresponding frequency values can be found in Table 7 (see 
Appendix I). 
 
It was striking that the signals stemming from the choline group of PtC had much lower 
calibration factors than those of fatty acids, for details see the peak information file of 
QUANTIFY attached in Appendix II. This means that at the same concentration, the 
choline group will show a much lower signal than e.g. the methyl group of a fatty acid. 
This may be due to the rapid spin relaxation present in long-chain fatty acids, leading to 
strong signals in the beginning of the FID, with the choline group showing a slower 
decay. The slower-decaying but weaker choline signals get additionally weakened by the 
window function used to avoid FID truncations by reducing signals from the later parts of 
the FID. 
 
OMS as Internal Standard 
TMS is the commonly used frequency reference substance for NMR measurements of 
organic solvents such as chloroform. When using TMS as a concentration reference in 
chloroform liver extracts, high variance of replicate samples was observed. This is 
probably due to the volatility of TMS with a boiling point of 26 °C, causing strong 
concentration differences due to minimal differences in sample handling times. A 
common procedure to avoid these variances is to use the signal of residual protonated 
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chloroform in the deuterated chloroform as a concentration reference. This has two 
drawbacks: chloroform is volatile, too, and may therefore be present in different 
concentrations in different samples due to differences in pipetting. Secondly, the residual 
chloroform concentration is varying between different charges of deuterated chloroform. 
Therefore, OMS was tested as a substitute. The boiling point of OMS is 175 °C. 
 
To assess the precision of technical replicates, a mouse liver sample was extracted by 
Caridad Louis and the chloroform extract prepared with OMS as internal standard. The 
extract was measured 14 times on different days and stored at -20 °C between the 
measurements. The OMS integral was used as a concentration standard. RSD’s were 
calculated for all lipid signals. On average, the RSD was 2.3 ± 2.1 %. For comparison 
reasons, integrals were recalculated relative to the signal of residual protonated 
chloroform. Here, higher RSD’s of 3.5 ± 1.5 % were observed (mean over the RSD’s of all 
lipid signals ± SD). On average, using OMS reduced the RSD’s by 43.6 %. 
 
For analysis of the precision of extraction replicates, mouse liver was extracted repeatedly 
by Caridad Louis. Lipid signals were quantified as above. With chloroform as 
concentration reference, relative standard deviations of 10.0 ± 4.8 % were observed. When 
using OMS, the corresponding values dropped to 7.4 ± 0.5 %. This means that using OMS 
as concentration standard leads to lower variances in quantification results as compared 
to using chloroform as concentration standard. Additionally, these variances are of the 
same range for all signals analyzed, whereas different signals quantified relative to 
chloroform also have very different variances. 
 
These results show that using OMS as a concentration reference, reproducible 
quantification results can be achieved. Additionally, OMS can serve as a frequency 
calibration standard with its resonance frequency at 0.094 ppm for 1H and 0.7 ppm in the 
13C dimension. 
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2.10 Measurement of Blood Serum and Blood Plasma 
 
Blood is a very complex matrix, with solid, emulsified and solved contents. In plasma and 
serum, the solid compounds have been mostly removed. Still, a large amount of protein 
remains, which induces broad and unspecific NMR signals. There are several approaches 
to measure such samples. 
 
Ultrafiltration 
This approach is identical to the protocol for milk ultrafiltration described in Section 2.8. 
 
Pure Samples 
A simple approach is to mix 300 µL of plasma or serum with an equal amount of buffer. 
The buffer was prepared as follows: 0.4 g TSP, 10.05 g disodium phosphoric acid 
heptahydrate and 5 mL sodium azide (4 %) were dissolved in 380 mL water. The pH was 
adjusted to 7.4 with small amounts of 1 mol/L sodium hydroxide or hydrochloric acid. 
Water was added to reach a volume of 400 mL. After this, 100 mL deuterated water were 
added to yield a final volume of 500 mL of buffer. To remove the signals of 
macromolecules, a CPMG experiment was employed. The cpmgpr1d (Bruker BioSpin, 
Rheinstetten, Germany) pulse program was used to collect 65536 data points in 128 scans, 
an acquisition time of 3.07 seconds and a relaxation delay of 4.0 seconds. Four dummy 
scans were discarded at the beginning of each measurement. This resulted in a total 
acquisition time per spectrum of 15 minutes and 47 seconds. The number of loops was set 
to 128, resulting in a filtering delay of 76.8 milliseconds before the start of the FID 
acquisition. 
 
As the macromolecules bind to TSP, the reference signal is observed with a large line 
width and shifted from its original position. Additionally, its intensity is lowered 
dramatically, leading to a large concentration overestimation of the other metabolites. As 
a result, neither frequency calibration nor absolute quantification is possible in this way. 
Instead, frequencies were calibrated using the alanine doublet at 1.48 ppm.  
 
2D HSQC spectra were recorded in the same way as described in Section 2.4 for urine, 
showing only little disturbance caused by protein content, apart from reduced intensity 
and shifting of the TSP signal.  
 
As a first step, a relative quantification was performed, where the integrals were divided 
by the TSP integral. The calibration factors for pure compounds were divided by a factor 
of 1.56 to correct for the lowered intensity values caused by the filtering of the CPMG 
pulse program. This value was determined as the ratio of the alanine signal of a standard 
sample measured with the CPMG program divided by the alanine integral obtained using 
a 1D NOESY spectrum of the same sample. For absolute quantification, a solution of 
standard metabolites was prepared in the same way as the blood samples. This standard 
sample was measured before and after each batch of blood samples. For each sample, 
absolute TSP integrals were calculated. The previously obtained relative quantification 
results were corrected for each sample as follows: 
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where the c’s are the metabolite concentrations and the I’s represent the TSP integral of 
the sample or the mean of the TSP integrals of the standard samples, respectively. 
 
To develop a suitable protocol for measuring plasma and serum samples, different pulse 
programs and sample preparations were tested. The analyzed samples included mouse 
serum and cow plasma. 
 
Validation of Quantification Results 
To test the quantification results, a spike-in experiment was performed on three cow 
plasma samples. Different amounts of a solution containing common metabolites were 
added to the samples, resulting in concentration levels raised by 0.91, 0.45 or 0.23 mmol/L, 
respectively. These spiked plasma samples were then prepared both as pure samples with 
buffer addition as well as with ultrafiltration in order to compare the different preparation 
methods. When the quantification results were plotted against the expected 
concentrations, for all used preparation protocols and pulse programs linear responses 
were obtained with R² values near one. Except for the CPMG spectra of unfiltered plasma, 
the slope of the observed dose-response-curves was close to one, indicating correct 
quantification results. The only exception was citric acid, where lower mean slopes of 0.79 
(unfiltered samples) and 0.69 (filtered samples) were obtained, indicating consistently too 
low quantification values.  
In the CPMG spectra of unfiltered plasma, too low slope values were observed for all 
metabolites, usually in the range of 0.45. As the slope for HSQC spectra of unfiltered 
plasma were close to one, the effect observed in the CPMG spectra cannot be explained by 
binding of metabolites to proteins. 
 
Fourteen serum samples from dairy cows were provided by Stefanie Klinger of the 
Tierärztliche Hochschule Hannover (Hannover, Germany). Samples were prepared by 
ultrafiltration by Caridad Louis, and measured and quantified using 2D spectra. Glucose 
and BHBA were quantified photometrically by the staff of the Tierärztliche Hochschule 
Hannover (Hannover, Germany) using the Glucose Hexokinase Fluid 5+1 kit (mti 
diagnostics, Idstein, Germany) and the Ranbut kit (Randox Laboratories, Crumlin, Co. 
Antrim, UK), respectively. The comparison to 2D NMR quantification results is shown in 
Figure 23.  
 
As can be seen, the methods agree well with each other, with R2 values of 0.86 and 0.85 for 
glucose and BHBA, respectively. NMR showed slightly higher values, resulting in slopes 
of 1.10 for glucose and 1.04 for BHBA. This was possibly due to TSP binding to remaining 
low-molecular weight proteins. 
 
Long Term Stability 
Ten mouse serum specimens were provided by Claus Hellerbrand at the University Clinic 
of Regensburg (Regensburg, Germany). The samples were prepared and measured 
without filtering as described above. When the samples were measured again two weeks 
later after storage at -20 °C, strong differences were visible. Signals appeared or grew 
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strongly, for example at 3.6382, 3.6281, 3.6086, 3.2319, 3.2057 and 0.1664 ppm. On the other 
hand, signals at 2.2370, 1.9233, 1.3390 and 1.3279 ppm decreased in intensity. After storing 
these samples for two days in the cooled sample changer at 4 °C, these changes had 
increased again, thus meaning that the changes were not only due to freezing and 
thawing, but also occur at cooled storage. This means that untreated serum samples are 
subject to strong concentration changes, possibly due to residual enzyme activity.  
 
 
        
Figure 23. Comparison of serum quantification results by 2D NMR and photometric methods for 
glucose (A) and BHBA (B). 
 
 
Stability was assessed for unfiltered lithium heparin cow plasma. Two samples were 
stored for one week at -20 °C and 4 °C, respectively. As for serum, strong changes were 
visible, although to a smaller extent. Signals at 3.2043 ppm and 0.1634 ppm had increased 
both at -20 °C and 4 °C. Citric acid had decreased and shifted in position for both 
temperatures. A signal at 7.7969 ppm had shifted to 7.8005 ppm during sample storage at 
4 °C. During storage at -20 °C, no shifting was observed for this signal. 
 
A second experiment was performed on cow plasma samples that were ultrafiltrated by 
Caridad Louis. The samples were stored at 4 °C for one week. Interestingly, these samples 
showed much less time-dependent changes than the unfiltered samples mentioned above. 
No shifting was observed for the citric acid signal. Intensities stayed within a 20 %-margin 
after one week, indicating only slow changes, the most prominent increase was observed 
for signals a 3.2043 ppm and 0.1634 ppm. A slight frequency shift was observed for the 
signal at 7.8586 ppm that shifted to 7.8563 ppm after four days.  
 
These observations show that plasma is overall more stable than serum and that 
ultrafiltration seems to be a more convenient preparation method than measuring 
untreated samples. It has been shown recently that ultrafiltration also enables measuring 
low-intensity signals that are not visible in pure samples at all (Stolzenburg et al. 2011). 
 
Methanol/Chloroform Extraction 
For lipid measurements, plasma was extracted using the following protocol: 100 µL of 
plasma were added to 500 µL 2:1 chloroform/methanol mixture and vortexed. 100 µL of 
0.2 mol/L potassium chloride solution was added, and after vortexing the sample was 
centrifuged at ambient temperature at 5700 g for 10 minutes. The lower phase was 
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removed. Two washing steps were performed by adding chloroform/methanol mixture 
and repeating the above procedure. After each washing step, the lower phase was 
collected. The collected phases were pooled and dried under a stream of nitrogen. The 
residue was dissolved in 650 µL of deuterated chloroform with OMS as internal standard. 
Quantification was performed as described in Section 2.9. For PtC, results were validated 
by spike-in experiments. Known amounts of an aqueous PtC emulsion were added to the 
plasma sample prior to extraction. In comparison to the unspiked sample, the PtC 
concentration increased in the expected manner. 
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2.11 Data Preprocessing for Machine Learning Algorithms 
 
Due to the complex nature of NMR spectra, they are not easily interpreted by machine 
learning algorithms such as PCA, ICA and SVM. This renders preprocessing steps 
necessary.  
 
Spectral Binning 
One of the most common methods is spectral binning. Here, the spectrum is split into 
small areas called bins or buckets. For each bin, the contained signals are integrated. The 
bin is then assigned the integral value. Thereby, a less complex spectrum is created. This 
method compensates for small signal shifts caused by differences in pH and salt 
concentration. The signal that exhibits the highest inter-sample shifts is citric acid. The bin 
size should be at least the average peak width. Larger bins can correct larger signal shifts, 
but will result in loss of information as signals of different metabolites are summed up. 
Figure 24 shows an example for a binned spectrum. 
 
 
 
 
 
Figure 24. Exemplary binning shown for a section of a urinary 1D NMR spectrum. The spectrum 
(green line) is split into evenly spaced bins (black dotted line). For each bin the spectrum within the 
bin is integrated. 
 
 
Binning replaces a complex spectrum with a vector of integral values that can be more 
easily handled by computer algorithms. 1D spectra were evenly split into bins of 
0.01 ppm width using Amix 3.92 (Bruker BioSpin, Rheinstetten, Germany). For 2D HSQC 
spectra, a bin size of 1.50 ppm and 0.05 ppm was used in the 13C and the 1H direction, 
respectively. Bins were created in the regions between 150.00 - 5.00 ppm (13C direction) 
and 9.00 - 0.50 ppm (1H direction). The solvent area was excluded from the binning, for 
details see Table 8 in Appendix I. Urea caused a very broad peak due to proton exchange 
with the presaturated water protons. Therefore, the urea peak was excluded from binning 
as well. As methanol impurities were inconsistently present in different buffer batches, 
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the methanol signal was excluded from binning in case more than one buffer batch was 
used for the preparation of the analyzed sample set. 
 
In a PCA analysis on 2D spectra of milk samples, signals in the lactose region caused a 
group separation that seemed to have no biological background. This clustering is due to 
the fact that the lactose signal is higher by a factor of 104 compared to the smallest 
observed concentrations, and even small technical variances will lead to enormous 
differences. A typical technically caused SD of 3 % would yield a concentration difference 
of more than 4 mmol/L, this is still by a factor of 20 more than the smallest observed 
concentrations. Additionally, the large lactose signals cause large baseline fluctuations in 
their surroundings due to wiggles caused by technical imperfections in the FID’s. This is 
especially true for 2D spectra. The lactose region was therefore excluded from further 
analyses. In the filter used for milk ultrafiltration glycerol and TEG were present even 
after rinsing the filters with water. Therefore, the corresponding spectral regions were 
excluded from binning. All excluded areas can be found in Table 8 (see Appendix I). 
 
Scaling and Normalizing 
After binning, different scaling and normalization methods may be used (Kohl et al. 2011). 
These methods aim at removing disturbing technical or biological variances. 
 
One of the most basic methods is normalization to the sum of all bins of one spectrum. 
This shall correct for dilution effects such as in urine and for differences in signal 
intensities due to technical reasons. Each bin value is divided through the sum of all bin 
values. 
 
Another method commonly used for urine samples is normalization to creatinine content. 
As urine may be diluted in different specimens depending on the amount of water 
consumption of the individual, a compound is needed that is excreted in constant 
amounts throughout the day. Creatinine is usually chosen for this aim. In creatinine 
normalization, all bin intensities are divided by the intensity of one of the bin of the 
creatinine signals. 
 
Beside these very basic transformations, a plethora of other scaling and normalization 
methods is available. The most common transformations have been tested and compared 
recently by Stefanie Kohl (Kohl et al. 2011). For this publication, a Latin Square design 
was set up. A Latin Square design is a sample set that shall allow the assessment of the 
quality of data analysis methods. In this design, several compounds are spiked into 
aliquots of a reference sample in different concentrations. The difference to a dilution 
series is that all compounds added to one aliquot have different concentrations. In total, 
the sum of concentrations of added compounds is identical for each aliquot. This is done 
to avoid confusing effects that might occur when the aliquots have very differing overall 
concentrations in the end. Eight metabolites present in urine were chosen as spike-in 
compounds in a manner that their signals showed no overlapping regions. Aliquots of a 
reference urine sample were spiked with the chosen eight compounds by Nadine 
Nürnberger. Two Latin Square sets with different concentration ranges were prepared in 
this way. For the two sets, 1D 1H and 2D 1H-13C HSQC spectra were recorded. 
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3 Biomedical Application 
 
3.1 Autosomal Dominant Polycystic Kidney Disease 
 
In Chapter 2 it was shown that quantification results from 1D and 2D NMR spectra have a 
high accuracy and precision and that the spectra are well suited for disease analysis. 
Therefore, other meaningful applications of the technique were looked for. Autosomal 
dominant polycystic kidney disease (ADPKD) is an inherited kidney disease that leads to 
the formation of cysts in the kidney. These cysts are growing slowly, yet continuously, 
resulting in reduced kidney function and, eventually, kidney failure (Gabow 1993). As 
ADPKD is manifested in the kidney, changes in the urinary profile are to be expected. 
Therefore, ADPKD was chosen as an aim for an NMR-aided disease diagnosis approach. 
  
Urine specimens from 64 ADPKD patients, 46 healthy volunteers and 68 patients with 
other kidney diseases were provided by the University of Erlangen-Nürnberg (Nürnberg, 
Germany) and the University Clinic of Regensburg (Regensburg, Germany). Samples 
were prepared and measured as described in Sections 2.4 and 2.5. The spectra were 
evaluated using a support vector machine (SVM) by Wolfram Gronwald (Gronwald et al. 
2011). The SVM could distinguish between ADPKD patients and healthy controls as well 
as other kidney diseases with an accuracy of more than 85 %. Unknown discriminating 
compounds were identified jointly together with Wolfram Gronwald. Among the 
significantly different metabolites, methanol was the most unexpected one. To ensure that 
the observed signal really stems from methanol, several spike-in experiments were 
performed. Additionally, methanol was quantified by Liane Paul and Thomas Gilg at the 
Institute of Forensic Medicine, Ludwigs-Maximilians-University (Munich, Germany) 
using headspace-gas chromatography. These measurements confirmed the assumption 
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that raised methanol levels were observed for ADPKD patients. Other discriminating bins 
contained signals at typical protein signal positions. To confirm the identification as 
protein signals, CPMG spectra were recorded to remove the protein signals. In addition, 
an acid hydrolysis of the urine was performed by Caridad Louis to remove proteins. After 
hydrolysis, the samples were evaporated and redissolved in pure water. After pH 
adjustment, the samples were measured again. The concerning signals had disappeared, 
while amino acid signals had risen. By this result, the discriminating signals could be 
positively identified as protein signals. 
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3.2 Metabolic Differences Between Dairy Cow Breeds 
 
In the previous sections, NMR was successfully employed for metabolite quantification in 
urine samples and for discrimination of samples from human disease patients from 
healthy control samples. Besides projects considering human diseases, one of the main 
topics of this thesis is related to animal health issues, especially those of dairy cows. In the 
following sections, analyses performed on biofluid specimens collected from dairy cows 
are presented. The chemical analyses in this section were performed jointly with Martin 
Almstetter. They have in parts already been published (Klein et al. 2010) and are also part 
of the Ph.D. thesis of Martin Almstetter. 
  
Over the last few decades milk production in dairy cows has dramatically increased. 
However, this has been accompanied by a substantially raised rate of health and fertility 
problems (Pryce et al. 1997). The enhanced energy requirements during early lactation 
due to selection of high-yielding cows result in an increased allocation of available energy 
resources to milk synthesis and less to functions relevant to fertility and fitness 
(Hüttmann et al. 2009). If energy requirements exceed energy availability from daily food 
intake, body fat is mobilized (Banos et al. 2005), which is a physiological mammalian 
process. However, excessive mobilization is thought to play a major role in the increased 
occurrence of so-called production diseases. In addition, the presence of health problems 
has been related to the extent and duration of the energy deficit in early lactation (Collard 
et al. 2000).  
 
Production diseases are the main health issues in dairy cows, including ketosis, mastitis 
and ruminal acidosis, which lead to animal suffering, reduced longevity and economic 
loss (Ingvartsen et al. 2003). Ketosis is a condition where large amounts of ketone bodies 
(acetone, beta-hydroxybutyric acid (BHBA) and acetoacetic acid) are released into the 
blood stream (Geishauser et al. 2000). These ketones are formed in the liver from acetyl-
CoA from fatty acid breakdown and serve as energy sources in the body. Ruminal 
acidosis is the lowering of the pH value in the rumen below physiological levels caused 
by an imbalance between production and use of lactic acid. Ruminal acidosis is often 
caused by digestion of non-fiber carbohydrates from high grain diets (Huber 1976). 
Mastitis is an inflammation of the udder. The economic costs of production diseases 
amount for hundreds of millions of euro per year for France and the UK alone (Bishop 
et al. 2009).  
 
Measurement of selected milk constituents to monitor the udder health or the metabolic 
status of cows has attracted much attention in dairy research and is widely used on dairy 
farms. Milk somatic cell count (SCC) and N-acetyl-β-D-glucosaminidase activity are well-
known indicators of intramammary infections (Pyörälä 2003). Furthermore, the 
biochemical milk profile has been related to the health status of the cow and, in particular, 
to imbalances during early lactation (Duffield et al. 2009). Acetone, acetoacetic acid and 
BHBA in milk are biomarkers for subclinical ketosis. BHBA milk concentrations 
≥ 0.10 millimole per liter (mmol/L) indicate subclinical ketosis yielding a sensitivity, 
specificity and a positive and negative predictive value of 69, 95, 75 and 93 %, 
respectively. In another study, thresholds of 0.16 mmol/L for milk acetone and 
0.07 mmol/L for milk BHBA have been proposed (Enjalbert et al. 2001). On the basis of the 
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close interaction between blood circulation and milk secretion, changes in additional milk 
metabolites that have yet to be defined can be assumed to reflect the metabolic and health 
conditions of the cow and the mammary gland. Previously, both NMR (Belloque & Ramos 
2002; Hu et al. 2007) and gas chromatography-mass spectrometry (GC-MS) (Toso et al. 
2002; Boudonck et al. 2009) have been applied successfully to the analysis of compounds 
in commercially available milk samples. Here, NMR and GC-MS were applied to the 
determination of a total of 44 milk compounds in milk specimens obtained from 
individual dairy cows of two different breeds during early and late lactation, with an 
emphasis on metabolites related to energy metabolism. The ultimate aim of the study was 
to identify compounds that are highly correlated to the metabolic status of the individual 
animals.  
 
Collection of Milk Samples 
Morning milk specimens were collected by Steffi Wiedemann and Gregor Schlamberger 
from the Department of Physiology of the Technical University Munich (Freising, 
Germany) at two research farms from cow breeds representing different milk production 
levels. At the research farm Veitshof (Freising, Germany; farm #1), milk samples were 
collected from highly productive Brown Swiss cows with an average 305-day milk yield 
of 9200 kilogram (kg). Samples were collected for three groups of animals: 27 samples in 
early lactation (42.8 ± 25.3 days in milk (DIM)), seven samples in mid lactation 
(143.4 ± 21.5 DIM) and 24 samples in late lactation (345.7 ± 159.2 DIM). At the Bavarian 
State Research Center for Agriculture (Grub, Germany; farm #2), milk samples of 
Simmental Fleckvieh cows with an average 305-day milk yield of 8300 kg were collected. 
Twenty-eight samples were collected in early lactation (25.0 ± 12.3 DIM) and 20 samples 
were collected in late lactation (261.8 ± 41.3 DIM). All cows were offered ad libitum a 
partial total mixed ration (TMR) based on corn and grass silage. Concentrates were 
offered according to milk yield.  
 
One aliquot of the collected milk samples was analyzed by MPR Bayern (Wolnzach, 
Germany) for milk protein, fat, lactose, urea and pH by MilkoScan FT 6000 and for SCC 
by Fossomatic-FC. The second aliquot was defatted by centrifugation for 15 minutes at 
3000 gravitational accelerations (g) at a temperature of four degrees Celsius (°C), and skim 
milk was immediately stored at -20 °C until analysis. 
 
Twenty-three metabolites were quantified in the milk samples using one-dimensional 
(1D) and two-dimensional (2D) NMR. These metabolites were amenable to NMR analysis 
due to their high abundance respectively a high number of chemically equivalent protons 
giving rise to a single signal. Concentrations of amino acids, BHBA, glucose and citric acid 
were determined by means of GC-MS by Martin Almstetter (Klein et al. 2010). Analysis of 
the results was performed jointly with Martin Almstetter. Bland-Altman analyses were 
performed by Wolfram Gronwald. 
 
Analysis of Milk Metabolites 
The observed concentration range for each of the milk metabolites analyzed exclusively 
by NMR is given in Table 9 (see Appendix I). The ranges were calculated over all milk 
samples from both farms, and, because for some metabolites concentration values above 
their lower limit of quantification (LLOQ) were not available for all samples, no average 
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values and standard deviations are given. As expected from the literature, concentrations 
of lactose in milk fell within a relatively narrow concentration range of 118 to 160 mmol/L 
(Roginski & Fuquay 2004). In contrast, metabolites such as phosphocholine (PC) showed 
an almost 10-fold difference between the lowest (0.143 mmol/L) and the highest 
(1.355 mmol/L) concentration measured. 
 
Pearson correlation coefficients between the quantified metabolites were calculated and 
are shown in Table 10 (Appendix I). Significant correlations were marked, using 
conservative global limits for the correlation coefficient R above 0.5 and below -0.5. At the 
5 % level, statistical significance is generally reached with these R values for a sample size 
less than 20. For some metabolites up to 106 measurements above the individual LLOQ 
were available, while the number was considerably smaller for others. Therefore, these 
global limits for R ensured that only significant correlations were marked as such.  
 
Investigation of Metabolic Status During Early Lactation 
An important objective of this thesis was the measurement of metabolites that might serve 
as indicators of a metabolic imbalance during early lactation. In the following, metabolites 
quantified by NMR are reported and discussed. For analytes measured by GC-MS see 
(Klein et al. 2010) and the Ph.D. thesis of Martin Almstetter.  
 
Figure 25A shows the correlation between lactation day and observed acetone 
concentration for farm #1. Some cows yielded significantly increased acetone values above 
the threshold concentration for detection of subclinical ketosis of 0.16 mmol/L during the 
first days of lactation (Enjalbert et al. 2001). Drastically lower acetone values of about 
0.04 mmol/L were found for other cows at a similar lactation stage. Generally, acetone 
values decreased during the first 70 days of lactation and remained fairly constant 
thereafter. Figure 25B shows the correlation between acetone concentration and lactation 
day for farm #2. Here, only slightly increased acetone concentrations of up to 
0.088 mmol/L were observed for a few cows during the first 70 days of lactation. 
 
 
 
 
 
Figure 25. Correlation between lactation day and acetone concentration [mmol/L] for milk 
specimens from farm #1 (A) and farm #2 (B). To clarify the general trend of the data, potential 
regression lines were added. Adapted from (Klein et al. 2010). 
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Generally, the observed acetone concentrations were lower for cows from farm #2. During 
late lactation, average values of 0.024 mmol/L were observed for cows from farm #2, while 
the corresponding values for farm #1 were about 0.030 mmol/L. Similar but less 
pronounced effects were observed for BHBA (Figure 26). 
 
 
 
 
Figure 26. Correlation between lactation day and BHBA concentration [mmol/L] for milk 
specimens from farm #1 (A) and farm #2 (B). To clarify the general trend of the data, a potential 
regression line was added. Adapted from (Klein et al. 2010). 
 
 
In the early lactation period, increased values above the threshold concentration of 
70 µmol/L for the detection of subclinical ketosis (Enjalbert et al. 2001) were found in 29 
cows from farm #1. Note that for one cow increased BHBA values were obtained during 
late lactation, indicating a possible health problem. In contrast to farm #1, cows from farm 
#2 showed constant BHBA concentrations over the entire lactation period. Acetone and 
BHBA showed a good correlation over all cows, with a Pearson correlation coefficient of 
R = 0.69 (Table 10, Appendix I). 
 
This is in agreement with a published correlation of milk acetone to BHBA of R = 0.68 
(Enjalbert et al. 2001). Citric acid has been suggested as a marker of energy status in the 
dairy cow, being correlated with ketones in milk and de novo fatty acid synthesis (Baticz 
et al. 2002). This suggestion is supported by the data with an observed Pearson correlation 
coefficient of R = 0.45 between citric acid and acetone in milk and a corresponding 
correlation coefficient of R = 0.39 between citric acid and BHBA. Milk citric acid 
concentration has been found to vary widely throughout lactation (Garnsworthy et al. 
2006) depending on nutrition and season (Holt & Muir 1979). Generally, it is higher in 
early lactation and decreases gradually as lactation progresses (Konar et al. 1971). In the 
study reported here, citric acid remained fairly constant throughout lactation 
(6.270 ± 1.311 mmol/L), but concentrations that were determined by GC-MS were higher 
than those obtained by NMR in commercial milk in a previous study (Hu et al. 2007). In 
this context, it should be noted that citric acid was also determined by 2D NMR. 
However, spike-in experiments where known amounts of citric acid were added to milk 
showed that, for this metabolite, the GC-MS measurements were more accurate. One 
likely explanation for the observed discrepancies to the NMR measurements is that milk 
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citric acid is located in part in the colloidal phase of milk and, therefore, could not be 
determined by NMR. The analysis of specific metabolites throughout lactation showed 
increased PC concentrations for all cows in early lactation (Figure 27), with a maximum of 
1.355 and 0.991 mmol/L for cows from farm #1 and farm #2, respectively.  
 
 
 
 
Figure 27. Correlation between lactation day and PC concentration [mmol/L] for milk specimens 
from farm #1 (A) and farm #2 (B) as measured by 2D NMR. To clarify the general trend of the data, 
a potential regression line was added. Adapted from (Klein et al. 2010). 
 
 
Around day 70 of lactation, PC concentrations had decreased to approximately 
0.25 mmol/L at both farms and remained relatively constant thereafter. Note that in the 
last lactation third, PC concentrations had decreased below the LLOQ in some cows. PC is 
a precursor of choline and serves as its storage form within the cytosol. It showed a 
slightly negative correlation with DIM (R = -0.42). Choline values in early lactation were 
found to be somewhat lower than values from the last lactation third (R = 0.38). These 
findings agree only partly with those in human milk, where a distinct decrease during 
lactation in the concentrations of PC and free choline was found, but only for the first 90 
days and three weeks, respectively, after delivery (Holmes et al. 2000). Choline in milk 
can be derived by active uptake from maternal circulation (Chao et al. 1988) and from de 
novo synthesis within the mammary gland. Higher needs of dairy cows for the limiting 
amino acid methionine for transmethylation reactions and milk protein synthesis lead to 
altered methyl group metabolism (Pinotti et al. 2002). Choline plays an important role in 
the metabolic pathways of methyl groups via the tetrahydrofolate system, which might 
explain the correlation between milk protein content and free choline in milk (R = 0.50). 
Furthermore, it has been demonstrated previously that abomasal infusion of choline and 
administration or feeding of rumen-protected choline increases milk protein content 
(Sharma & Erdman 1989; Erdman & Sharma 1991). The quantification of N-acetyl-
carbohydrates (N-acetyl-lactosamine and N-acetyl-glucosamine) by NMR was described 
previously and values were in a similar range as those presented here (Hu et al. 2007). 
Acetyllactosamine is found in many glycoproteins and glycolipids. That might explain the 
correlation between N-acetylcarbohydrates and protein content in milk (R = 0.57) and 
between other membrane-associated analytes such as PC (R = 0.57) and betaine (R = 0.74). 
As seen in Figures 25, 26 and 27, metabolite concentrations differ between the two 
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analyzed breeds both in metabolites connected to energy metabolism such as acetone and 
in metabolites connected to other areas of the metabolism. To analyze these differences, 
metabolites were selected for which a sufficient number of measurements were available 
for the last lactation third. The median concentrations of most metabolites were higher in 
milk samples from Brown Swiss cows than from Simmental Fleckvieh cows. A metabolite 
that should remain almost constant is lactose and, as expected, almost no difference was 
observed between the two breeds. The metabolic differences observed between the herds 
are most likely associated with differences in breed and feed management. 
 
Correlations Between Milk and Plasma Metabolites 
Plasma samples from the animals analyzed above were provided from the Department of 
Physiology of the Technical University Munich (Freising, Germany). Plasma metabolites 
were quantified by means of GC-MS by Martin Almstetter. Martin Almstetter compared 
the plasma metabolite levels to the milk metabolite levels quantified by NMR and GC-MS. 
This work is currently being prepared for submission by Martin Almstetter. To assess the 
correlation between milk and plasma metabolites, an algorithm for correction of 
correlation coefficients according to partial correlations was developed as described in 
Section 2.3. The algorithm uses partial correlation coefficients to find significant “real” 
correlations, in the meaning that these correlations do not depend on correlations to a 
third metabolite that both metabolite in question share. The R code can be found in 
Appendix II. Results showed that metabolites connected to energy metabolism such as 
acetone and BHBA were highly correlated between plasma and milk, whereas most other 
metabolites do not show strong correlations. 
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3.3 Metabolic Predictors for Dairy Cow Health Status 
 
In the previous chapter, milk samples from two different herds were analyzed. However, 
for each animal, only one sample was available. As the results revealed partly 
pronounced changes in milk composition throughout lactation, a second study was 
performed on a large herd of highly productive Holstein-Friesian (HF) cows. For each 
animal, a time course of milk samples was measured to specifically search for metabolites 
that show prognostic potential with regard to animal health. This section has been 
published in part (Klein et al. 2011a).  
 
Of the production diseases, ketosis is one of the most common ailments. In milk, elevated 
levels of the ketone bodies BHBA, acetoacetate and acetone are accepted biomarkers for 
ketotic conditions (Geishauser et al. 2000; Enjalbert et al. 2001). However, currently no 
biomarkers are available that show long-term prognostic potential, i.e. which predict a 
cow’s susceptibility to ketosis during lactation prior to a rise in the milk levels of the 
ketone bodies. Such biomarkers are of great interest for an early treatment of susceptible 
animals and for the selection of metabolically stable animals for breeding purposes. 
Therefore, the detection of prognostic metabolic biomarkers was the aim of this study.  
 
Since milk can be collected on a routine and non-invasive basis, it is well suited for 
metabolic analyses in dairy cows (Klein et al. 2010). In this study, individual time series 
analyses of milk constituents were performed for animals from a herd of HF cows, 
reflecting levels and changes of milk metabolites during early and mid lactation. For all 
animals a complete description of health issues that had occurred during the study period 
was available. 
 
Collection of Milk and Plasma Samples 
Milk samples from HF cows were collected by the staff of the Karkendamm research farm 
(Bimöhlen, Germany) and provided by Nina Buttchereit from the Christian-Albrechts-
University (Kiel, Germany). Preselected high yielding cows with an average energy 
corrected milk yield of 32.8 ± 4.7 kg per day were investigated. The animals were offered a 
TMR ad libitum. To all cows in the first lactation fixed amounts of concentrates were 
offered until DIM 180 (average 2.3 ± 0.5 kg). Composition of TMR varied over the 
observation period. Crude protein, bypass protein and the net energy content for lactation 
(NEL) of TMR were kept relatively constant. NEL of TMR ranged between 6.9 and 7.2 
megajoule per kilogram (MJ/kg) of dry matter. A detailed overview of the feeding practice 
is given in a previous publication (Buttchereit et al. 2010a). 
 
From each cow weekly evening milk samples were collected during the first five weeks of 
lactation and an additional milk sample in month six postpartum (mid lactation). At this 
time point, performance data collected so far was evaluated by the research farm staff 
according to a bull dam test for a subset of cows in their first lactation. Under-performing 
cows were sent off the farm. For the remaining (heavily selected) animals, another milk 
sample was collected around day 305, prior to the cows being dried off. In total, 1587 milk 
samples were collected from 308 animals between October 2008 and June 2010. At the 
research farm in Karkendamm mostly cows in the first lactation are kept, resulting in a 
smaller number of animals from higher lactations. Note that due to various reasons (e.g. 
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serious health issues), a complete time series could not be obtained for all cows. Milk 
yield was recorded on a daily basis and milk composition was analyzed weekly based on 
samples from two consecutive milkings by the staff of the research farm. Animals were 
held with permission of the Christian-Albrechts-University (Kiel, Germany), and were 
treated in conformance with commonly practiced ethical standards. Breeding values for 
energy balance (EB) and fat-to-protein ratio (FPR) were estimated by Nina Buttchereit 
from the Christian-Albrechts-University (Kiel, Germany). 
 
Blood was drawn from the vena caudalis mediana into lithium heparin coated tubes at 
varying time points during the first five weeks of lactation. Plasma was prepared by 
immediately centrifuging the collection tube at 2800 g and 15 °C for 20 minutes. Plasma 
was stored at -80 °C until analysis. Milk samples were prepared and measured jointly 
with Sebastian Miemczyk, Ann-Kathrin Immervoll, Caridad Louis and Nadine 
Nürnberger. 
 
Choice of Milk Samples 
The selection step described above, the so-called bull dam test, changes the group 
composition drastically after lactation month six. Therefore, the milk samples from day 
305 were excluded from further analyses to avoid misleading correlation patterns 
resulting from group inhomogeneities (Köhler et al. 2002). 1267 milk specimens from 264 
animals in the first lactation and 232 milk specimens from 57 animals in lactation two to 
seven were chosen for further analysis. For the analysis of blood plasma metabolites, 88 
plasma specimens from different cows were analyzed. Of these, 66 samples were obtained 
for the investigation of hydrophilic metabolites. Lipophilic plasma metabolites were 
analyzed from the remaining 22 plasma samples collected in the second week of lactation.  
 
Observed Diseases 
Metadata for the cows were collected based on the data received from Nina Buttchereit. 
Considering only the animals from the first lactation, 51 out of 264 animals suffered from 
ruminal acidosis during the lactation. Fourteen out of 264 animals suffered from ketosis. 
Apart from these metabolic diseases, 90 of the 264 animals enrolled in the study suffered 
from mastitis at least once during the lactation. 57 of the total 308 animals had stayed 
healthy throughout the whole observed period. Animals diagnosed with mastitis were 
treated as acutely ill for five days, as the milk of diseased cows had to be discarded for 
five days on average. For the other diseases analyzed in this study, a time of eight days 
was used before an animal was classed as healthy again (Buttchereit 2011). All metabolic 
health issues diagnosed for animals in their first lactation are shown in Table 11 (see 
Appendix I). 
 
As animals were treated as soon as a diagnosis had been made, the samples marked as 
acutely ill may contain drug traces or may show other alterations due to treatment-related 
metabolic changes. Therefore, these samples were not a good base for searching 
biomarkers and were not used for discriminatory analyses. Instead, all samples from 
animals that suffered from a certain disease at least once during lactation were assigned to 
a diseased during lactation group. 
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Pre-Investigations 
An initial principal component analysis (PCA) analyses performed on samples from 
lactation month six showed a slight group separation mainly driven by the citric acid 
signal. The signal intensities showed no significant differences between the groups, but 
the citric acid signal showed shifts in position. pH values of 16 samples with extreme 
shifts of the citric acid signal were measured, but no significant differences between the 
groups observed in PCA were found. Possibly, the group separation depended more on 
other factors such as salt concentration. The groups observed showed no correlation to 
disease status. 
 
Main Investigations 
Milk metabolites were quantified as described in Section 2.8. In Table 12 (Appendix I), 
milk metabolite concentrations of cows in the first lactation are shown. Metabolites that 
could only be quantified with concentration values above the individual LLOQ in less 
than 20 % of the samples were excluded from further analyses. As can be seen, many 
compounds are subject to strong concentration changes during the first weeks of lactation.  
 
Time Series 
For ketone bodies, time series were analyzed. The animals that were not diagnosed as 
diseased at any time were used as a healthy control group. Most milk samples taken 
within one month before an acute ketosis showed raised levels of acetone and BHBA. For 
acetoacetic acid no clear trend was visible in this direction. At the time of an acute disease, 
acetone and BHBA levels had dropped strongly in all cases and were mostly in the 
normal range. As animals diagnosed with ketosis received either glucose infusions or 
orally administered glucoplastic substances, the drop in ketone bodies is most probably 
treatment-related. After acute disease, the ketone levels were in the range of the healthy 
control group. Two striking findings became obvious: Not all animals diagnosed with 
ketosis showed raised levels of acetone or BHBA before or during the disease. Ketosis had 
been diagnosed mostly based on the experience of the farm staff, not on laboratory tests. 
This raised the possibility of false positive diagnoses. The second finding was that even in 
the healthy control group more than 10 animals showed ketone levels above the threshold 
for subclinical ketosis. All of these animals had normal levels at mid-lactation. This might 
be due to undiagnosed ketosis, or due to the fact that this group of animals can cope 
better with negative energy balance and raised ketone levels. Ketone levels were generally 
higher in milk from HF cows than in milk from the Brown Swiss and Simmental Fleckvieh 
cows analyzed in Section 3.2. This fits with the finding that HF cows have the highest milk 
yield of these three breeds (Zobel et al. 2011). A high milk yield leads to high energy 
requirements and, thus, may lead to stronger negative energy balance, causing more body 
fat mobilization and ketosis. 
 
Searching for Genetic Subgroups 
The main aim of this study was the identification of metabolic factors indicating an 
inheritable long-time metabolic stability. In Section 3.2 it was shown that different animals 
of the same breed kept under identical conditions on the same farm coped quite 
differently with the metabolic stress of early lactation. Therefore, the presence of 
genetically different subgroups in the population analyzed here was suspected. It can be 
expected that within these subgroups metabolites connected directly or indirectly to the 
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respective genes are affected and that for some metabolites in each subgroup a distinct 
distribution of concentrations is observed. In turn, this will lead to non-normally 
distributed data when considering the whole population, with a distinct two-peak 
distribution in case of two subgroups. To test for this, milk samples from lactation month 
six were chosen, as the strong concentration fluctuations of milk constituents in the first 
lactation third had diminished which led to almost stable levels by then.  
 
All quantified milk compounds were tested for agreement with a normal distribution. For 
most compounds, normal distributions were found. In contrast, for GPC, fumarate and 
oxaloacetate, two-peak distributions were found with significant deviations from normal 
distributions with p-values of 0.014, 0.0025 and 5.8*10-6, respectively.  
 
In Figure 28, N-acetyl-carbohydrate (NAC) and GPC concentrations are shown as 
examples for normally and non-normally distributed compounds. A Gaussian 
distribution and a sum of two Gaussian distributions were used to approximate the 
observed data, respectively.  
 
 
 
 
Figure 28. Histograms of normally and non-normally distributed metabolite concentrations 
[mmol/L], exemplarily shown in (A) for NAC and in (B) for GPC in lactation month six of the first 
lactation. One respectively two Gaussian functions were fitted to illustrate the different 
distributions. The frequency values indicate the number of animals contributing to one bar of the 
shown histograms. Adapted from (Klein et al. 2011a). 
 
 
For each of the three non-normally distributed compounds, the population was divided 
into two subgroups with high respective low values. The threshold was calculated as the 
inter-peak minimum of the fitted sum of Gaussians.  
To assess the validity of the mentioned group classification, milk samples from other time 
points were analyzed. Only for GPC the difference in concentration levels was conserved 
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throughout the whole lactation, i.e. animals with high (respectively low) GPC values in 
mid lactation also had high (respectively low) GPC values in early and late lactation. This 
indicates that GPC is a robust measure for the underlying, metabolically differing, 
subgroups.  
Therefore, the subsequent analyses concentrated on the differences in GPC. For GPC, the 
calculated threshold was 0.87 mmol/L.  
Next, it was analyzed whether correlations between the GPC value and disease status 
were present. Animals were grouped for each disease into one of two groups: Group #1 
contained all animals that were diagnosed at least once considering the whole lactation 
period with a certain disease, e.g. ketosis, while group #2 contained all other animals. The 
subgroup with ketosis had significantly lower GPC values compared to the non-ketotic 
subgroup, with a p-value of 0.036. For the other metabolic diseases shown in Table 11 (see 
Appendix I), no significant correlations to GPC were found. The distributions of GPC for 
ketotic and non-ketotic animals are shown as a density plot in Figure 29. 
 
 
 
 
Figure 29. Distribution of GPC concentrations [mmol/L] for ketotic and non-ketotic cows in month 
six of the first lactation. The group of ketotic animals contained all animals that were diagnosed at 
least once with ketosis during the entire lactation period, while the non-ketotic animals stayed 
healthy throughout lactation. Both curves were normalized to a total area of one and were 
smoothed using a Gaussian kernel density estimator. Adapted from (Klein et al. 2011a). 
 
 
The figure shows that the concentration distributions differ both in range and maximum 
position between  ketotic and non-ketotic animals . The shoulders left of the maximum of 
the non-ketotic group and right of the maximum of the ketotic group are striking. The 
first shoulder might be caused by animals with an undiagnosed, subclinical ketosis. The 
second shoulder might then be due to healthy animals that were erroneously diagnosed 
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with ketosis. It is obvious that the maxima of the ketotic and the non-ketotic population 
correspond to the two peaks of the overall distribution seen in Figure 28. 
In the group of animals with above-threshold GPC levels, significantly lower PC 
concentrations were observed during the first four lactation weeks, with p-values of 0.013, 
2.5*10-5, 9.8*10-3 and 2.6*10-4, for week one, two, three and four, respectively. 
Due to the observed interdependence of GPC and PC, the ratio GPC/PC was calculated 
from the respective molar concentrations. For the GPC/PC ratio, density plots were 
calculated for ketotic and non-ketotic animals according to the definitions given above. As 
an example, the density plots for lactation week three are shown in Figure 30. 
 
 
 
 
Figure 30. GPC/PC ratios for ketotic and non-ketotic cows at week three of the first lactation. The 
group of ketotic animals contained all animals that were diagnosed at least once with ketosis 
during the entire lactation period, while the non-ketotic animals stayed healthy throughout 
lactation. Both curves were normalized to a total area of one and were smoothed using a Gaussian 
kernel density estimator. Adapted from (Klein et al. 2011a). 
 
 
The distributions of GPC/PC ratios for ketotic and non-ketotic animals are very similar 
concerning maximum and width, but differ in the right-hand tail for healthy animals. 
Obviously, animals with high GPC/PC ratios are less prone to ketosis. This effect can be 
seen in the first four weeks of lactation but vanishes later on. This is due to the fact that 
GPC and PC levels decrease almost exponentially during the first weeks of lactation, but 
as PC continues to drop, GPC levels start rising again around week five, approaching the 
starting concentration by mid lactation (Table 12 in Appendix I). 
The observations made so far clearly show that it is possible to define a threshold for the 
GPC/PC ratio above which healthy animals are safely detected. A ratio of 2.5 for GPC/PC 
was manually selected to identify healthy animals within the population. Using this 
threshold, the samples from the first four lactation weeks were classified. Most of the 
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animals that were above threshold dropped below threshold at least once during the first 
four lactation weeks. To take this into account, the GPC/PC ratio was determined several 
times during the first four weeks of lactation, and all animals showing ratios above 
threshold at least once were selected. This resulted in 41 out of 260 animals (16 %) with at 
least one milk sample above the threshold. 
No animal in this subgroup suffered from ketosis at any time during the entire lactation 
period, compared to an incidence of 6.4 % in the subgroup below threshold. This means 
that during the first few weeks of lactation a safe prognosis for animals that will not 
develop ketosis later on is possible based on the GPC/PC ratio. Correspondingly, acetone 
and BHBA values were lower in the high GPC/PC group during the first four lactation 
weeks, indicating lower incidence of acute subclinical ketosis in this group. The difference 
in acetone was significant in weeks one, three and four, with p-values of 4.6*10-2, 2.1*10-2 
and 4.1*10-3, respectively. The difference in BHBA was significant in weeks three and four, 
with p-values of 4.3*10-2 and 1.0*10-3, respectively. 
A low ketosis risk in the first lactation is expected to be predictive for the health during 
the next lactations, as high correlations have been observed between ketosis incidences in 
different lactations (Erb & Grohn 1988). In the analyzed data set, disease data from the 
second lactation was only available for four of the 41 animals above GPC/PC threshold in 
the first lactation period. None of these four had developed ketosis during the next 
lactation. Although this number is very low, it supports the idea that the GPC/PC ratio 
has predictive abilities for following lactations. 
Milk parameters were compared between the groups above and below GPC/PC threshold. 
Milk yield, fat and protein content of each animal were averaged over all measurements 
for week one to five and for month six. For milk yield and protein content no significant 
differences were observed between the groups at any time point. For fat content, the 
group above threshold showed lower values at all six time points. This difference was 
significant at all six time points with p-values of 1.4*10-3, 3.2*10-3, 1.0*10-2, 7.4*10-4, 4.2*10-5 
and 7.1*10-5, respectively. On average, the milk of animals above the threshold contained 
0.4 % less fat than milk from animals below threshold. The concentration values are 
shown in Table 13 (see Appendix I). 
 
As an alternative for using the GPC/PC ratio, in cases where no values from the first 
weeks of lactation are available, GPC concentrations from mid lactation were evaluated 
for their ketosis predictive power. From Figure 29 it is obvious that at high GPC values 
only healthy individuals are present. As a threshold, a value of equal or greater than 
1.2 mmol/L was chosen: 9.3 % of the samples lay above this threshold and no animal in 
this group had developed ketosis, compared to 7.5 % incidence in the group below 
threshold. Only one animal above the GPC/PC threshold was available from the second 
lactation. This animal had not developed ketosis during the second lactation, neither, 
again hinting at the predictive power of the measurement. Further comparison of Figures 
29 and 30 shows that by using the GPC/PC ratio substantially more animals can be 
detected than by GPC values alone. 
 
Correlations Between Milk Metabolites and EB and FPR Breeding Values 
EB and FPR are genetically determined (with low and moderate heritability, respectively) 
and have been shown to be associated with liability to metabolic disorders, with high EB 
and low FPR values being favorable (Buttchereit et al. 2010b; Buttchereit 2011). Breeding 
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values provide estimates whether the progeny of an animal will have desired or 
undesired values considering a certain feature, for example disease liability or milk yield. 
Breeding values for EB and FPR were estimated for the animals in this study by Nina 
Buttchereit from the Christian-Albrechts-University (Kiel, Germany) as described in 
(Klein et al. 2011a). Breeding values for FPR were multiplied by (-1) as a low FPR is 
considered to be preferable. Milk GPC, PC and GPC/PC values determined in this study 
were analyzed for correlations with EB and FPR breeding values.  
 
For EB breeding values, only GPC showed a significant positive correlation (p = 4.1*10-3). 
For FPR breeding values, all correlations were significant, with p-values of 1.8*10-3, 1.0*10-
8 and 5.5*10-8 for PC, GPC and GPC/PC, respectively. High GPC values and low PC values 
were connected to high FPR values. Please note that high FPR breeding values indicate 
low fat-to-protein ratios due to the definition of FPR breeding values. FPR can serve as an 
indicator whether cows can or cannot adapt to the challenge of early lactation (Buttchereit 
et al. 2010b). This fits with the finding of GPC and PC values being indicators for 
susceptibility to ketosis. 
 
Plasma Analyses 
Next, hydrophilic metabolites in 66 plasma specimens collected within the first five weeks 
of lactation were analyzed. No PC values could be obtained above the LLOQ. For GPC, 
values of 5.3 ± 1.9 µmol/L (mean ± standard deviation (SD), n = 23) were observed. 
However, no significant correlation between blood and milk GPC was observed. As GPC 
is formed in the breakdown of phosphatidylcholine (PtC), PtC concentrations were 
estimated for 22 plasma samples obtained in the second week of lactation. For this, the 
choline content of lipophilic plasma extracts was quantified (Cheung & Olson 1990). The 
observed concentrations ranged between 59.4 and 970 µmol/L. Obtained values were 
validated by spike-in experiments and extraction of aqueous PtC emulsions. Blood PtC 
was positively correlated to milk PC and negatively correlated to milk GPC and milk 
GPC/PC ratios with Spearman correlation coefficients of R = 0.35, -0.37 and -0.38, 
respectively. However, these correlations were not significant at the 5 % level with p-
values of 0.12, 0.10 and 0.092, respectively. Free fatty acids were quantified in plasma, but 
no significant differences could be observed. The corresponding signals were close to the 
noise level and thus not very reliable, though. 
 
Validation of the Results 
In the following, the results obtained so far were validated on additional groups of 
animals. As the threshold of 2.5 for the GPC/PC ratio was based only on samples from the 
HF herd that were collected during the first lactation, milk samples from higher lactations 
(lactation two to seven) of the same herd were analyzed as well. Although this group 
contained only samples from 57 animals, a similar distribution with a tail of healthy 
animals at high GPC/PC ratios was observed. However, one of the samples with a 
GPC/PC ratio above threshold came from a diseased animal, leading to 5.0 % ketotic 
animals in the group above threshold, compared to 11 % ketosis incidence in the group 
below threshold. Odds ratios were calculated as described in Section 2.3. An odds ratio of 
2.38 was found, indicating a more than double ketosis risk in the group below the 
threshold. The acetone and BHBA values were generally lower in the high GPC/PC 
group, indicating a lower incidence of acute ketosis, although this difference was not 
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significant. When looking at GPC concentrations at mid lactation, 5.3 % of the animals 
were above the threshold of 1.2 mmol/L. None of these animals developed ketosis during 
the lactation, compared to 11 % incidence in the group below threshold. These findings 
indicate that the suggested thresholds generally hold true even for higher lactations of the 
observed breed. 
In a second step, the animal collective presented in Section 3.2 was re-evaluated. For the 
herd of 31 Brown Swiss cows, 22 % of the animals were above the GPC/PC threshold 
during the first four weeks of lactation. For this herd only severe diseases had been 
recorded. One of the observed animals was downed (unable to stand) due to ketosis. This 
animal was in the group below threshold, consistent with the assumption of low ketosis 
risk in the group above threshold. The subgroup above threshold had significantly lower 
acetone and BHBA levels with p-values of 0.030 and 0.012, respectively. This indicates a 
lower incidence of acute subclinical ketosis in the subgroup above the threshold. 
In the 39 Simmental Fleckvieh cows from the same study, 73 % of the animals were above 
the GPC/PC threshold in the first weeks of lactation. This high number of animals above 
threshold fits with the finding that this breed has drastically lower acetone and BHBA 
values in early lactation compared to Brown Swiss and HF cows, implying considerably 
lower ketosis susceptibility in this breed. Ketosis values were not available for this herd, 
but animals downed due to metabolic diseases were recorded. The number of animals 
downed at least once during this lactation was 20 % for the subgroup below threshold 
and 14 % in the group above threshold, corresponding to an odds ratio of 1.5. This means 
that high GPC/PC values are favorable even concerning overall metabolic health. 
In the Brown Swiss herd, the GPC values at mid and late lactation were above the 
threshold for 86 % of the samples, and in the Simmental Fleckvieh herd 90 % were above 
the GPC threshold in late lactation. These numbers are much higher than those obtained 
for the corresponding GPC/PC ratios. It seems that the absolute GPC value is varying 
greatly between different breeds, depending on different milk yields and breed-specific 
differences in milk composition, and that using the GPC/PC ratio corrects for the 
differences in absolute concentration levels. 
 
Cortisol Values 
Cortisol values were measured in a subset of the milk samples by Heike Kliem from the 
Department of Physiology of the Technical University Munich (Freising, Germany). 
Cortisol values from the first half of the first lactation were analyzed for correlations using 
Spearman rank correlation coefficients and a Benjamini-Hochberg false discovery rate 
(FDR) of 5 % as a significance threshold. Significant correlations were found for the 
energy markers acetone (Spearman R = 0.19, p = 5.5*10-4), BHBA (Spearman R = 0.23, p = 
7.7*10-5) and acetoacetic acid (Spearman R = 0.20, p = 1.1*10-3). This means that cortisol 
values may be markers for energy disbalance, with raised values in acute ketosis. Other 
significant correlations were observed for lactose content (Spearman R = -0.16, p = 4.9*10-
3), glycine (Spearman R = 0.27, p = 8.2*10-5) and galactose-1-phosphate (Spearman R = 0.15, 
p = 1.5*10-2). Cortisol has been described to prevent lactose leakage from the mammary 
epithelium into the blood plasma (Stelwagen et al. 1998). This might explain the positive 
correlation between cortisol and milk lactose content. An increase in plasma glycine of 
lactating cows has been shown upon administration of adrenocorticotrophic hormone to 
increase plasma cortisol values (Ndibualonji et al. 1995).  
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Discussion 
GPC is an osmolyte that is accumulated in renal medulla cells to protect the cells against 
high interstitial salt and urea concentrations present in the kidney (Gallazzini & Burg 
2009). GPC is formed in the breakdown of PtC, the connected synthesis and catabolism 
pathway is shown in Figure 31 (Gallazzini & Burg 2009; Iorio et al. 2005). This pathway is 
active in many body tissues, including mammary tissue (Holmes-McNary et al. 1996). The 
mammary gland has been shown to break down blood PtC to GPC and free fatty acids to 
gain fatty acids for the synthesis of milk triacylglycerides and phospholipids (Easter et al. 
1970). Therefore, the measured milk GPC probably stems from mammary gland 
breakdown of blood PtC. This assumption is supported by the negative correlation of 
blood PtC to milk GPC values. As no correlation was found between milk GPC and 
plasma GPC, the GPC found in milk is probably not GPC absorbed from the blood 
stream. In comparison to blood GPC values reported for humans (Ilcol et al. 2005), 
considerably lower values were observed in the bovine plasma. The same is true for PtC, 
where the bovine plasma values of this study are distinctively lower than those 
previously published on other animals (Easter et al. 1970; Kuksis et al. 1983). As expected 
from literature values reported for human specimens (Ilcol et al. 2005) no bovine plasma 
PC values were observed above the LLOQ. 
 
 
 
 
Figure 31. The main parts of the GPC pathway. Adapted from (Klein et al. 2011a). 
Abbreviations: CDP: Cytidine diphosphate; Cho: Choline; ck: Choline kinase; ct: Cytidylyltransferase;  
lpl: Lysophospholipase; nte: Neuropathy target esterase; pct: Phosphocholine transferase;  
pla: Phospholipase A2 and A1; plb/c/d: Phospholipase B/C/D; pd: Glycerophosphocholine phosphodiesterase 
 
 
Changes concerning GPC and PC levels have been reported in a wide range of research. 
Hypoxia, which is present in many cancers, is known to cause raised PC levels, whereas 
GPC levels are not affected (Glunde et al. 2008). A change of the GPC/PC ratio has been 
noticed for cancer and immortalized cell lines of humans. There, in comparison to healthy 
cells, a decrease in the GPC/PC ratio has been observed (Iorio et al. 2005; Podo 1999; 
Aboagye & Bhujwalla 1999). In tumors, PtC degradation via phospholipase C (plc), 
respectively phospholipase D (pld) and subsequent choline kinase (ck) are the main 
3 Biomedical Application 3.3 Metabolic Predictors for Dairy Cow Health Status 
 
77 
causes of changed PC levels (Iorio et al. 2010). An increase of GPC and a decrease in PC 
was observed in mouse cell lines under a slow acidosis, i.e. lowering the pH from 7.3 to 6.5 
for around 12 hours (Galons et al. 1995). They suggested as an explanation for this so-
called GPC to PC switch the activation of phospholipid breakdown as an alternative 
energy source for the cells, as glycolysis was hampered due to the low pH. The 
breakdown of PtC via phospholipase A2  and A1 (pla) and lysophospholipase (lpl) 
respectively phospholipase B (plb) subsequently leads to GPC accumulation. Recently it 
has been shown that plb is identical to neuropathy target esterase (nte) (Gallazzini et al. 
2008). In renal medulla, the pathway via plb/nte has been shown to be the dominant way 
of PtC breakdown for GPC production (Gallazzini & Burg 2009). Regarding the 
differences observed in milk between ketotic and non-ketotic animals, these most closely 
resemble the changes observed in the slow acidosis experiment by (Galons et al. 1995). 
However, no hints for acidic conditions were observed in the investigated bovine plasma 
samples.  
The differences observed in this study between healthy animals and animals suffering 
from ketosis can be summarized as follows: Healthy animals have higher levels of milk 
GPC and lower levels of milk PC. The animals were divided into two groups according to 
their GPC/PC ratio. The subgroup with high GPC/PC ratios showed lower plasma PtC 
levels and lower milk fat levels. 
 
Based on these observations, a possible explanation for the positive effect of high GPC 
values might be as follows. High GPC/PC ratios and GPC concentrations, respectively, are 
caused by a high rate of blood PtC breakdown, possibly due to higher enzyme 
concentrations or activities of pla and lpl, respectively plb/nte. These animals can, 
therefore, use more blood PtC as a fatty acid source for milk lipids. It has been previously 
shown that fatty acids derived from blood PtC may be utilized by the mammary gland for 
milk triacylglyceride synthesis (Easter et al. 1970).  
An alternative source for fatty acids for milk lipid synthesis are free blood fatty acids. Free 
blood fatty acids are produced by the mobilization of body fat, with excessive body fat 
mobilization being suspected to decrease the food intake of cows (Ingvartsen & Andersen 
2000). In addition, body fat mobilization leads to the formation of ketone bodies such as 
acetone and BHBA in the liver. Using more PtC for milk lipid synthesis, and thus saving 
free blood fatty acids, may, therefore, lower the body fat mobilization. Animals with 
lower fat mobilization will suffer less from the negative side effects such as the decrease in 
food intake. This, in turn, has positive effects on the energy balance and thus prevents 
metabolic diseases. Additionally, in animals with high GPC/PC ratios a decreased milk fat 
content was observed. These two effects together, namely high blood PtC breakdown as 
evidenced by high GPC/PC ratios together with lower milk fat content, will lead to a 
decreased mobilization of body fat. Animals with lower PtC breakdown rates will 
develop a more negative energy balance and a higher body fat mobilization during the 
first weeks of lactation, leading to a higher risk of metabolic disorders. The assumption of 
a constantly higher PtC breakdown in the high GPC/PC group is backed by the fact that 
GPC shows high levels not only during the negative energy balance of the first lactation 
weeks, but throughout the whole lactation period. 
Selecting animals with high GPC/PC or GPC values should yield animals that can cope 
better with the negative energy balance of the first lactation weeks and, therefore, are less 
prone to ketosis. The significant correlations between FPR based breeding values and PC, 
GPC and GPC/PC levels indicate that the observed metabolic differences are directly 
3 Biomedical Application 3.3 Metabolic Predictors for Dairy Cow Health Status 
 
78 
connected to genetic discrepancies and, therefore, a heritability of these effects can be 
expected. 
 
Conclusions 
Taking all results obtained so far into account, the ratio of GPC to PC during the first four 
weeks of lactation and the concentration of GPC at mid lactation may serve as markers to 
identify cows that cope well with metabolic stress. These data suggest that the GPC/PC 
threshold for determining ketosis risk could be universally applicable, being independent 
of lactation number, breed or feeding conditions. The chosen GPC threshold seems to be 
applicable only for HF cows, and will need to be individually recalculated for other 
breeds. To the best of my knowledge, this is the first report of GPC and PC values 
indicating the ketosis risk in dairy cows. The measurement of GPC and PC is superior to 
using just thresholds for acetone and BHBA, as these values can only identify acute 
ketosis (Enjalbert et al. 2001). In contrast, the method proposed here allows the early 
identification of metabolically stable animals that are not prone to ketosis for breeding 
purposes. 
 
Reconsidering the milk samples analyzed in this thesis, it could be shown that NMR is a 
versatile tool for the investigation of the health status of dairy cows. In three different 
breeds metabolites representative for the health status of the cows were analyzed. Based 
on the analysis of metabolites of energy metabolism it could be shown that animals of the 
same breed cope quite differently with the metabolic stress of early lactation. Most 
interestingly it was possible to predict the risk for developing ketosis based on GPC/PC 
values, with odds ratios between 1.5 and 2.38, although these ratios are based on a very 
low number of animals and may therefore be imprecise. Taken together these findings 
should help in selecting metabolically stable animals for breeding purposes.  
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3.4 Nonalcoholic Fatty Liver Disease and Steatohepatitis 
 
In the previous chapters it was discussed that during the first lactation days dairy cows 
needed more energy than food intake could deliver (Collins & Reid 1980). To compensate 
for this negative balance, first glycogen and then lipids are mobilized as energy source. 
This puts great pressure on the organism, especially on the liver metabolism. Mobilized 
lipids are transported to the liver for subsequent metabolization. When the amount of 
mobilized lipids is too high or insufficient energy supplies for the metabolization are 
available, the lipids accumulate in the liver and lead to steatosis (Kalaitzakis et al. 2010). 
Steatosis has a quite benign prognosis but may develop into a steatohepatitis, where 
inflammation and accumulation of fibers are observed in the liver. To distinguish this 
ailment from steatohepatitis caused by alcohol abuse, it is usually referred to as non-
alcoholic steatohepatitis (NASH). NASH has a malign prognosis and may develop further 
to liver cirrhosis. The causes of NASH are still mostly unknown. To gain more insight into 
the pathophysiology of NASH, samples from a murine NASH model were analyzed and 
compared to a mouse model for steatosis and a healthy mouse control group. This chapter 
has in part already been published (Klein et al. 2011b). 
 
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of hepatic 
dysfunction affecting about one third of the population in western countries. The 
spectrum of NAFLD ranges from simple fatty liver to NASH, in which fibrosis may 
progress to cirrhosis, resulting in significant morbidity and mortality (Brunt 2010). 
 
Sonography is commonly used to assess hepatic steatosis (Saverymuttu et al. 1986). 
However, it does not allow a distinction between simple steatosis and NASH. Therefore, 
assessment of the degree of inflammation and hepatic fibrosis, which are hallmarks of 
NASH, still requires the histopathological examination of liver biopsies (Adams & Lindor 
2007).  
 
The aim of this study was the detection of metabolic changes associated with NAFLD and 
NASH in mouse livers and urine by NMR measurements. Urine measurements are a 
noninvasive tool and liver analyses may also be performed noninvasively using in vivo 
NMR spectroscopy. In this study, however, liver extracts were used for liver analysis. The 
NMR measurements were combined with subsequent independent component analysis 
(ICA). To that end, three groups of BALB/c mice were studied: A healthy control group, a 
group suffering from NAFLD without significant inflammation and a group diseased 
with NASH.  
 
Collection of Mouse Urine and Liver Samples 
Christoph Dorn at the University Clinic Regensburg (Regensburg, Germany) provided 
liver and urine specimens from male BALB/c mice. Three equal groups of six animals each 
were fed for 12 weeks either a control diet, a high-fat diet (HFD) containing 30 weight 
percent (wt%) lard or a so-called Paigen diet containing in addition to 30 wt% lard 
1.25 wt% cholesterol and 0.5 wt% sodium cholate (ssniff Spezialdiäten GmbH, Soest, 
Germany). As shown recently (Dorn et al. 2010a; Dorn et al. 2010b), both HFD’s induce 
significant steatosis, while hepatic inflammation is only observed in the Paigen group. 
Liver tissue and urine specimens were stored at -80 °C. All animals received human care 
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and the study protocols complied with guidelines of the central animal facility at the 
University of Regensburg (Regensburg, Germany). 
 
Urine specimens of 30 microliter (µL) to 100 µL were prepared jointly with Ann-Kathrin 
Immervoll as described in Section 2.5. Liver specimens of approximately 30 milligram 
were extracted by Ann-Kathrin Immervoll as described in Section 2.9. Urine, lipophilic 
and hydrophilic liver extracts were measured by 1D and 2D NMR. Spectra were binned 
and normalized to a total sum of one. No further scaling was performed on the data.  
 
NMR Analysis of Lipophilic Liver Extracts 
To gain deeper insight in the data, ICA was performed for each sample type. Figure 32 
shows the ICA of 1D NMR fingerprints of the chloroform liver extracts of six mice each 
fed a standard chow or diets inducing simple steatosis and NASH, respectively.  
 
 
 
 
Figure 32. ICA of 1D NMR spectra of lipophilic liver extracts 
Circles: Standard chow; Squares: Steatosis-inducing diet; Triangles: NASH-inducing diet.  
Abbreviations: IC 1: First independent component; IC 2: Second independent component. 
Adapted from (Klein et al. 2011b). 
 
 
A complete group separation was achieved. In Figure 33, a typical 1D spectrum of a 
lipophilic liver extract from a NASH mouse (Figure 33A) is compared to a spectrum-like 
visualization of the loading factors obtained for the first two independent components 
(IC’s). Positive areas in Figures 33B and 33C indicate correlated signals, while negative 
areas are anti-correlated. 
 
An ICA of the 2D spectra of the chloroform extracts also yielded a complete group 
separation (Figure 34). The IC’s of the 2D spectra were used to identify the compounds 
distinguishing the groups. To that end, the 25 highest rated bins of each of the two shown 
IC’s were further analyzed (for loadings see Tables 14 and 15 in Appendix I).  
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To verify that these bins contained indeed the group separating information, all but the 25 
highest ranked bins of each IC were set to 0 and multiplied by the so-called un-mixing 
matrix of the original ICA. The resulting group separation was almost identical to that 
obtained with the original data (Figure 35). 
 
 
 
 
Figure 33. 1D NMR spectrum of a lipophilic liver extract and derived IC loadings.  
A: Exemplary NMR spectrum of a lipophilic liver extract of a mouse NASH model in the 
0.75 - 5.3 ppm region; Loadings of IC 1 (B) and IC 2 (C). Adapted from (Klein et al. 2011b). 
 
 
 
 
 
Figure 34. ICA of 2D NMR spectra of lipophilic liver extracts.  
Circles: Standard chow; Squares: Steatosis-inducing diet; Triangles: NASH-inducing diet. 
Abbreviations: IC 1: First independent component; IC 2: Second independent component. 
Adapted from (Klein et al. 2011b). 
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The separation of the steatosis model from the other two groups in IC 1 depended mostly 
on an elevated signal at 1.26 ppm, which was attributed to the fatty acyl protons of the 
methylene groups of both free and esterified fatty acids. Several signals, belonging to free 
cholesterol, cholesterol ester and lipids, accounted for the group separation in the second 
dimension. The lipid signals resulted again mostly from the lipid methylene resonance, 
but some of the signals also originated from monounsaturated and polyunsaturated fatty 
acids. Of the highest rated bins, these compounds explained all but one unknown peak at 
1.135 ppm. 
 
 
 
 
Figure 35. ICA reconstructions based only on the 25 best 1D bins of the two used IC’s.  
A: Lipophilic liver extracts; B: Hydrophilic liver extracts; C: Urine.  
Circles: Standard chow; Squares: Steatosis-inducing diet; Triangles: NASH-inducing diet.  
Abbreviations: IC 1: First independent component; IC 2: Second independent component; IC 4: 
Fourth independent component; IC 5: Fifth independent component. 
Adapted from (Klein et al. 2011b). 
 
 
The concentrations of the substances identified as discriminatory by the ICA were 
measured and are shown in Table 16 (see Appendix I). Due to technical reasons, three 
spectra were excluded from quantification. Cholesterol ester showed a more than 20-fold 
increase in NASH mice compared to the control group. Free cholesterol was also 
significantly increased in the NASH group. No significant differences for free cholesterol 
and cholesterol ester were found between controls and the steatosis group. 
 
For the lipid signals, the trend is not clear. While some signals are positively correlated to 
the cholesterol signal, others show a negative correlation. This indicates not only a change 
in the overall concentration, but also in the composition of lipids. The estimated total lipid 
content (Table 16, Appendix I) was increased in both HFD groups, albeit not significantly, 
with the highest values in the NASH group. The molar concentration of the glycerol 
group contained in lipids such as triacylglycerides and phospholipids was also increased, 
albeit not significantly, with the highest values observed in the steatosis model. 
 
Next, the saturation index (SI), the polyunsaturation index (PUI) and the ratio of poly-
unsaturated fatty acids to monounsaturated fatty acids (PUFA/MUFA) were estimated 
from the lipid signals (Table 16 in Appendix I). The SI was significantly elevated in both 
the steatosis and the NASH group. The PUI was significantly decreased in the steatosis 
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group and lowest in the NASH group. A significant decrease of the PUFA/MUFA score 
was observed in both NAFLD groups, as the composition of lipids shifted from 
polyunsaturated to monounsaturated fatty acids. Significant reductions of 38 % (p = 
3.0*10-3) and 51 % (p = 5.3*10-4), respectively, were observed for the concentrations of 
polyunsaturated bonds in the steatosis and NASH groups. The value determined for 
unsaturated bonds includes both lipids with mono- and polyunsaturated bonds. Since the 
amount of polyunsaturated bonds can be determined from the diallylic signal, the amount 
of lipids with monounsaturated bonds can be estimated indirectly. As the total amount of 
unsaturated bindings showed no significant difference it can be assumed that the decrease 
in polyunsaturated bonds in the NAFLD groups was connected with a simultaneous 
increase in MUFA concentrations. 
 
For the highest ranked bins, a heatmap was generated (Figure 36). The values of the bins 
were represented by a color code, where high, median and low values were depicted as 
yellow, black and blue, respectively. A hierarchical clustering seen at the top of the figure 
sorted the samples into their correct groups, once again showing a clear group separation. 
 
 
 
 
Figure 36. Heatmap of the highest ranked 1D bins of the lipophilic liver extracts.  
Blue: Low values; Black: Medium values; Yellow: High values. Adapted from (Klein et al. 2011b). 
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Hydrophilic Liver Extracts 
Next, the 1D NMR spectra of the aqueous liver extracts were analyzed by ICA (Figure 37). 
A clear clustering of the three groups, albeit not as complete as for the chloroform 
extracts, was observed. In IC 1, a partial separation is apparent between all three groups. 
IC 2 further discriminated the steatosis group from the other two groups. The use of 2D 
spectra did not improve the group separation. 
 
 
 
 
Figure 37. ICA of 1D NMR spectra of hydrophilic liver extracts.  
Circles: Standard chow; Squares: Steatosis-inducing diet; Triangles: NASH-inducing diet.  
Abbreviations: IC 1: First independent component; IC 2: Second independent component. 
Adapted from (Klein et al. 2011b). 
 
 
In Figure 38A, a spectrum of an aqueous NASH liver extract is shown together with the 
separating IC’s (Figures 38B and 38C). The 25 highest loadings for each of these IC’s are 
shown in the Tables 17 and 18 in Appendix I. Betaine, glucose and taurine could be 
identified as discriminatory metabolites. Other peaks contributing to group separation 
were tentatively identified as isoleucine, lactate, leucine and valine. Amongst the highest 
rated bins of both IC’s, 19 bins could be assigned to specific compounds. 
 
Betaine, lactate and taurine showed high loadings in both dimensions. Isoleucine, leucine 
and valine were found in IC 1, thus separating all three groups. Glucose showed high 
values only in IC 2 and separated the steatosis group from the other two groups. 
Quantitative data for the metabolites identified, except for betaine that could not be 
measured above the LLOQ, and the p-values for the analysis of variance (ANOVA) tests 
and all t-statistics are given in Table 19 (see Appendix I). For taurine significantly 
increased values were found in the steatosis group compared to both the control and the 
NASH group. 
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Figure 38. 1D NMR spectrum of a hydrophilic liver extract and derived IC loadings.  
A: Exemplary NMR spectrum of a hydrophilic liver extract of a NASH model mouse in the 
1.0 - 8.5 ppm region; Loadings of IC 1 (B) and IC 2 (C). Abbreviations: Leu: Leucine; Ile: Isoleucine; 
Val: Valine. Adapted from (Klein et al. 2011b). 
 
 
Urine Samples 
Next, nine urine specimens from the control group, four from the steatosis model and five 
from the NASH model were analyzed. The difference in the number of samples analyzed 
per group was due to the inability to obtain sufficient amounts of urine from all animals 
studied and the inclusion of additional controls held under identical conditions, 
respectively. An ICA of the urinary NMR spectra is shown in Figure 39.  
 
Samples from the second cohort were marked as empty circles in Figure 39 as it has been  
shown previously that different cohorts of the same strain of animals can differ in 
differential analyses (Schnackenberg et al. 2007; Jahns et al. 2009). A complete separation 
of the three groups was achieved by a single IC (IC 5), with IC 4 adding to the separation 
of the steatosis group. Note, IC’s 1 to 3 reflect inter-sample variance not related to 
steatosis and NASH.  
 
An exemplary NASH urine spectrum is shown in Figure 40A, together with the loadings 
of IC 4 and IC 5 (Figures 40B and 40C). In Tables 20 and 21 (see Appendix I), the highest 
loading factors are shown. Ascorbic acid, citric acid, creatinine, leucine, phenylalanine, 
phosphocreatine, taurine, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) 
showed up in both ICA’s performed on 1D and 2D NMR data and, therefore, were 
considered as unambiguously identified. Signals with high loadings only in the ICA 
performed on 1D NMR data were tentatively identified as ethanolamine and isoleucine. 
These metabolites represented 40 of the highest ranked bins.  
 
While most metabolites showed high loadings in both dimensions, ethanolamine, 
phenylalanine and phosphocreatine were found only in IC 5; they facilitated the 
separation of all three groups seen in Figure 39. Leucine showed high loadings only in IC 
4 and separated the steatosis group from the other two groups. In Table 22 in Appendix I, 
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quantitative results and p-values of the ANOVA tests and all t-statistics for these 
compounds are shown. 
 
 
 
 
Figure 39. ICA of urinary 1D NMR spectra.  
Circles: Standard chow; Squares: Steatosis-inducing diet; Triangles: NASH-inducing diet. 
Abbreviations: IC 4: Fourth independent component; IC 5: Fifth independent component. 
The filled and empty circles represent the first and second cohort of the control group, respectively. 
Adapted from (Klein et al. 2011b). 
 
 
 
 
 
Figure 40. 1D NMR spectrum of urine and derived IC loadings.  
A: Exemplary NMR spectrum of urine recorded for a NASH model mouse in the 1.0 - 8.7 ppm 
region; Loadings of IC 4 (B) and IC 5 (C). Adapted from (Klein et al. 2011b). 
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Discussion of the NASH Analyses 
 
Analysis of Liver Tissue 
Free cholesterol and cholesterol ester were significantly increased in the lipophilic liver 
extracts of NASH mice over controls and mice with simple steatosis. A similar increase in 
free cholesterol has been reported for chloroform/methanol extracts of human NASH liver 
biopsies (Puri et al. 2007). The latter study, however, failed to detect the significant 
increase in cholesterol ester observed in the present study. Another striking difference 
between human NAFLD and the BALB/c mouse model studied here concerns the absence 
of a significant increase in di- and triacylglycerol, which is generally considered a 
hallmark of human NAFLD (Puri et al. 2007). Both studies observed a decreased ratio of 
PUFA to MUFA in NAFLD. But in contrast to the human situation, there was a systematic 
decrease in the concentration of PUFA, both in this and a previously reported mouse 
model (Cobbold et al. 2009). A reduced PUFA/MUFA ratio is considered a marker of lipid 
peroxidation in association with oxidative stress (Serkova et al. 2006). 
The behavior of the saturation and polyunsaturation indices (Table 16 in Appendix I) 
agrees with the finding that SI and PUI are correlated and anti-correlated, respectively, 
with the fibrosis grade in hepatitis C patients (Cobbold et al. 2010). It is noteworthy that a 
similar trend was observed in both humans and mice. The significant increase in the lipid 
methylene resonance observed in animals fed a HFD (Table 14 in Appendix I) is in 
concordance with the previously reported increased expression levels of fatty acid 
synthase in an identical mouse model of simple steatosis (Dorn et al. 2010b).  
ICA of the aqueous liver extracts showed increased levels of betaine, an intermediate of 
the methionine cycle, in the NASH model, probably reflecting an impaired conversion of 
homocysteine to methionine (Abdelmalek et al. 2009). In contrast, lactic acid 
concentrations were significantly (p = 2.05*10-2) decreased in the NASH model compared 
to the mice with simple steatosis, indicating that adaptive glycolysis was upregulated in 
the latter model. In a study of obese Zucker rats, increased lactic acid levels were 
observed in both blood and liver tissues compared to lean controls (Serkova et al. 2006), 
while an in vitro study on hepatocytes isolated from obese and lean Zucker rats showed 
the opposite effect (Seoane et al. 1999). These findings together with the data of this study 
indicate that regulation of glycolysis depends on a variety of factors and might change as 
the disease progresses. 
Taurine is of interest, because its administration in rats and children has proven effective 
in treating fatty liver (Chen et al. 2006; Obinata et al. 1996). In the present study, taurine 
was significantly elevated in the hydrophilic liver extracts of the steatosis group as 
compared to the other two groups (Table 19, Appendix I), probably in response to the 
oxidative stress associated with HFD intake. The comparatively lower levels of taurine in 
the NASH model, on the other hand, may be either a consequence of increased 
tauroconjugation in response to an increased dietary intake of sodium cholate (Hardison 
& Proffitt 1977), or a sign of increased microbial degradation of taurine due to obesity-
associated changes in gut flora composition (Turnbaugh et al. 2006; Backus et al. 1994). 
 
Analysis of Urine 
Literature search indicates that this may be the first report on the successful 
discrimination of simple steatosis from NASH based on changes in the composition of 
urine. Previous studies had reported only the successful discrimination of NAFLD from 
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healthy controls in mice using NMR metabolite fingerprinting (Dumas et al. 2006), 
respectively of human NASH patients from controls on the basis of elevated urinary 
levels of neopterin (Yaman et al. 2005), an indicator of activated immune cells, and 8-
isoprostane (Kojima et al. 2007), a marker of oxidative stress due to increased lipid 
peroxidation. 
Among the discriminating urinary metabolites found here was ascorbic acid. In contrast 
to humans, mice can synthesize ascorbic acid. Urinary levels of ascorbic acid were 
increased slightly, albeit significantly with a p-value of 3.33*10-2 in the NAFLD group 
(Table 22 in Appendix I). This agrees with the finding of increased ascorbic acid synthesis 
in mice suffering from health problems (Mårtensson & Meister 1992). In humans, liver 
disease is typically associated with decreased urinary levels of ascorbic acid (Dubey et al. 
1987). 
Urinary levels of citric acid were significantly decreased in both steatosis and NASH, with 
respective p-values of 2.53*10-3 and 3.33*10-3. In a recent study on mice, an elevated 
expression of hepatic ATP-citrate lyase was linked to a derangement of the lipid 
metabolism (Wang et al. 2009). Urinary levels of leucine were also significantly decreased, 
as a result of either a reduced dietary intake of leucine, as 30 % of the standard chow had 
been replaced with lard, or an increased demand of leucine for processes such as the 
synthesis of alanine and glutamine and the maintenance of glucose homeostasis. For 
phenylalanine, a somewhat different picture was observed; its urinary concentration was 
decreased significantly only in the steatosis model, but did not differ between the control 
and the NASH group. 
For phosphocreatine, reduced urinary values were seen in both steatosis and NASH mice. 
Phosphocreatine acts as a store and transporter of high-energy phosphate. The reduced 
urinary levels seen here may be due to dietary reasons: About half of the daily 
requirement of creatine comes from dietary intake, while the remainder is synthesized 
from glycine, arginine and methionine, the content of all being reduced in the HFD. 
Urinary levels of taurine were significantly reduced in both steatosis and NASH mice, 
with respective p-values of 5.48*10-4 and 2.39*10-4. Taurine forms conjugates with cholic 
acid and chenodeoxycholic acid, thereby ensuring that they are negatively charged at the 
pH found in the intestinal tract and, thus, improving their surfactant properties. As the 
amount of tauroconjugated bile acids will rise with increasing dietary fat intake, levels of 
free taurine will decrease (Hardison & Proffitt 1977). The reduced renal excretion of 
taurine may also be caused by its increased microbial degradation in the intestine as a 
result of obesity-associated changes in gut microflora composition (Turnbaugh et al. 2006; 
Backus et al. 1994). 
For TMA decreased levels were observed for both HFD groups. TMA is a product of the 
metabolism of dietary choline by intestinal bacteria (Zeisel et al. 1989). Both HFD’s 
contained reduced amounts of choline. As a consequence, the observed differences in 
TMA levels were most probably due to dietary effects. However, urinary levels of 
microbiota-derived methylamines may vary significantly depending on the mouse strain 
used to study the pathophysiological effects of fat feeding (Dumas et al. 2006). 
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3.5 Analysis of Early Liver Disease Progression  
 
A second mouse model of NASH was analyzed. Here, female C57/BL6 mice were fed 
either a NASH-inducing Paigen diet or a control diet. The aim of this study was the 
assessment of early disease progression. Animals were sacrificed at day two, four, six, 10, 
14, 20, 30 and 40, and liver samples were collected. Samples were provided by Anja 
Thomas, sample extraction was performed jointly with Anja Thomas, Ann-Kathrin 
Immervoll and Caridad Louis as described in Section 2.9. For lipophilic liver extracts, 1D 
spectra were recorded, while for hydrophilic extracts both 1D and 2D spectra were 
acquired. The differences observed between the NASH group and the control group were 
similar to those observed for BALB/c mice described in Section 3.4. One interesting 
observation was that already after two days of feeding, a significantly higher hepatic 
triacylglyceride content was observed for the NASH group, as evidenced by the glycerol 
content of lipophilic extracts. In the BALB/c mice, no significant difference in glycerol was 
observed even after 12 weeks of Paigen diet. This fits with the finding that C57/BL6 mice 
show much stronger HFD-induced metabolic changes than BALB/c mice (Olson et al. 
2010). Additionally, a stronger difference in liver taurine levels was observed in the 
C57/BL6 mice as compared to BALB/c mice, with taurine being significantly decreased in 
the NASH group. The importance of taurine in liver diseases has been pointed out in 
Section 3.4. Other findings of the studies performed by Anja Thomas showed that while 
signs of hepatic steatosis are visible very fast, inflammatory and fibrotic conditions were 
not seen before day 40 (data to be published). This fits with the finding from the study on 
BALB/c mice, where taurine was significantly decreased in the steatosis group, but not in 
the NASH group. 
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4 Summary 
 
Three specific aims were pursued in this thesis. The first aim was to elucidate whether 
reliable quantification can be performed using nuclear magnetic resonance (NMR) spectra 
of complex biofluids. Novel quantification methods were developed using two-
dimensional (2D) proton-carbon-13 (1H-13C) heteronuclear single quantum coherence 
(HSQC) spectra acquired at natural 13C-abundance by means of a cryo-probe. It was 
shown that these 2D spectra allow the reliable quantification of metabolites present in 
native urine samples at micromole per liter (µmol/L) levels over a concentration range 
spanning three orders of magnitude. As shown by the results presented for the analysis of 
urinary metabolites, one-dimensional (1D) NMR is often not as quantitatively accurate as 
2D NMR. However, the price for this gain in accuracy is a longer NMR acquisition time. 
Precision and accuracy of 2D NMR measurements increase with the number of well-
resolved signals integrated per analyte provided that separate calibration curves are 
generated for the different signals. A software tool named QUANTIFY was developed to 
overcome some of the pitfalls of NMR quantification from biofluids, such as unforeseen 
signal overlap due to metabolites inconsistently present in the samples. Lower limits of 
quantification (LLOQ’s) were found to be the lowest for metabolites containing multiple 
methyl groups such as trimethylamine-N-oxide. Including quantification results from 1D 
spectra, the range of reliably measured concentrations spanned five orders of magnitude. 
Limits of detection may be further lowered by moving to higher field strengths or by 
using considerably longer measurement times. NMR quantification results were found to 
agree well with those obtained by mass spectrometry (MS) and other methods commonly 
used in clinical chemistry. NMR measurements are less prone to errors due to interfering 
compounds or matrix effects including ion suppression, which are common occurrences 
in the mass spectrometric analysis of complex biological matrixes. Further, while 
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hyphenated MS methods are more sensitive than NMR, their application is typically 
limited to compounds sharing similar physicochemical properties. In contrast, NMR is a 
more universal detector as exemplified by the different metabolites that could be detected 
in this thesis. The comparison of NMR results obtained for urine and milk spectra with 
both gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) measurements showed a good agreement 
between the methods.  
 
The second specific aim was to identify whether the health status of an individual gives 
rise to a distinct change in its body fluid composition, and if this change is within the 
scope of the used measurement techniques. One main topic of this thesis was related to 
the health status of dairy cows. In this context two extensive sets of milk samples derived 
from three different breeds of dairy cows were investigated. With regard to human 
diseases, non-alcoholic steatohepatitis (NASH) was investigated in samples derived from 
a mouse model. In addition, human urinary samples were measured for the analysis of 
autosomal dominant polycystic kidney disease. However, data analysis of the latter 
samples was beyond the scope of this thesis. 
With regard to the project on NASH, male BALB/c mice were fed for 12 weeks either a 
control or two different high-fat diets leading to hepatic steatosis and NASH, respectively. 
Metabolic differences were determined by independent component analysis (ICA) of 
NMR spectra of lipophilic and hydrophilic liver extracts and urine specimens. The results 
from ICA clearly discriminated the three investigated groups. Discriminatory biomarkers 
in the lipophilic liver extracts were free cholesterol, cholesterol ester and lipid methylene. 
Discrimination of the hydrophilic liver extracts was mainly mediated by betaine, glucose 
and lactate, whereas in urine taurine, trimethylamine-N-oxide and trimethylamine were 
the most discriminatory biomarkers. In summary, a clear discrimination between the 
three investigated groups of mice was obtained. Especially, NMR metabolite 
fingerprinting of spot urine samples allowed the noninvasive distinction of NASH and 
steatosis. This is of special interest, as this might pave the way for a non-invasive 
diagnosis of NASH. At the moment, a definitive diagnosis of NASH still requires a liver 
biopsy. Whether these results from mouse strains will hold true for humans will require 
further studies. 
 
In the set of milk samples from Brown Swiss and Simmental Fleckvieh cows, the 
abundance of numerous milk metabolites in early and late lactation was systematically 
investigated, with an emphasis on metabolites related to energy metabolism. The aim of 
the study was the identification and correlation of milk constituents to the metabolic 
status of the cows. To investigate the influence of lactation stage on physiological and 
metabolic variables, two breeds of different productivity were selected. Forty-four 
different milk metabolites could be reliably quantified. Large differences in concentrations 
of known biomarkers of energy metabolism such as acetone and beta-hydroxybutyric acid 
were observed during early lactation, indicating that individual animals cope very 
differently with the metabolic stress in this period. This was particularly true for high-
producing animals that yielded highly discrepant values for these markers. These two 
sample sets demonstrate the ability of NMR to identify profiles of different metabolic 
states of an organism, and that the distinguishing molecules may be deduced from these 
profiles. 
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The third specific aim concerned the prediction of so-called production diseases in 
lactating dairy cows on the basis of metabolic fingerprints of milk and other physiological 
fluids.. Results from a herd of Holstein-Friesian cows showed a high predictive potential 
for two milk compounds, namely glycerophosphocholine (GPC) and phosphocholine (PC) 
that are well-known milk constituents. GPC and PC are part of the phosphatidylcholine 
(PtC) breakdown pathway (Holmes-McNary et al. 1996). High PtC breakdown seems to 
be beneficial concerning the ketosis risk, possibly due to a reduced need for fatty acids 
from body fat mobilization. Although GPC and PC levels have been previously assessed 
using a variety of methods, including high pressure liquid chromatography and GC-MS 
(Pomfret et al. 1989), NMR (Govindaraju et al. 2000) and enzymatic assays (Chap et al. 
1988; Murray et al. 1990) their relation to production diseases such as ketosis was not 
known so far. Results were validated on samples obtained from two other breeds, namely 
Brown Swiss and Simmental Fleckvieh, indicating the general applicability of the 
findings. This shows that NMR analyses are not only able to identify metabolites with 
prognostic value, but that new hypotheses for (patho-)physiological mechanisms may be 
deduced using NMR results. 
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Table 1. Analysis of Human Urinary Metabolites: Chemical Shift Values of Urinary 
Metabolites for the High-Resolution 2D 1H-13C HSQC Spectrum of a Healthy Control 
Urine Specimen (Figure 11). Adapted from (Gronwald et al. 2011). 
 
13C Frequency  
[ppm] 
1H Frequency  
[ppm] 
Compound 
36.74 3.74 
30.62 3.23 
30.62 3.20 
30.62 3.15 
30.62 3.12 
1-methylhistidine 
123.12 7.10 1-methylhistidine/anserine 
51.43 4.48 1-methylnicotinamide 
118.28 7.01 2,5-furandicarboxylic acid 
24.14 1.63 
32.94 1.86 
57.68 3.74 
2-aminoadipic acid 
36.27 2.28 
36.33 2.25 
2-hydroxyglutaric acid 
29.65 1.36 2-hydroxyisobutyric acid 
46.25 3.78 
14.02 0.89 
2-methylbutyrylglycine 
46.25 3.81 2-methylbutyrylglycine/ tiglyglycine 
24.32 0.93 2-oxo-isocaproic acid 
32.15 3.38 
31.10 3.43 
3,7-dimethyluric acid 
45.45 3.11 
45.28 3.04 
3-aminoisobutyric acid 
18.05 1.19 3-aminoisobutyric acid/ methylmalonic acid 
29.01 1.32 
51.40 2.46 
51.41 2.43 
3-hydroxy-3-methylglutaric acid 
52.37 2.37 3-hydroxyisovaleric acid 
30.94 1.27 3-hydroxyisovaleric acid/ caprylic acid 
42.86 2.44 
61.89 3.80 
3-hydroxypropionic acid 
27.56 3.33 
27.56 3.28 
3-methylhistidine 
35.45 3.79 3-methylhistidine/anserine 
56.73 3.93 3-methylhistidine/ phosphocreatine/creatine 
32.23 3.52 3-methylxanthine 
27.71 1.82 
37.08 2.25 
43.68 3.20 
4-guanidinobutyric acid 
46.73 3.94 
118.44 6.97 
132.31 7.75 
4-hydroxyhippuric acid 
46.27 3.45 4-hydroxyphenylacetic acid 
118.28 6.87 
133.43 7.16 
4-hydroxyphenylacetic acid/N-acetyltyrosine 
29.33 1.68 
25.30 1.64 
5-aminopentanonic acid 
39.64 2.24 5-aminopentanonic acid/2-aminoadipic acid 
26.11 1.92 acetic acid 
33.06 2.23 acetone 
23.43 2.15 
43.35 2.55 
acetyl-L-carnitine 
56.73 3.20 acetyl-L-carnitine/choline/isobutyrylcarnitine 
43.35 2.72 acetyl-L-carnitine/ guanidinosuccinic acid 
69.60 5.60 
70.91 3.88 
71.07 3.61 
acetyl-L-carnitine/ isobutyrylcarnitine 
53.50 3.79 
19.02 1.48 
alanine 
66.24 5.40 allantoin 
138.48 8.27 anserine 
73.47 3.59 
73.32 3.94 
arabitol 
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65.75 3.84  
43.51 3.24 
26.75 1.65 
arginine 
26.62 1.72 arginine/ethylmalonic acid 
30.46 1.92 arginine/ornithine/N-acetyl-L-glutamine 
37.55 2.88 
37.54 2.94 
54.32 4.01 
asparagine 
36.59 2.58 
39.68 3.19 
β-alanine 
68.97 3.90 
56.24 3.26 
betaine 
36.27 3.92 
146.76 7.89 
caffeine 
33.08 3.42 
30.54 3.29 
caffeine/1,3-dimethyluric acid 
72.84 3.43 
45.77 2.44 
56.91 3.23 
66.98 4.57 
carnitine 
70.42 3.52 
58.34 4.06 
choline 
46.41 3.14 
128.43 5.81 
cis-aconitic acid 
49.47 2.65 
28.04 1.34 
citramalic acid 
47.86 2.71 
47.86 2.68 
47.86 2.56 
47.86 2.54 
citric acid 
39.81 3.04 creatine/phosphocreatine/N-acetyltyrosine 
59.14 4.06 
33.04 3.04 
creatinine 
56.24 4.13 
40.29 3.16 
40.63 3.41 
40.67 3.38 
40.64 3.20 
cystine 
74.29 3.97 
74.48 4.28 
72.68 3.66 
D-galactonic acid 
32.24 2.68 dihydrouracil 
37.58 2.73 dimethylamine 
72.20 3.80 
66.23 3.88 
D-mannitol 
73.83 3.77 D-mannitol/arabitol 
66.07 3.68 D-mannitol/galactitol/threonic acid/arabitol/D-galactonic acid 
76.39 3.95 
77.03 4.14 
76.55 4.10 
74.77 4.08 
D-saccharic acid 
99.59 4.58 
95.25 5.20 
68.01 3.32 
77.03 3.23 
72.35 3.62 
75.74 3.65 
78.75 3.42 
D-xylose 
65.59 3.77 
65.59 3.79 
erythritol 
19.18 1.15 ethanol/2-methylbutyryl-glycine 
60.59 3.83 
44.32 3.16 
ethanolamine 
14.80 0.88 ethylmalonic acid 
72.36 3.69 galactitol 
73.00 3.98 galactitol/D-galactonic acid 
104.31 5.46 
67.90 4.10 
68.02 3.76 
73.01 3.54 
glucosan 
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73.75 3.68 
79.11 4.63 
 
74.94 3.69 glucosan/erythritol 
75.58 3.73 
74.45 3.84 
72.52 3.41 
63.66 3.91 
63.66 3.89 
63.66 3.72 
63.49 3.85 
63.33 3.79 
95.10 5.25 
98.95 4.64 
77.05 3.25 
78.73 3.48 
glucose 
74.42 3.54 glucose/D-xylose 
33.68 2.45 
29.17 2.14 
glutamine 
57.21 3.78 glutamine/lysine/arginine/glutamic acid/ornithine 
44.48 3.57 glycine 
64.14 3.95 glycolic acid 
27.24 1.64 
25.14 0.93 
23.54 0.89 
glycyl-L-leucine 
47.52 3.80 guanidinoacetate 
43.35 2.74 
57.70 4.24 
guanidinosuccinic acid 
43.35 2.53 guanidinosuccinic acid/ isobutyrylcarnitine 
135.04 7.64 
131.66 7.55 
130.05 7.82 
46.73 3.97 
hippuric acid 
120.22 7.19 
57.37 4.01 
29.98 3.22 
30.13 3.31 
29.98 3.28 
29.98 3.23 
histidine 
70.39 4.38 
27.89 2.15 
hydroxyacetone 
119.08 7.35 
115.08 7.50 
120.27 7.69 
indoxyl sulfate 
59.78 3.96 isethionic acid 
20.79 1.14 
43.04 2.62 
isobutyrylcarnitine 
21.43 1.12 isobutyrylglycine 
51.64 3.00 
40.35 2.53 
40.33 2.48 
isocitric acid 
22.96 1.33 
71.83 4.11 
lactic acid 
24.82 0.97 
23.69 0.96 
26.98 1.73 
26.97 1.70 
leucine 
61.24 4.18 
32.55 2.40 
28.20 2.51 
28.20 2.04 
L-pyroglutamic acid 
32.88 1.92 
32.71 1.91 
29.33 1.73 
29.17 1.75 
24.33 1.47 
24.33 1.41 
24.17 1.53 
24.17 1.51 
24.17 1.44 
24.17 1.49 
lysine 
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42.22 3.03 lysine/4-hydroxyphenylacetic acid/5-aminopentanoic acid 
131.66 7.36 
130.21 7.41 
mandelic acid 
52.00 3.37 methanol 
27.72 2.61 methylamine 
30.17 2.83 methylguanidine 
18.18 1.24 methylmalonic acid 
55.76 3.16 methylmalonic acid/ isethionic acid 
75.10 4.07 
74.77 3.61 
73.85 3.54 
77.04 3.29 
myo-inositol 
62.85 3.72 
46.41 2.93 
N,N-dimethylglycine 
41.74 3.20 
24.82 1.99 
N8-acetylspermidine 
26.75 2.09 N8-acetylspermidine/2-oxoisocaproic acid 
24.82 2.03 
57.69 4.18 
34.48 2.27 
30.47 2.12 
N-acetyl-L-glutamine 
59.30 4.43 
24.66 1.94 
N-acetyltyrosine 
28.85 2.92 N-methylnicotinamide 
138.29 8.16 N-methylnicotinamide/ histidine 
71.39 3.52 
23.37 0.93 
21.92 0.89 
71.39 3.41 
78.65 3.99 
pantothenic acid 
45.12 3.67 phenylacetylglycine 
46.25 3.75 phenylacetylglycine/2-methylbutyrylglycine/1-isobutyrylglycine 
131.82 7.42 phenylacetylglycine/ phenylalanine/mandelic acid/tropic acid/ phenylethylamine 
132.14 7.36 phenylacetylglycine/ phenylalanine/ phenylethylamine 
130.21 7.36 phenylacetylglycine/ phenylalanine/tropic acid/phenylethylamine 
39.16 3.27 
58.85 4.04 
phenylalanine 
43.09 3.29 
35.92 3.04 
phenylethylamine 
24.32 1.67 
25.16 1.78 
47.54 3.17 
piperidine 
73.81 4.15 
76.22 4.29 
144.55 7.66 
86.22 4.02 
81.87 4.69 
64.46 3.86 
64.46 3.84 
64.46 3.73 
pseudouridine 
18.37 2.48 pyridoxine 
29.33 2.38 pyruvic acid 
76.55 3.35 scyllo-inositol 
63.17 4.01 
63.17 3.98 
63.17 3.96 
63.17 3.94 
59.30 3.85 
serine 
31.26 1.30 suberic acid/sebacic acid/azelaic acid/caprylic acid 
40.29 2.19 suberic acid/sebacic acid/valeric acid/azelaic acid 
28.52 1.55 suberic acid/sebaic acid/azelaic acid 
36.78 2.41 succinic acid 
32.39 2.80 succinimide 
75.58 3.77 
72.20 3.48 
65.43 3.82 
64.30 3.68 
63.01 3.82 
95.00 5.42 
84.11 3.87 
sucrose 
Appendix Appendix I: Tables 
 
113 
79.37 4.22 
76.86 4.06 
75.26 3.84 
73.97 3.56 
 
76.86 4.34 tartaric acid 
50.44 3.27 taurine 
38.35 3.43 taurine/dihydrouracil 
146.82 7.91 
36.27 3.93 
31.86 3.48 
theobromine 
45.78 3.49 thiodiacetic acid/thioglycolic acid 
75.74 3.98 threonic acid 
75.26 4.02 threonic acid/2-hydroxyglutaric acid/ 
65.59 3.64 threonic acid/erythritol 
68.97 4.27 
22.24 1.33 
threonine 
63.49 3.60 threonine/valine 
14.33 1.85 
136.17 6.49 
tiglyglycine 
40.15 3.46 trans-aconitic acid 
51.12 4.44 
130.54 8.08 
trigonelline 
62.37 3.27 trimethylamine-N-oxide 
66.23 3.87 
131.02 7.36 
tropic acid 
114.91 7.54 
121.37 7.72 
128.13 7.32 
29.34 3.47 
tryptophan 
125.21 7.27 
122.80 7.20 
tryptophan/indoxyl sulfate 
118.77 6.89 
38.19 3.05 
58.79 3.93 
tyrosine 
133.43 7.16 tyrosine/4-hydroxyphenyl-acetic acid/N-acetyltyrosine 
24.66 1.31 valeric acid 
16.12 0.87 
24.73 1.29 
valeric acid/caprylic acid 
20.79 1.04 
19.50 0.98 
31.99 2.28 
valine 
 
In case that more than one compound contributed to a signal all corresponding names are given. 
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Table 2. Analysis of Human Urinary Metabolites: Chemical Shift Values and LLOQ’s of 
Urinary Metabolites Quantified in this Thesis. Adapted from (Gronwald et al. 2008). 
 
Compound 
Number of  
Protons 
1H Frequency 
[ppm] 
13C Frequency 
[ppm] 
LLOQ  
[µmol/L] 
Quantified 
From 1D or 2D 
Spectra 
Acetic acid 3 1.92 25.8 78 2D 
1 4.02 72.4 
1 4.52 81.2 Ascorbic acid 
2 3.74 65.2 
312 2D 
Alanine 3 1.48 18.9 78 2D 
3-Aminoisobutyrate 1 2.62 42.0 312 2D 
2 1.74/1.66 26.6 
Arginine 
2 3.20 43.4 
312 2D 
2 3.90 68.7 
Betaine 
3 3.26 56.0 
78 2D 
1 2.67 49.2 
Citric acid 
1 2.55 49.2 
312 2D 
1 2.70 47.6 
Citric acid_2 
1 2.54 47.6 
312 2D 
2 4.06 59.0 
Creatinine 
3 3.05 32.8 
78 2D 
2 3.83 60.3 
Ethanolamine 
2 3.15 44.0 
312 2D 
1 3.4 72.2 
1 3.46 78.2 
1 3.82 63.5 
1 3.55 74.4 
1 3.25 76.9 
1 4.65 98.7 
1 3.84 74.3 
Glucose 
1 5.24 94.8 
563 2D 
2 2.14 28.9 
Glutamine 
2 2.45 33.6 
312 2D 
Glycine 2 3.57 44.2 156 2D 
1 7.55 131.2 
1 7.64 134.8 Hippurate 
1 7.84 129.6 
312 2D 
Histidine 1 7.12 119.6 156 2D 
Lactate 3 1.332 - 3.25 1D 
6 0.96 23.9 
1 1.73 26.8 
2 1.73 42.6 
Leucine 
1 3.74 56.2 
156 2D 
2 1.908 32.6 
2 1.45/1.48 24.1 
2 1.73 29.2 
Lysine 
2 3.03 42.0 
312 2D 
3 3.71 36.1 
1 7.03 122.4 1-Methylhistidine 
1 7.75 140.7 
312 2D 
2 3.30/2.25 27.5 
3 3.74 34.7 3-Methylhistidine 
1 7.14 125.7 
78 2D 
1 3.28 39.0 
1 3.98 58.5 
1 3.12 39.0 
2 7.42 131.7 
2 7.33 131.7 
Phenylalanine 
1 7.38 130.3 
141 2D 
3 3.03 39.1 
Phosphocreatine 
2 3.93 56.1 
141 2D 
2 3.43 38.2 
Taurine 
2 3.27 50.2 
312 2D 
TMA 9 5.16 47.4 39 2D 
TMAO 9 3.27 62.1 39 2D 
 
Appendix Appendix I: Tables 
 
115 
Table 3. Reproducibility of 2D NMR-Based Quantification: Average Concentrations and 
Ranges for Selected Urinary Metabolites. Adapted from (Gronwald et al. 2008). 
 
Compound 
Concentration 
Mean ± SD 
[µmol/L] 
RSD [%] 
(n = 6) 
Range 
[µmol/L] 
Acetic acid 367 ± 284 9.6 88 - 931 
Alanine 194 ± 84 20.6 86 - 465 
3-Aminoisobutyrate 1505 ± 437 6.9 898 - 2037 
Arginine ND ND ND 
Betaine 176 ± 105 19.6 37 - 637 
Citrate 1421 ± 593 14.8 152 - 2673 
Creatinine 7069 ± 2748 2.0 3069 - 13593 
Ethanolamine 363 ± 47 14.8 176 - 496 
Glutamine 431 ± 121 19.4 314 - 666 
Glycine 953 ± 472 4.8 355 - 1976 
Hippurate 2140 ± 1434 4.6 372 - 5392 
Histidine 626 ± 264 10.4 165 - 1297 
Lysine 544 ± 159 13.4 90 - 832 
1-Methylhistidine 215 ± 109 14.0 78 - 569 
3-Methylhistidine 450 ± 393 13.1 80 - 1640 
Taurine 868 ± 502 3.7 224 - 2571 
Trimethylamine-N-
oxide 
650 ± 745 3.4 61 - 2419 
 
 
 
 
Table 4. Accuracy of 2D NMR Quantification: Concentrations of Amino Acids in a 
Certified Standard in Comparison to Reference Values. Adapted from (Gronwald et al. 
2008). 
 
Compound 
2D NMR 
Concentration 
[mmol/L] 
(n = 3) 
NIST 
Certified 
Concentration 
[mmol/L] 
NIST 
Gravimetric 
Value 
[mmol/L] 
Analyte 
Recovery 
[%]  
Alanine 2.44 ± 0.08 2.51 ± 0.09 2.50 97 
Arginine 3.09 ± 0.40 2.94 ± 0.14 2.83 105 
Glycine 2.45 ± 0.13 2.45 ± 0.08 2.51 100 
Histidine 3.14 ± 0.55 2.83 ± 0.11 2.49 111 
Lysine 2.45 ± 0.25 2.47 ± 0.10 2.51 99 
 
Recovery of amino acids for 2D NMR is based on the NIST certified concentrations. 
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Table 5. Quantitative Comparison of NMR and Alternative Methods: Analysis of Human 
Urine. Adapted from (Gronwald et al. 2008). 
 
Linear Regression Bland-Altman 
Method Compound Y-Intercept 
[µmol/L] 
Slope R2 
Difference 
[µmol/L] 
1.96 SD 
PAP Creatinine 273 1.09 0.99 -924 719 
Jaffe Creatinine 245 1.16 0.99 -1401 1082 
Alanine 28 0.96 0.83 -19 73 
3-Aminoisobutyrate 314 1.06 0.80 -407 461 
Glutamine 28 0.86 0.86 32 91 
Glycine 72 0.87 0.98 48 169 
Hippurate 115 0.94 0.99 22 313 
Histidine 47 0.84 0.88 53 183 
GC-MS 
Lysine -93 0.91 0.87 141 116 
Alanine 49 0.93 0.79 -36 81 
3-Aminoisobutyrate 370 0.82 0.91 -101 279 
Glutamine 25 0.99 0.82 -22 110 
Glycine 107 0.90 0.97 -13 170 
Histidine 91 0.84 0.85 8 202 
Lysine -174 1.11 0.81 115 176 
3-Methylhistidine 2 1.10 0.97 46 179 
LC-MS/MS 
Taurine 73 1.05 0.97 -117 174 
 
For each comparison the y-intercept, slope and R2 value of the linear regression are given. Additionally, 
Bland-Altman analyses were conducted. Given are the mean difference and 1.96 times the standard deviation 
(± 1.96 SD) of the differences. For normally distributed differences, it can be expected that 95 % of all 
differences lie within the limits of agreement defined as ± 1.96 SD. 
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Table 6. Chemical Shift Values for Bovine Milk Metabolites. Adapted from (Klein et al. 
2010). 
 
Compound 
Number of 
Protons 
1H Frequency 
[ppm] 
13C Frequency 
[ppm] 
LLOQ 
[µmol/L] 
Quantified 
From 1D or 2D 
Spectra 
2-oxoglutaric acid 2 3.009 - 3.25 1D 
Acetate 3 1.923 - 3.25 1D 
Acetoacetate 3 3.447 - 2.5 1D 
Acetone 6 2.236 - 1.76 1D 
Alanine 3 1.482 - 3.25 1D 
Betaine 2 3.90 67.7 450 2D 
BHBA 3 1.203 - 1.62 1D 
Carnitine 2 2.44 44.8 281 2D 
Choline 2 3.51 69.9 141 2D 
Cis-aconitate 1 5.725 - 3.25 1D 
1 2.70 46.7 
Citrate 
1 2.54 46.7 
312 2D 
Creatinine 3 3.05 31.3 78 2D 
2 3.83 60.3 
Ethanolamine 
2 3.15 44.0 
312 2D 
Fumarate 2 6.522 - 3.25 1D 
Galactose α 1 4.07 72.8 1125 2D 
1 4.57 98.8 
Galactose β 
1 3.49 74.4 
1125 2D 
1 4.18 73.3 
1 4.00 71.6 
1 3.91 71.7 
1 5.46 95.9 
Galactose-1-Phosphate 
1 3.78 71.3 
281 2D 
Glutamate 2 2.358 - 3.25 1D 
2 4.32 62.1 
GPC 
2 3.87 69.4 
141 2D 
Glycine 2 3.57 42.9 156 2D 
Lactate 3 1.332 - 3.25 1D 
1 4.45 105.0 
1 3.73 77.6 Lactose (total) 
1 3.94 71.0 
453 2D 
1 5.23 94.2 
Lactose α 
2 3.88 62.3 
1813 2D 
1 4.67 98.2 
1 3.29 76.2 
1 3.96 62.4 
Lactose β 
1 3.60 77.3 
1813 2D 
2 3.30/2.25 27.5 
3 3.74 34.7 3-Methylhistidine 
1 7.14 125.7 
78 2D 
N-acetyl-carbohydrates 3 2.05 23.8 141 2D 
Orotate 1 6.19 104.0 156 2D 
Oxaloacetate 2 2.376 - 3.25 1D 
2 4.16 60.6 
Phosphocholine 
2 3.58 69.0 
141 2D 
3 3.03 39.1 
Phosphocreatine + Creatine 
2 3.93 56.1 
141 2D 
2 3.43 38.2 
Taurine 
2 3.27 50.2 
312 2D 
Trimethylamine-N-oxide 3 3.27 62.1 39 2D 
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Table 7. Investigation of Lipophilic Tissue Extracts: Chemical Shifts of Quantified 
Compounds. Adapted from (Klein et al. 2011b). 
 
Extract 
Type 
Compound Explanation 
1H Frequency 
[ppm] 
Number 
of Protons 
Molecular Mass 
Lipid methene* -CH=CH- 5.45 - 5.20 2 26.0 (2H + 2C) 
Lipid diallylic* =CH-CH2-CH= 2.90 - 2.74 2 14.0 (2H + C) 
Lipid allylic* -CH2-CH=CH- 2.14 - 1.93 2 14.0 (2H + C) 
Lipid methylene* -CH2- 1.41 - 1.20 2 14.0 (2H + C) 
Lipid methyl* -CH3 0.94 - 0.80 3 15.0 (3H + C) 
Lipid α-methylene to 
carboxyl* 
COO-CH2-CH2- 2.3326 - 2.250 2 58.0 (2H + 2C + 2O) 
Free fatty acid α-
methylene to 
carboxyl* 
COO-CH2-CH2- 2.3773 - 2.3326 2 58.0 (2H + 2C + 2O) 
 4.325 - 4.260 2 41.0 (5H + 3C) 
Lipid glycerol* 
 4.175 - 4.110 2  
Cholesterol  1.009 3 not used 
Cholesterol ester  1.019 3 not used 
Lipophilic 
Phosphatidylcholine  3.233 9 not used 
GPC  3.231 9 not used 
Hydrophilic 
PC  3.222 9 not used 
 
*Signals used for the estimation of the total lipid content. 
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Table 8. Preprocessing for Statistical Data Analysis: Areas Excluded from Spectral 
Binning. Adapted from (Klein et al. 2011b). 
 
Sample Type Spectrum Type 1H Area [ppm] 13C Area [ppm] Compound 
1D 6.2 - 4.7 - Water, urea 
Urine 
2D 6.2 - 4.0 150 - 5 Water, urea 
4.9 - 4.7 - Water 
3.371 - 3.359 - Methanol 
3.815 - 3.755 - Glycerol 
3.681 - 3.626 - Glycerol, TEG 
3.592 - 3.3 - Glycerol 
3.77 - 3.705 - TEG 
4.7 - 4.655 - Lactose 
4.484 - 4.429 - Lactose 
4.0 - 3.52 - Lactose 
3.33 - 3.258 - Lactose 
3.24 - 3.208 - GPC, PC 
3.714 - 3.57 - GPC, PC 
3.986 - 3.854 - GPC, PC 
4.212 - 4.12 - GPC, PC 
1D 
4.37 - 4.29 - GPC, PC 
5.6 - 4.0 150 - -5 Water, Lactose 
3.85 - 3.7 76.3 - 73.0 Glycerol 
3.7 - 3.5 66.33 - 64.12 Glycerol 
3.41 - 3.29 52.74 - 50.56 Methanol 
3.85 - 3.6 78.4 - 59.0 TEG 
4.1 - 3.61 65.4 - 60.8 Lactose 
4.08 - 3.8 75.4 - 69.0 Lactose 
3.86 - 3.39 82.8 - 71.6 Lactose 
Milk 
2D 
3.45 - 3.12 78.3 - 74.6 Lactose 
1D 4.9 - 4.7 - Water Other aqueous 
samples 2D 5.6 - 4.0 150 - 5 Water 
1D 7.6 - 6.9 - Chloroform 
Lipophilic extracts 
2D 7.6 - 6.9 85 - 75 Chloroform 
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Table 9. Brown Swiss and Simmental Fleckvieh Cows: Milk Metabolites Quantified by 
NMR. Adapted from (Klein et al. 2010). 
 
Metabolite 
TE  
(n = 2) 
[mmol/L] 
Number of  
Values Above  
LLOQ1 
Milk Concentration  
Range [mmol/L] 
Acetic acid 0.090 25 0.108 - 0.7013 
Acetone 0.002 106 0.012 - 0.6614 
Betaine 0.564 24 0.459 - 1.4103 
Carnitine 0.084 1 0.3462,3 
Choline 0.112 56 0.150 - 0.9973 
Creatinine 0.034 73 0.080 - 0.1673 
Ethanolamine 0.026 1 0.3232,3 
α-Galactose 0.468 5 1.200 - 1.7603 
Glycerophosphocholine 0.095 106 0.284 - 1.4603 
Lactose (total) 2.131 106 118.186 - 160.1213 
α-Lactose 1.768 106 45.792 - 61.2433 
β-Lactose 2.179 106 75.067 - 99.3603 
3-Methylhistidine 0.168 2 0.103 - 0.1513 
N-Acetyl-carbohydrates 0.086 106 1.135 - 4.2403 
Phosphocholine 0.082 56 0.143 - 1.3553 
Phosphocreatine 0.179 106 0.585 - 2.5673 
Taurine 0.076 3 0.327 - 0.6213 
Trimethylamine-N-oxide ND 2 0.043 - 0.0463 
 
1 The number of values above LLOQ varies from metabolite to metabolite because individual LLOQ were 
determined for each metabolite; also the abundance of the various metabolites greatly varies. In total, 106 milk 
samples were analyzed, which results in a maximum number of 106 values that could be obtained for a single 
metabolite. 
2 Only one value detected. 
3 Concentrations obtained from 1H-13C 2D HSQC spectra. 
4 Concentrations obtained from 1H 1D NMR spectra. 
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Days in Milk 1.00 -0.29 0.34 0.83 0.08 -0.48 0.65 -0.20 0.09 -0.37 -0.37 -0.03 0.38 -0.04 -0.15 0.01 -0.03 -0.29 0.27 -0.38 0.31 0.11 0.07 -0.20 0.14 0.51 0.15 0.13 -0.19 0.06 -0.42 -0.17 -0.11 0.06 -0.32 0.03 0.48 -0.07 0.09
Milk [kg] -0.29 1.00 -0.29 -0.37 0.44 0.04 n.d. -0.10 0.14 0.04 n.d. -0.32 -0.28 -0.04 0.06 -0.03 0.02 0.15 0.05 0.13 -0.24 0.20 -0.12 0.08 -0.05 -0.09 -0.06 -0.09 -0.03 -0.02 0.02 0.14 0.40 -0.11 -0.01 0.20 -0.23 n.d. 0.18
Fat [%] 0.34 -0.29 1.00 0.36 0.19 0.13 0.38 0.44 0.00 -0.43 0.50 0.56 0.44 0.49 0.05 -0.22 0.50 -0.34 -0.12 0.10 0.34 0.25 -0.21 0.06 0.13 0.10 0.51 0.30 -0.44 0.17 0.30 0.27 0.19 -0.22 -0.51 0.62 0.08 0.39 -0.04
Protein [%] 0.83 -0.37 0.36 1.00 0.02 -0.37 0.71 -0.06 -0.06 -0.38 -0.15 0.16 0.50 0.22 -0.49 -0.12 -0.10 -0.27 0.12 -0.35 0.51 0.23 0.03 -0.11 0.37 0.57 -0.01 0.57 -0.17 0.18 0.08 -0.07 -0.10 0.00 -0.27 0.16 0.38 0.64 0.13
Somatic Cell Count 0.08 0.44 0.19 0.02 1.00 0.08 -0.14 0.08 -0.03 -0.26 0.19 0.37 0.07 0.05 0.21 0.20 0.18 -0.26 -0.12 0.05 -0.15 0.07 -0.08 -0.13 0.11 0.11 0.40 0.06 -0.27 0.08 0.29 0.05 0.16 -0.10 -0.24 0.21 0.21 -0.35 0.03
α-Aminobutyricacid -0.48 0.04 0.13 -0.37 0.08 1.00 -0.33 0.13 0.45 0.31 0.29 0.00 -0.08 0.42 0.21 0.14 0.17 0.40 -0.21 0.66 0.06 0.16 -0.22 0.17 0.07 -0.39 0.04 0.21 -0.07 0.14 0.44 0.47 0.29 -0.25 0.12 0.15 -0.12 0.37 0.24
Acetate 0.65 n.d. 0.38 0.71 -0.14 -0.33 1.00 0.30 -0.32 -0.14 n.d. 0.26 0.39 -0.13 0.15 -0.05 -0.09 -0.19 -0.12 -0.25 -0.07 0.08 0.52 -0.01 -0.03 0.38 -0.01 -0.15 0.49 -0.04 0.18 -0.10 -0.14 0.43 0.25 -0.22 0.25 n.d. -0.16
Acetone -0.20 -0.10 0.44 -0.06 0.08 0.13 0.30 1.00 -0.35 -0.11 0.13 0.69 -0.15 0.03 0.45 -0.12 0.22 -0.01 -0.27 0.28 -0.30 0.25 -0.13 0.02 0.08 -0.07 0.24 0.02 -0.20 0.11 0.22 0.16 0.03 -0.11 0.03 -0.09 -0.15 0.46 -0.04
Alanine 0.09 0.14 0.00 -0.06 -0.03 0.45 -0.32 -0.35 1.00 0.29 0.41 -0.34 0.22 0.35 -0.23 0.42 0.03 0.41 0.17 0.22 0.39 0.29 -0.10 0.05 0.27 -0.03 -0.14 0.36 0.03 0.32 0.10 0.30 0.44 -0.18 0.05 0.24 0.33 0.36 0.51
Aspartate -0.37 0.04 -0.43 -0.38 -0.26 0.31 -0.14 -0.11 0.29 1.00 -0.01 -0.23 -0.17 -0.02 0.04 0.37 -0.26 0.61 -0.03 0.16 -0.02 -0.08 0.43 0.03 -0.13 -0.32 -0.45 -0.07 0.49 -0.06 -0.02 0.05 0.05 0.42 0.44 -0.24 -0.08 -0.14 0.04
Betaine -0.37 n.d. 0.50 -0.15 0.19 0.29 n.d. 0.13 0.41 -0.01 1.00 0.06 -0.04 0.77 -0.34 0.39 0.32 -0.14 -0.58 0.39 0.71 0.43 -0.09 0.46 0.39 -0.21 -0.13 0.74 -0.18 0.45 0.32 0.55 0.60 -0.27 0.05 0.33 0.25 n.d. 0.67
β-Hydroxybutyrate (NMR) -0.03 -0.32 0.56 0.16 0.37 0.00 0.26 0.69 -0.34 -0.23 0.06 1.00 0.08 -0.15 0.39 -0.11 0.33 0.01 -0.26 0.13 -0.31 0.47 -0.11 -0.04 0.37 0.15 0.46 -0.08 -0.28 0.30 0.07 -0.11 0.07 -0.07 -0.13 -0.06 0.04 0.60 0.08
Choline 0.38 -0.28 0.44 0.50 0.07 -0.08 0.39 -0.15 0.22 -0.17 -0.04 0.08 1.00 0.26 -0.28 0.22 0.18 -0.25 -0.15 -0.17 0.00 0.45 0.02 -0.02 0.37 0.44 0.22 0.29 -0.16 0.44 -0.42 -0.08 0.37 -0.08 -0.25 0.13 0.47 0.47 0.44
Cholinecompounds -0.04 -0.04 0.49 0.22 0.05 0.42 -0.13 0.03 0.35 -0.02 0.77 -0.15 0.26 1.00 -0.16 0.21 0.13 -0.13 -0.30 0.58 0.67 0.27 -0.07 0.12 0.26 -0.05 -0.18 0.85 -0.13 0.35 0.70 0.66 0.57 -0.13 -0.03 0.19 0.13 0.32 0.59
Citrate -0.15 0.06 0.05 -0.49 0.21 0.21 0.15 0.45 -0.23 0.04 -0.34 0.39 -0.28 -0.16 1.00 -0.12 0.31 0.12 0.00 0.26 -0.36 0.13 0.03 0.14 -0.04 -0.28 0.47 -0.21 -0.16 -0.05 0.09 0.05 -0.15 0.14 0.03 -0.12 -0.03 -0.15 -0.19
Creatinine 0.01 -0.03 -0.22 -0.12 0.20 0.14 -0.05 -0.12 0.42 0.37 0.39 -0.11 0.22 0.21 -0.12 1.00 -0.01 0.12 -0.16 0.12 0.29 0.21 0.29 -0.04 0.27 0.08 -0.21 0.24 0.23 0.35 0.04 0.14 0.38 0.14 0.11 0.13 0.22 0.17 0.42
Fumarate -0.03 0.02 0.50 -0.10 0.18 0.17 -0.09 0.22 0.03 -0.26 0.32 0.33 0.18 0.13 0.31 -0.01 1.00 -0.11 -0.11 0.06 0.04 0.30 -0.26 0.08 0.23 -0.09 0.72 0.21 -0.42 0.36 -0.08 0.18 0.35 -0.22 -0.20 0.18 -0.04 0.36 0.10
Glutamate -0.29 0.15 -0.34 -0.27 -0.26 0.40 -0.19 -0.01 0.41 0.61 -0.14 0.01 -0.25 -0.13 0.12 0.12 -0.11 1.00 0.44 0.12 -0.05 0.13 -0.17 0.24 0.04 -0.37 -0.07 -0.10 0.12 -0.07 -0.11 -0.09 0.02 -0.18 0.19 -0.10 -0.06 0.17 0.12
Glucose 0.27 0.05 -0.12 0.12 -0.12 -0.21 -0.12 -0.27 0.17 -0.03 -0.58 -0.26 -0.15 -0.30 0.00 -0.16 -0.11 0.44 1.00 -0.32 0.08 -0.16 -0.29 0.00 -0.07 -0.05 0.04 -0.13 0.01 -0.23 -0.37 -0.26 -0.27 -0.27 -0.14 0.01 0.04 -0.30 -0.05
Glycine -0.38 0.13 0.10 -0.35 0.05 0.66 -0.25 0.28 0.22 0.16 0.39 0.13 -0.17 0.58 0.26 0.12 0.06 0.12 -0.32 1.00 0.04 0.23 -0.10 0.15 0.08 -0.27 -0.07 0.46 -0.08 0.18 0.81 0.67 0.30 -0.13 0.29 0.11 -0.03 0.44 0.35
Glycerophosphocholine 0.31 -0.24 0.34 0.51 -0.15 0.06 -0.07 -0.30 0.39 -0.02 0.71 -0.31 0.00 0.67 -0.36 0.29 0.04 -0.05 0.08 0.04 1.00 0.14 0.05 0.00 0.27 0.08 -0.21 0.67 -0.05 0.29 0.17 0.34 0.48 -0.02 -0.16 0.21 0.23 0.16 0.49
Isoleucine 0.11 0.20 0.25 0.23 0.07 0.16 0.08 0.25 0.29 -0.08 0.43 0.47 0.45 0.27 0.13 0.21 0.30 0.13 -0.16 0.23 0.14 1.00 -0.16 -0.17 0.85 0.29 0.26 0.40 -0.18 0.80 0.19 0.18 0.59 -0.20 0.00 -0.01 0.42 0.76 0.72
Lactate 0.07 -0.12 -0.21 0.03 -0.08 -0.22 0.52 -0.13 -0.10 0.43 -0.09 -0.11 0.02 -0.07 0.03 0.29 -0.26 -0.17 -0.29 -0.10 0.05 -0.16 1.00 -0.05 -0.10 0.06 -0.43 -0.11 0.67 0.02 -0.15 -0.04 -0.01 0.87 0.36 -0.23 0.13 -0.04 -0.09
Lactose -0.20 0.08 0.06 -0.11 -0.13 0.17 -0.01 0.02 0.05 0.03 0.46 -0.04 -0.02 0.12 0.14 -0.04 0.08 0.24 0.00 0.15 0.00 -0.17 -0.05 1.00 -0.26 -0.40 0.14 -0.01 0.02 -0.22 0.11 0.05 -0.13 -0.05 -0.05 0.07 -0.19 -0.07 -0.18
Leucine 0.14 -0.05 0.13 0.37 0.11 0.07 -0.03 0.08 0.27 -0.13 0.39 0.37 0.37 0.26 -0.04 0.27 0.23 0.04 -0.07 0.08 0.27 0.85 -0.10 -0.26 1.00 0.44 0.12 0.40 -0.12 0.90 0.05 0.09 0.67 -0.14 -0.06 -0.05 0.54 0.69 0.80
Lysine 0.51 -0.09 0.10 0.57 0.11 -0.39 0.38 -0.07 -0.03 -0.32 -0.21 0.15 0.44 -0.05 -0.28 0.08 -0.09 -0.37 -0.05 -0.27 0.08 0.29 0.06 -0.40 0.44 1.00 0.02 0.06 -0.09 0.35 -0.27 -0.20 0.10 0.08 -0.08 -0.02 0.39 0.08 0.29
Malate 0.15 -0.06 0.51 -0.01 0.40 0.04 -0.01 0.24 -0.14 -0.45 -0.13 0.46 0.22 -0.18 0.47 -0.21 0.72 -0.07 0.04 -0.07 -0.21 0.26 -0.43 0.14 0.12 0.02 1.00 -0.09 -0.63 0.09 -0.16 -0.06 -0.06 -0.37 -0.36 0.16 -0.02 0.05 -0.16
N-Acetylcarbohydrates 0.13 -0.09 0.30 0.57 0.06 0.21 -0.15 0.02 0.36 -0.07 0.74 -0.08 0.29 0.85 -0.21 0.24 0.21 -0.10 -0.13 0.46 0.67 0.40 -0.11 -0.01 0.40 0.06 -0.09 1.00 -0.22 0.46 0.57 0.60 0.64 -0.16 -0.01 0.15 0.28 0.38 0.65
Ornithine -0.19 -0.03 -0.44 -0.17 -0.27 -0.07 0.49 -0.20 0.03 0.49 -0.18 -0.28 -0.16 -0.13 -0.16 0.23 -0.42 0.12 0.01 -0.08 -0.05 -0.18 0.67 0.02 -0.12 -0.09 -0.63 -0.22 1.00 -0.02 -0.16 -0.12 -0.03 0.62 0.42 -0.23 -0.04 0.13 -0.05
Phenylalanine 0.06 -0.02 0.17 0.18 0.08 0.14 -0.04 0.11 0.32 -0.06 0.45 0.30 0.44 0.35 -0.05 0.35 0.36 -0.07 -0.23 0.18 0.29 0.80 0.02 -0.22 0.90 0.35 0.09 0.46 -0.02 1.00 0.06 0.26 0.79 -0.04 0.10 -0.08 0.48 0.66 0.76
Phosphocholine -0.42 0.02 0.30 0.08 0.29 0.44 0.18 0.22 0.10 -0.02 0.32 0.07 -0.42 0.70 0.09 0.04 -0.08 -0.11 -0.37 0.81 0.17 0.19 -0.15 0.11 0.05 -0.27 -0.16 0.57 -0.16 0.06 1.00 0.59 0.13 -0.18 0.08 0.26 0.07 -0.19 0.33
Phosphocreatine -0.17 0.14 0.27 -0.07 0.05 0.47 -0.10 0.16 0.30 0.05 0.55 -0.11 -0.08 0.66 0.05 0.14 0.18 -0.09 -0.26 0.67 0.34 0.18 -0.04 0.05 0.09 -0.20 -0.06 0.60 -0.12 0.26 0.59 1.00 0.45 -0.11 0.13 0.20 0.07 0.25 0.32
Proline -0.11 0.40 0.19 -0.10 0.16 0.29 -0.14 0.03 0.44 0.05 0.60 0.07 0.37 0.57 -0.15 0.38 0.35 0.02 -0.27 0.30 0.48 0.59 -0.01 -0.13 0.67 0.10 -0.06 0.64 -0.03 0.79 0.13 0.45 1.00 -0.08 0.13 0.02 0.28 0.45 0.76
Pyruvate 0.06 -0.11 -0.22 0.00 -0.10 -0.25 0.43 -0.11 -0.18 0.42 -0.27 -0.07 -0.08 -0.13 0.14 0.14 -0.22 -0.18 -0.27 -0.13 -0.02 -0.20 0.87 -0.05 -0.14 0.08 -0.37 -0.16 0.62 -0.04 -0.18 -0.11 -0.08 1.00 0.30 -0.32 0.07 -0.07 -0.16
Succinate -0.32 -0.01 -0.51 -0.27 -0.24 0.12 0.25 0.03 0.05 0.44 0.05 -0.13 -0.25 -0.03 0.03 0.11 -0.20 0.19 -0.14 0.29 -0.16 0.00 0.36 -0.05 -0.06 -0.08 -0.36 -0.01 0.42 0.10 0.08 0.13 0.13 0.30 1.00 -0.44 0.01 0.04 0.08
Threonine 0.03 0.20 0.62 0.16 0.21 0.15 -0.22 -0.09 0.24 -0.24 0.33 -0.06 0.13 0.19 -0.12 0.13 0.18 -0.10 0.01 0.11 0.21 -0.01 -0.23 0.07 -0.05 -0.02 0.16 0.15 -0.23 -0.08 0.26 0.20 0.02 -0.32 -0.44 1.00 -0.01 0.03 0.11
Trpytophane 0.48 -0.23 0.08 0.38 0.21 -0.12 0.25 -0.15 0.33 -0.08 0.25 0.04 0.47 0.13 -0.03 0.22 -0.04 -0.06 0.04 -0.03 0.23 0.42 0.13 -0.19 0.54 0.39 -0.02 0.28 -0.04 0.48 0.07 0.07 0.28 0.07 0.01 -0.01 1.00 0.44 0.48
Tyrosine -0.07 n.d. 0.39 0.64 -0.35 0.37 n.d. 0.46 0.36 -0.14 n.d. 0.60 0.47 0.32 -0.15 0.17 0.36 0.17 -0.30 0.44 0.16 0.76 -0.04 -0.07 0.69 0.08 0.05 0.38 0.13 0.66 -0.19 0.25 0.45 -0.07 0.04 0.03 0.44 1.00 0.55
Valine 0.09 0.18 -0.04 0.13 0.03 0.24 -0.16 -0.04 0.51 0.04 0.67 0.08 0.44 0.59 -0.19 0.42 0.10 0.12 -0.05 0.35 0.49 0.72 -0.09 -0.18 0.80 0.29 -0.16 0.65 -0.05 0.76 0.33 0.32 0.76 -0.16 0.08 0.11 0.48 0.55 1.00
Positive correlation coefficients above 0.5 and below -0.5 are marked in green and red, respectively. Only metabolites for which a sufficient number of measurements was 
available (N ≥ 10) were included. For the number of available measurements see Table 9. Individual pairs of metabolites, for which only few corresponding pairs of 
measurements were available, are indicated by n.d. These are all correlations between milk yield, acetic acid, betaine, and tyrosine. Note that correlation coefficients for 
tyrosine with other metabolites should be treated with care, because only 20 measurements were available for tyrosine. Note the entry “choline compounds” summarizes all 
compounds that contain a quaternary ammonium ion. The somatic cell count is given in 1000 cells/mL. 
Table 10. Brown Swiss and Simmental Fleckvieh Cows: Pearson Correlation Matrix of Milk Features. Adapted from (Klein et al. 2010). 
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Table 11. Analysis of Holstein-Friesian Cows: Diagnosed Metabolic Disorders. Adapted 
from (Klein et al. 2011a). 
 
 
 
Week 11 Week 21 Week 31 Week 41 Week 51 Month 61 Whole Lactation2 
Ruminal acidosis 8.3 % 3.9 % 3.0 % 2.2 % 0.9 % 1.8 % 19.3 % 
Ketosis 0.9 % 2.2 % 1.3 % 0.4 % 0.9 % 0.0 % 5.3 % 
Milk fever 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 
Fever 0.0 % 0.4 % 0.0 % 0.4 % 0.4 % 0.0 % 1.1 % 
Healthy 90.8 % 93.5 % 95.7 % 97.0 % 97.8 % 98.2 % 74.3 % 
Number of animals 109 230 232 223 223 164 264 
        
        
 Low incidence  High incidence  
 
1 Listed is the health status diagnosed within the same week in which the corresponding milk sample was 
collected. This is also true for the penultimate column corresponding to lactation month six. 
2 Listed is the health status diagnosed at any time point over the whole lactation period irrespectively of time 
points of milk collection. 
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Table 12. Analysis of Holstein-Friesian Cows: Milk Metabolite Concentration Ranges 
Throughout Lactation. Adapted from (Klein et al. 2011a). 
 
  Week 1 Week 2 Week 3 Week 4 Week 5 Month 6 
max 75 81 88 96 101 156 
2-oxoglutarate1 
min 38 37 41 45 50 70 
max 35 36 36 37 37 29 
Acetate1 
min 15 13 14 13 13 14 
max 13 14 11 14 10 7 
Acetoacetate1 
min 4 4 4 4 4 4 
max 497 211 111 106 64 40 
Acetone1 
min 29 22 20 20 19 17 
max 74 78 64 55 54 57 
Alanine2 
min 33 35 33 29 30 30 
max 1263 947 837 864 794 761 
Betaine2 
min 626 575 508 509 489 497 
max 121 97 69 82 63 40 
BHBA1 
min 17 12 13 14 13 15 
max 446 432 476 380 320 479 
Choline2 
min 152 154 159 154 158 180 
max 140 140 141 142 142 157 
Cis-aconitate1 
min 76 73 79 82 84 102 
max 7435 6921 6368 6395 6428 5776 
Citrate2 
min 4156 3768 3692 4021 3832 3719 
max 114 125 111 115 113 114 
Creatinine2 
min 83 81 81 81 81 82 
max 16 18 17 19 18 23 
Fumarate1 
min 8 7 8 9 9 10 
max 592 734 740 703 629 597 
Glutamate2 
min 270 316 331 316 311 306 
max 855 578 414 346 312 244 
Glycine2 
min 274 193 171 163 164 163 
max 2070 1878 1503 1422 1227 856 
GP2 
min 1188 1078 932 835 700 561 
max 1217 1001 949 872 895 1162 
GPC2 
min 572 482 439 413 395 663 
max 136 87 87 68 70 95 
Lactate1 
min 40 35 33 32 32 45 
max 144329 148278 150414 151672 153216 150268 
Lactose2 
min 124736 130102 133692 135328 135972 135185 
max 3138 2560 2147 2021 1950 2155 
NAC2 
min 2204 1794 1567 1467 1361 1537 
max 439 498 533 552 577 1002 
Orotate2 
min 208 251 253 286 309 475 
max 24 24 22 19 19 25 
Oxaloacetate1 
min 7 8 7 7 7 8 
max 941 825 640 566 495 278 
Phosphocholine2 
min 483 419 322 287 234 183 
max 2311 1929 1632 1528 1423 1186 
Phosphocreatine+Creatine2 
min 1392 1170 983 962 868 800 
        
        
  Low concentrations  High concentrations 
 
Concentrations in µmol/L. Min and max refer to the 10 and 90 % concentration quantiles, respectively. The 
color code was individually determined for each metabolite with the highest and lowest observed 
concentrations of a given metabolite corresponding to dark red and dark blue, respectively. 
1 Concentrations determined by 1D NMR. 
2 Concentrations determined by 2D NMR 
Appendix Appendix I: Tables 
 
124 
Table 13. Analysis of Holstein-Friesian Cows: Milk Fat Content of Animals Above and 
Below GPC/PC Threshold1. Adapted from (Klein et al. 2011a). 
 
Mean Concentration Number of Animals 
Time Point 
Animals 
Below 
Threshold 
Animals 
Above 
Threshold 
Below 
Threshold 
Above 
Threshold 
P-Value 
Week 1 5.93 % 5.21 % 97 24 1.4*10-3 
Week 2 5.02 % 4.60 % 198 33 3.2*10-3 
Week 3 4.38 % 4.06 % 204 42 1.0*10-2 
Week 4 4.16 % 3.86 % 203 38 7.4*10-4 
Week 5 3.98 % 3.62 % 205 41 4.2*10-5 
Month 6 3.58 % 3.26 % 202 36 7.1*10-5 
 
1 A GPC/PC ratio equal or larger than 2.5 was chosen to select animals not prone to ketosis. 
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Table 14. Investigation of Non-Alcoholic Steatohepatitis: Loadings of IC 1 of Lipophilic 
Liver Extracts. Adapted from (Klein et al. 2011b). 
 
Factor 
1H 
Frequency 
[ppm] 
Compound 
P-Value 
Control / 
NAFLD 
P-Value 
Control / 
NASH 
P-Value 
NAFLD / 
NASH 
-1.51*10-2 1.255 (CH2)n 4.25*10-5 2.73*10-4 1.80*10-7 
-4.12*10-3 1.265 (CH2)n 8.86*10-5 2.51*10-7 9.28*10-2 
-2.66*10-3 1.275 (CH2)n 4.86*10-4 9.46*10-8 7.68*10-1 
2.38*10-3 0.675 Cholesterol (total) 1.18*10-2 4.18*10-5 4.15*10-5 
-2.20*10-3 1.245 (CH2)n 9.76*10-3 1.11*10-1 3.69*10-4 
-2.06*10-3 1.285 (CH2)n 5.60*10-3 2.21*10-3 7.62*10-2 
2.03*10-3 1.015 Cholesterol ester 2.21*10-2 7.65*10-5 6.57*10-5 
1.70*10-3 0.865 CH3 1.34*10-4 6.60*10-6 5.53*10-6 
1.54*10-3 0.855 CH3 4.11*10-1 4.16*10-5 1.21*10-5 
1.25*10-3 0.905 CH3 9.26*10-11 5.14*10-2 4.53*10-5 
1.18*10-3 0.915 CH3 7.20*10-5 5.59*10-5 3.06*10-5 
-1.13*10-3 0.885 CH3 3.95*10-2 5.10*10-1 2.46*10-2 
9.18*10-4 1.025 Cholesterol ester 1.86*10-1 1.96*10-5 1.23*10-5 
8.90*10-4 1.345 (CH2)n 1.09*10-6 3.34*10-6 3.18*10-2 
8.24*10-4 1.305 (CH2)n 1.85*10-2 4.29*10-4 7.95*10-1 
8.07*10-4 2.265 (CH2COO) 8.04*10-2 5.53*10-6 1.54*10-5 
7.85*10-4 1.355 (CH2)n 8.00*10-9 9.61*10-8 3.13*10-1 
7.48*10-4 1.135 ? 2.88*10-1 3.19*10-5 2.18*10-5 
-7.46*10-4 2.005 CH2C=C 1.84*10-6 9.87*10-9 5.04*10-2 
6.90*10-4 0.925 CH3 1.52*10-2 1.83*10-5 5.45*10-6 
6.82*10-4 1.335 (CH2)n 7.66*10-2 1.31*10-2 1.65*10-2 
-6.72*10-4 2.015 CH2C=C 7.28*10-8 2.87*10-9 1.02*10-2 
-6.51*10-4 1.295 (CH2)n 3.69*10-1 3.46*10-2 8.55*10-1 
6.23*10-4 1.845 (CH2CH=CH) 1.24*10-1 3.14*10-5 2.48*10-6 
6.10*10-4 0.875 CH3 3.58*10-1 3.83*10-5 2.21*10-3 
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Table 15. Investigation of Non-Alcoholic Steatohepatitis: Loadings of IC 2 of Lipophilic 
Liver Extracts. Adapted from (Klein et al. 2011b). 
 
Factor 
1H 
Frequency 
[ppm] 
Compound 
P-Value 
Control / 
NAFLD 
P-Value 
Control / 
NASH 
P-Value 
NAFLD / 
NASH 
-6.19*10-3 1.265 (CH2)n 8.86*10-5 2.51*10-7 9.28*10-2 
-5.81*10-3 1.275 (CH2)n 4.86*10-4 9.46*10-8 7.68*10-1 
4.74*10-3 1.255 (CH2)n 4.25*10-5 2.73*10-4 1.80*10-7 
-3.70*10-3 0.865 CH3 1.34*10-4 6.60*10-6 5.53*10-6 
3.58*10-3 2.055 CH2C=C 7.16*10-3 6.93*10-10 1.02*10-1 
-3.55*10-3 2.015 CH2C=C 7.28*10-8 2.87*10-9 1.02*10-2 
-3.55*10-3 2.005 CH2C=C 1.84*10-6 9.87*10-9 5.04*10-2 
3.44*10-3 2.045 CH2C=C 1.08*10-2 2.72*10-9 1.00*10-1 
-2.72*10-3 0.675 Cholesterol (total) 1.18*10-2 4.18*10-5 4.15*10-5 
-2.36*10-3 1.015 Cholesterol ester 2.21*10-2 7.65*10-5 6.57*10-5 
2.21*10-3 1.355 (CH2)n 8.00*10-9 9.61*10-8 3.13*10-1 
2.10*10-3 1.305 (CH2)n 1.85*10-2 4.29*10-4 7.95*10-1 
-2.02*10-3 1.995 CH2C=C 6.10*10-3 1.09*10-7 5.59*10-1 
-1.73*10-3 0.855 CH3 4.11*10-1 4.16*10-5 1.21*10-5 
-1.70*10-3 1.285 (CH2)n 5.60*10-3 2.21*10-3 7.62*10-2 
1.69*10-3 2.065 CH2C=C 1.86*10-1 2.76*10-5 1.60*10-1 
1.69*10-3 2.765 =CH-CH2-CH= 2.86*10-5 1.07*10-5 6.00*10-2 
-1.67*10-3 1.295 (CH2)n 3.69*10-1 3.46*10-2 8.55*10-1 
1.58*10-3 0.895 CH3 3.83*10-4 1.37*10-7 2.67*10-3 
1.57*10-3 5.375 CH=CH 3.41*10-6 7.49*10-6 6.03*10-2 
1.54*10-3 2.775 =CH-CH2-CH= 2.77*10-5 5.62*10-6 1.98*10-2 
1.46*10-3 2.035 CH2C=C 3.53*10-1 1.44*10-8 1.73*10-1 
1.41*10-3 1.345 (CH2)n 1.09*10-6 3.34*10-6 3.18*10-2 
1.38*10-3 1.365 (CH2)n 1.50*10-11 1.21*10-11 4.54*10-1 
1.36*10-3 5.365 CH=CH 1.87*10-6 5.73*10-6 7.16*10-2 
 
 
Appendix Appendix I: Tables 
 
127 
Table 16. Investigation of Non-Alcoholic Steatohepatitis: Compounds and Indices in 
Lipophilic Liver Extracts. Adapted from (Klein et al. 2011b). 
 
Compound 
Control 
(n = 6) 
Steatosis 
(n = 4) 
NASH 
(n = 5) 
ANOVA 
P-Value 
P-Value 
Control / 
Steatosis 
P-Value 
Control / 
NASH 
P-Value 
Steatosis / 
NASH 
Free cholesterol¹ 0.57 ± 0.15 0.60 ± 0.13 1.03 ± 0.12 2.8*10-4 ** 7.6*10-1 3.8*10-4 ** 2.1*10-3 * 
Cholesterol ester¹ 0.46 ± 0.16 0.34 ± 0.12 13.0 ± 2.8 3.2*10-8 ** 2.3*10-1 5.5*10-4 ** 5.3*10-4 ** 
Glycerol 
containing lipids¹ 
110 ± 25 129 ± 14 115 ± 19 3.9*10-1 1.6*10-1 6.7*10-1 2.7*10-1 
Total Lipids² 0.092 ± 0.019 0.105 ± 0.010 0.113 ± 0.015 1.1*10-1 1.6*10-1 6.2*10-2 3.7*10-1 
Unsaturated 
bonds¹ 
610 ± 120 624 ± 56 694 ± 96 3.8*10-1 8.0*10-1 2.3*10-1 2.2*10-1 
Polyunsaturated 
bonds¹ 
317 ± 57 197 ± 10 156 ± 18 4.2*10-5 ** 3.0*10-3 * 5.3*10-4 ** 4.5*10-3 * 
SI³ 0.7986 ± 0.0065 0.8365 ± 0.0017 0.8213 ± 0.0030 7.1*10-8 ** 9.3*10-6 ** 9.6*10-5 ** 4.5*10-5 ** 
PUI³ 0.0698 ± 0.0045 0.0361 ± 0.0028 0.0271 ± 0.0020 2.3*10-10 ** 4.9*10-7 ** 1.1*10-7 ** 2.6*10-3 * 
PUFA/MUFA³ 0.599 ± 0.029 0.363 ± 0.031 0.259 ± 0.022 3.6*10-10 ** 1.6*10-5 ** 4.3*10-9 ** 2.2*10-3 * 
 
Given are mean values and standard deviations in nanomole per milligram¹, weight percent² or molar ratios³. 
The number of values n is given in parentheses. For the t-statistics only p-values are marked as significant 
where the corresponding ANOVA p-values are significant. 
* p<0.05, ** p<0.001 
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Table 17. Investigation of Non-Alcoholic Steatohepatitis: Loadings of IC 1 of Hydrophilic 
Liver Extracts. Adapted from (Klein et al. 2011b). 
 
Factor 
1H 
Frequency 
[ppm] 
Compound 
P-Value 
Control / 
NAFLD 
P-Value 
Control / 
NASH 
P-Value 
NAFLD / 
NASH 
2.29*10-2 3.265 Betaine* 2.04*10-3 7.25*10-4 4.32*10-3 
-9.27*10-3 1.285 ? 3.45*10-2 5.07*10-2 5.58*10-1 
5.17*10-3 3.905 Betaine* 2.11*10-2 2.58*10-3 4.44*10-3 
-5.11*10-3 1.305 ? 7.86*10-2 2.06*10-1 2.69*10-1 
-4.82*10-3 1.315 ? 5.85*10-2 1.93*10-1 2.09*10-1 
-4.36*10-3 1.295 ? 3.53*10-1 5.89*10-1 5.05*10-1 
-3.68*10-3 1.275 ? 4.81*10-2 4.21*10-2 9.91*10-1 
-2.18*10-3 0.895 ? 3.42*10-2 1.66*10-1 1.18*10-1 
-2.03*10-3 1.325 Lactate 3.34*10-1 4.68*10-1 6.40*10-1 
-1.52*10-3 1.345 Lactate 5.94*10-2 2.26*10-1 1.72*10-1 
-1.51*10-3 0.885 ? 2.79*10-2 1.69*10-1 3.79*10-2 
-1.46*10-3 1.355 ? 3.66*10-2 1.50*10-1 1.37*10-1 
-1.44*10-3 2.245 ? 2.79*10-2 7.14*10-2 1.96*10-1 
-1.41*10-3 5.315 ? 2.53*10-2 7.08*10-2 1.44*10-1 
-1.40*10-3 2.055 ? 2.96*10-3 5.13*10-3 5.37*10-2 
1.40*10-3 3.275 Taurine* 1.31*10-2 3.52*10-1 1.93*10-2 
-1.26*10-3 5.325 ? 3.64*10-2 1.25*10-1 2.44*10-1 
-1.19*10-3 2.045 ? 4.48*10-3 1.47*10-2 1.69*10-2 
-1.17*10-3 1.365 ? 2.54*10-2 8.91*10-2 1.63*10-1 
-1.11*10-3 1.335 Lactate 5.46*10-1 6.83*10-1 7.83*10-1 
-1.09*10-3 2.255 ? 4.02*10-2 7.98*10-2 3.73*10-1 
-1.09*10-3 5.335 ? 3.03*10-2 4.47*10-2 7.22*10-1 
-1.08*10-3 0.905 
Isoleucine, 
leucine, 
valine 
7.34*10-2 3.70*10-1 1.51*10-1 
-1.03*10-3 1.585 ? 3.09*10-2 1.10*10-1 1.46*10-1 
-9.51*10-4 5.305 ? 3.04*10-2 4.15*10-2 5.90*10-1 
 
* Confirmed by 2D ICA 
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Table 18. Investigation of Non-Alcoholic Steatohepatitis: Loadings of IC 2 of Hydrophilic 
Liver Extracts. Adapted from (Klein et al. 2011b). 
 
Factor 
1H 
Frequency 
[ppm] 
Compound 
P-Value 
Control / 
NAFLD 
P-Value 
Control / NASH 
P-Value 
NAFLD / 
NASH 
1.04*10-2 3.265 Betaine* 2.04*10-3 7.25*10-4 4.32*10-3 
-9.09*10-3 3.425 Taurine* 2.71*10-3 7.04*10-1 2.92*10-3 
5.54*10-3 1.285 ? 3.45*10-2 5.07*10-2 5.58*10-1 
-5.49*10-3 3.415 Taurine* 2.47*10-3 7.08*10-1 2.82*10-3 
4.34*10-3 1.305 ? 7.86*10-2 2.06*10-1 2.69*10-1 
4.20*10-3 1.315 ? 5.85*10-2 1.93*10-1 2.09*10-1 
-4.10*10-3 3.435 Taurine* 2.83*10-3 7.85*10-1 3.67*10-3 
-3.98*10-3 3.255 Betaine* 1.70*10-3 9.98*10-1 5.45*10-3 
3.98*10-3 1.295 ? 3.53*10-1 5.89*10-1 5.05*10-1 
3.59*10-3 3.905 Betaine* 2.11*10-2 2.58*10-3 4.44*10-3 
-3.28*10-3 3.245 Betaine* 5.42*10-3 3.39*10-1 2.05*10-3 
-3.10*10-3 3.275 Taurine* 1.31*10-2 3.52*10-1 1.93*10-2 
2.16*10-3 1.325 Lactate 3.34*10-1 4.68*10-1 6.40*10-1 
2.00*10-3 0.895 ? 3.42*10-2 1.66*10-1 1.18*10-1 
1.88*10-3 1.275 ? 4.81*10-2 4.21*10-2 9.91*10-1 
-1.66*10-3 3.405 Glucose* 2.98*10-2 8.82*10-2 5.49*10-3 
1.54*10-3 1.345 Lactate 5.94*10-2 2.26*10-1 1.72*10-1 
1.45*10-3 0.885 ? 2.79*10-2 1.69*10-1 3.79*10-2 
-1.45*10-3 3.835 Glucose* 1.87*10-2 4.04*10-1 7.02*10-3 
1.42*10-3 1.335 Lactate 5.46*10-1 6.83*10-1 7.83*10-1 
-1.40*10-3 3.475 Glucose* 2.92*10-2 7.29*10-2 5.64*10-3 
-1.37*10-3 3.495 Glucose* 3.46*10-2 5.48*10-2 5.92*10-3 
-1.36*10-3 3.845 Glucose* 1.65*10-2 6.25*10-1 9.10*10-3 
-1.36*10-3 3.715 ? 2.12*10-2 1.66*10-1 6.14*10-3 
1.34*10-3 1.355 ? 3.66*10-2 1.50*10-1 1.37*10-1 
 
* Confirmed by 2D ICA 
 
 
Table 19. Investigation of Non-Alcoholic Steatohepatitis: Compounds in Hydrophilic 
Liver Extracts. Adapted from (Klein et al. 2011b). 
 
Compound Control Steatosis NASH 
ANOVA 
P-Value 
P-Value 
Control / 
Steatosis 
P-Value 
Control / 
NASH 
P-Value 
Steatosis / 
NASH 
Betaine ND ND 8.5 ± 2.9 (4) ND ND ND ND 
Glucose 13.7 ± 3.8 (5) 14.4 ± 3.7 (6) 10.3 ± 2.7 (3) 2.9*10-1 7.7*10-1 1.9*10-1 1.1*10-1 
Lactate 5.8 ± 2.2 (6) 6.12 ± 0.86 (6) 4.86 ± 0.71 (6) 3.0*10-1 7.5*10-1 3.5*10-1 2.1*10-2 
Taurine 11.8 ± 2.5 (6) 21.7 ± 2.5 (6) 10.3 ± 5.2 (5) 1.4*10-4 ** 4.5*10-5 ** 6.0*10-1 5.2*10-3 * 
 
Given are mean concentrations and standard deviations in nanomole per milligram. The number of values n is 
given in parentheses. For the t-statistics only p-values are marked as significant where the corresponding 
ANOVA p-values are significant. 
* p<0.05, ** p<0.001. 
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Table 20. Investigation of Non-Alcoholic Steatohepatitis: Loadings of IC 5 for Urine. 
Adapted from (Klein et al. 2011b). 
 
Factor 
1H 
Frequency 
[ppm] 
Compound 
P-Value 
Control / 
NAFLD 
P-Value 
Control / 
NASH 
P-Value 
NAFLD / 
NASH 
5.60*10-3 3.435 Taurine* 1.25*10-2 3.39*10-4 9.94*10-3 
5.25*10-3 3.265 TMAO* 6.43*10-3 2.59*10-3 3.11*10-2 
4.05*10-3 3.275 TMAO* 8.76*10-3 2.87*10-3 3.14*10-2 
3.34*10-3 3.425 Taurine* 9.51*10-4 4.03*10-5 1.16*10-2 
2.61*10-3 3.445 Taurine* 1.77*10-2 8.25*10-4 1.24*10-2 
2.41*10-3 3.255 Taurine* 2.90*10-3 4.84*10-5 1.90*10-2 
2.35*10-3 2.895 TMA* 9.02*10-3 2.29*10-2 1.10*10-1 
-1.01*10-3 4.055 Creatinine* 6.62*10-2 3.32*10-2 4.15*10-1 
9.08*10-4 3.935 Phosphocreatine* 1.29*10-1 2.20*10-1 3.11*10-2 
-9.07*10-4 3.045 Creatinine* 1.81*10-1 1.65*10-3 3.21*10-2 
-7.78*10-4 3.735 Ascorbic acid* 1.36*10-2 9.33*10-8 7.20*10-1 
-7.31*10-4 3.685 ? 8.73*10-1 5.25*10-4 3.26*10-3 
-7.19*10-4 4.515 Ascorbic acid* 4.32*10-3 6.16*10-6 7.38*10-1 
-7.07*10-4 3.745 Ascorbic acid* 9.03*10-3 2.67*10-5 4.79*10-1 
7.03*10-4 3.035 Phosphocreatine* 2.03*10-1 1.91*10-1 5.91*10-2 
7.03*10-4 2.695 Citrate* 3.92*10-2 1.33*10-2 4.12*10-1 
-6.98*10-4 4.025 Ascorbic acid* 1.06*10-2 5.84*10-6 9.35*10-1 
-6.96*10-4 1.245 ? 3.56*10-5 7.38*10-5 4.06*10-2 
5.95*10-4 3.145 Ethanolamine 2.66*10-1 3.49*10-1 4.88*10-1 
-5.89*10-4 3.675 ? 6.74*10-1 6.89*10-4 2.07*10-2 
-5.85*10-4 1.235 ? 3.96*10-5 1.68*10-4 2.51*10-2 
5.62*10-4 2.555 Citrate* 2.67*10-2 5.23*10-2 3.01*10-1 
-5.60*10-4 3.775 Ascorbic acid* 1.61*10-4 1.61*10-4 4.70*10-2 
-5.56*10-4 7.365 Phenylalanine* 6.78*10-1 4.71*10-3 1.79*10-2 
-5.25*10-4 3.755 Ascorbic acid* 7.02*10-3 1.76*10-2 2.31*10-1 
 
* Confirmed by 2D ICA 
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Table 21. Investigation of Non-Alcoholic Steatohepatitis: Loadings of IC 4 for Urine. 
Adapted from (Klein et al. 2011b). 
 
Factor 
1H 
Frequency 
[ppm] 
Compound 
P-Value 
Control / 
NAFLD 
P-Value 
Control / 
NASH 
P-Value 
NAFLD / 
NASH 
-8.88*10-3 2.895 TMA* 9.02*10-3 2.29*10-2 1.10*10-1 
-4.04*10-3 2.885 TMA* 1.95*10-1 2.13*10-1 1.57*10-2 
-4.04*10-3 3.265 TMAO* 6.43*10-3 2.59*10-3 3.11*10-2 
1.81*10-3 3.755 Ascorbic acid* 7.02*10-3 1.76*10-2 2.31*10-1 
-1.67*10-3 3.415 Taurine* 3.01*10-2 3.12*10-2 9.53*10-1 
1.61*10-3 3.045 Creatinine* 1.81*10-1 1.65*10-3 3.21*10-2 
-1.52*10-3 2.575 Citrate* 1.49*10-2 2.65*10-2 6.09*10-2 
-1.44*10-3 3.425 Taurine* 9.51*10-4 4.03*10-5 1.16*10-2 
-1.44*10-3 2.685 Citrate* 4.39*10-2 1.09*10-1 1.46*10-2 
-1.43*10-3 3.275 Taurine* 8.76*10-3 2.87*10-3 3.14*10-2 
1.29*10-3 3.765 Ascorbic acid* 5.72*10-3 2.21*10-2 8.07*10-2 
-1.19*10-3 2.715 Citrate* 1.21*10-1 1.40*10-1 8.09*10-1 
-1.13*10-3 3.435 Taurine* 1.25*10-2 3.39*10-4 9.94*10-3 
-9.99*10-4 3.255 Taurine* 2.90*10-3 4.84*10-5 1.90*10-2 
9.69*10-4 1.245 ? 3.56*10-5 7.38*10-5 4.06*10-2 
-8.89*10-4 2.545 Citrate* 5.08*10-2 6.81*10-2 1.02*10-1 
-8.59*10-4 3.445 Taurine* 1.77*10-2 8.25*10-4 1.24*10-2 
8.51*10-4 1.235 ? 3.96*10-5 1.68*10-4 2.51*10-2 
7.70*10-4 0.925 Leucine* 4.33*10-2 8.07*10-1 3.23*10-3 
7.42*10-4 3.775 Ascorbic acid* 1.61*10-4 1.61*10-4 4.70*10-2 
6.85*10-4 2.295 ? 6.32*10-2 5.85*10-1 2.07*10-4 
6.67*10-4 4.065 Creatinine* 2.84*10-1 1.82*10-2 2.26*10-1 
6.51*10-4 1.875 ? 2.53*10-2 9.66*10-1 1.91*10-3 
6.50*10-4 2.305 ? 2.98*10-2 1.59*10-1 4.50*10-3 
-6.41*10-4 2.725 ? 7.66*10-3 1.69*10-1 2.52*10-2 
 
* Confirmed by 2D ICA 
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Table 22. Investigation of Non-Alcoholic Steatohepatitis: Compounds in Urine. Adapted 
from (Klein et al. 2011b). 
 
Compound Control Steatosis NASH 
ANOVA 
P-Value 
P-Value 
Control / 
Steatosis 
P-Value 
Control / 
NASH 
P-Value 
Steatosis / 
NASH 
Ascorbic acid 0.93 ± 0.33 (9) 1.38 ± 0.26 (4) 1.09 ± 0.22 (5) 6.6*10-2 3.3*10-2 3.1*10-1 1.3*10-1 
Citrate 2.5 ± 1.6 (9) 0.173 ± 0.082 (4) 
0.278 ± 0.066 
(5) 
1.4*10-3 * 2.5*10-3 * 3.3*10-3 * 8.5*10-2 
Creatinine¹ 5.5 ± 2.0 (9) 10.9 ± 1.5 (4) 11.2 ± 0.51 (5) 
1.4*10-5 
** 
6.0*10-4 ** 1.6*10-5 ** 7.9*10-1 
Leucine 0.46 ± 0.11 (9) 0.271 ± 0.062 (4) 
0.235 ± 0.041 
(5) 
4.7*10-4 
** 
1.6*10-3 * 1.8*10-4 ** 3.1*10-1 
Phenylalanine 
0.725 ± 0.095 
(9) 
0.51 ± 0.12 (4) 0.75 ± 0.22 (5) 4.4*10-2 * 2.7*10-2 * 8.5*10-1 8.0*10-2 
Phosphocreatine 2.98 ± 0.82 (8) 0.97 ± 0.67 (4) 1.91 ± 0.37 (5) 2.6*10-3 * 2.3*10-3 * 8.9*10-3 * 5.9*10-2 
Taurine 6.8 ± 2.9 (9) 1.52 ± 0.48 (4) 
0.684 ± 0.070 
(2) 
4.4*10-4 
** 
5.5*10-4 ** 2.4*10-4 ** 3.7*10-2 * 
TMA 1.3 ± 1.5 (9) 0.114 ± 0.060 (4) 
0.166 ± 0.039 
(5) 
1.0*10-1 4.1*10-2 4.9*10-2 2.0*10-1 
TMAO 1.2 ± 1.7 (9) 0.051 ± 0.021 (4) 
0.070 ± 0.013 
(5) 
3.1*10-1 7.5*10-2 8.0*10-2 1.7*10-1 
 
Given are mean concentrations and standard deviations of molar ratios relative to the creatinine content. 
¹Creatinine concentrations are given in mmol/L. The number of values n is given in parentheses. For the t-
statistics only p-values are marked as significant where the corresponding ANOVA p-values are significant. 
* p<0.05, ** p<0.001 
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Appendix II: Attached Files 
 
In the printed version of this thesis, you will find a CD containing the attached files on the 
last page of the thesis. 
 
In the electronic .pdf version of this thesis, you will find the attached files on this page. 
Depending on your .pdf viewer, the files should show up as pin icons in the left upper 
corner of this page. To save the files to your computer, right-click on the pin icon and 
select the corresponding menu entry. The files come as zipped folders, in order to unzip 
the folders, the file extension .removethis has to be removed. For example, the file 
QUANTIFY.zip.removethis has to be renamed to QUANTIFY.zip. After this, the files may be 
unzipped. This procedure is necessary due to safety settings of the Adobe Reader.  
 
  
 
List of attached files: 
 
 - R code 
 - Python code 
 - QUANTIFY 1.0 
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1 License Agreement 
 
This program comes with no warranty, you use it at your own risk. You may use 
and distribute this program freely, as long as credit is given to the original author. 
 
All product, brand and company names in this document may be trademarks of 
their respective owners. 
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2 Introduction 
 
QUANTIFY is an aid for quantifying small molecules like amino acids in 1D and 2D 
NMR spectra of biologic fluid samples. Biofluids such as urine, blood plasma or 
milk and other biologic fluid samples such as liver extracts are very complex in 
their composition, and compounds may be present at high concentrations in some 
samples, while they may not be visible in other samples. This makes exact 
quantification of selected compounds a hard task, as each peak of the compound 
may or may not be overlapped with other compounds. This is not only true for 1D 
spectra, but also for 2D spectra such as 1H-13C HSQC spectra.  
 
QUANTIFY employs several algorithms to successfully detect and exclude such 
outliers. This leads to reliably accurate and precise quantification results.  
 
QUANTIFY takes peak integrals derived from NMR spectra as input and returns 
absolute concentration values of the observed compounds as output. 
 
 
 
The features of QUANTIFY include: 
 
• Multiplication of each integral with an individual calibration factor 
• Checking for obligatory peaks before quantification 
• Automatic outlier removal 
• Reliability checking for compounds where only few peaks are visible in the 
spectrum  
• Checking lower limits of quantification 
• Automatic normalization to single compounds, e.g. creatinine 
• Automatic correction for different dilutions 
• Calculation of means and technical errors for replicate measurements 
• Logging of the used parameters and configuration to allow reproducible 
results 
  
QUANTIFY 1.0  
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3 Installation 
 
3.1 System Requirements 
 
Quantify.exe may be run using the following operating systems: 
 
• Windows XP (Service Pack 1 or 2) 
• Windows 2000 (Service Pack 3 or 4) 
• Windows Server 2003 (Service Pack 1 or 2) 
• Windows Vista 
 
On other operating systems such as Linux or Mac OS X, you may run the source 
code file quantify.m directly. For this, it is required to have installed the 
mathematical software Matlab (The Mathworks, Natick, MA, USA). Copy the files 
quantify.m and quantify.fig from the folder QUANTIFY to your Matlab working 
directory, start Matlab and type quantify to start QUANTIFY. QUANTIFY is 
backward compatible at least until Matlab version 7.1.0.246 (R14) Service Pack 3. 
 
 
 
3.2 Installation 
 
Open the file quantify.zip with unzipping software (e.g. Winzip) and extract the 
files. 
 
Run the file MCRInstallerR2007b.exe. This installs the required Matlab run-time 
routines and should be available from the same source as the file quantify.zip, for 
example from the software section on http://genomics.uni-regensburg.de/. 
 
To start QUANTIFY, run the unzipped file quantify.exe. 
  
QUANTIFY 1.0  
 
4 
4 Manual 
 
4.1 User Files 
 
4.1.1 Required Files 
 
Peak Integral File 
A file containing the peak integral values from one spectrum or from several 
spectra is required to use QUANTIFY. This file may be a Microsoft Excel .xls file, a 
tab stop separated .txt file or an AMIX Analytic Profiler (Bruker BioSpin, 
Rheinstetten, Germany) .txt file. 
 
The data have to be present as follows in the file: 
 
 
title: Spectrum 1  
  
Compound A  
Peak 1 Integral value* 
Peak 2 Integral value* 
Peak 3 Integral value* 
  
Compound B  
Peak 1 Integral value* 
Peak 2 Integral value* 
  
title: Spectrum 2  
  
Compound A  
Peak 1 Integral value* 
Peak 2 Integral value* 
... ... 
 
 
* The integral values should have been divided by the number of nuclei 
contributing to the peak. 
 
Each spectrum title has to start with ‘title: ‘. Please make sure to include a blank 
line after each spectrum title and after the last peak of each compound. For each 
spectrum, the number and order of compounds has to be the same. Peaks that 
shall not be used for quantification may be included in the list, in these cases the 
integral values has to be replaced by a string, for example not used. For example 
files see the folder QUANTIFY\Examples. 
 
The .txt files have to contain exactly two columns that are separated by a 
tabulator. 
 
For using AMIX .txt files please see Chapter 6 for further information. 
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In case you want to use individual dilution factors (see Section 4.2 for details), the 
individual dilution factor has to be written at the end of the spectrum title and has 
to start with df. All concentrations of this spectrum will then be multiplied by this 
factor. The individual dilution factor has to consist of exactly four digits, including 
the decimal point (.). 
 
Example: You have diluted sample 1 by factor 4, sample 2 by factor 13.7 and 
sample 3 by factor 200. The peak integral file then has to look as follows: 
 
 
title: Spectrum 1 df4.00  
... ... 
title: Spectrum 2 df13.7  
... ... 
title: Spectrum 3 df200.  
... ... 
 
The dot (.) after 200 in sample 3 has to be inserted to achieve a length of four 
digits. 
 
In case you measure single samples repeatedly, QUANTIFY can calculate means 
and technical errors (see Section 4.2). Replicate spectra have to be titled *a, *b, *c 
and so on, where * may be any string in the peak integral file, e.g. sample1_a, 
sample1_b, sample1_c. 
 
 
 
4.1.2 Optional Files 
 
Optionally, a file containing peak information and a file containing lower limits of 
quantification may be used. 
 
Peak Information File 
This file contains additional information about the peaks of a compound to enable 
accurate quantification results. This file may be either a Microsoft Excel .xls file or 
a tab stop separated .txt file. The data have to be present in the file as in the 
following example: 
 
 
 
Obligatory 
peak 
Number 
of nuclei 
Calibration 
factor 
Compound A    
Peak 1 0 3 1.39 
Peak 2 1 1 1.12 
Peak 3 0 1 -1 
Compound B    
Peak 1 0 1 1.23 
Peak 2 0 2 1.07 
... ... ... ... 
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The column Obligatory peak can be used to mark single peaks as obligatory. This 
may be useful for molecules with both high-intensity and low-intensity peaks, 
where one strong peak that are often overlapped by other signals. By marking a 
weaker peak of the molecule as obligatory, this compound will only be quantified if 
the weaker peak is present. This is only meaningful if one of the weaker peaks is 
seldom overlapped. This will reduce the number of incorrect quantification results. 
Possible values are 0 and 1. 0 means that the peak is not required to be present 
and 1 means that the peak must be present to quantify the compound. Usually, 0 
should be chosen for all peaks. 
 
In the column Number of nuclei, the number of nuclei contributing to the peak has 
to be entered. This number is used for a reliability check in case less peaks than 
the peak threshold are available for one compound. 
 
In the column Calibration factor, calibration factors for each peak have to be 
entered. Negative values mean that the peak is not used for quantification. The 
calibration factors can be determined experimentally using a dilution series of the 
pure compound. The measured peak integrals and concentration values have to 
be fitted with a regression line going through the point of origin. The slope of the 
regression line is the calibration factor. 
 
The .txt file has to contain exactly four columns that are separated by a tab stop. 
 
 
Lower Limits of Quantification File 
In this file, the lower limits of quantification (LLOQ’s) are stored for automated 
checking of the quantification results. This file may be either a Microsoft Excel .xls 
file or a tab stop separated .txt file. The LLOQ’s may be any value and have to be 
present as follows in the file: 
 
 
Compound 
LLOQ 
[mmol/L] 
Compound A 0.15 
Compound B 0.30 
... ... 
 
 
The tab stop separated .txt file has to contain exactly two columns that are 
separated by one tab stop. 
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4.2 Step-by-Step Guide 
 
In this section, the usage of QUANTIFY will be described step by step. For each 
step an example is given (painted in blue). The main window of QUANTIFY 
(Figure 4.1) is divided into six panels that are intended to be filled out in their 
numerical order.  
 
 
 
 
Figure 4.1. The main window with default parameters 
 
For all fields of the main window, a help text is available that will pop up when you 
hold the mouse curser over the field. When starting QUANTIFY, default 
parameters will be filled out in most fields. In the following paragraphs, all items of 
QUANTIFY are described. 
 
 
Menu Bar 
 
File 
 
• Load default parameters will load the default parameters. 
• Load custom parameters will load previously saved parameters. 
• Save custom parameters will save the current parameters except for the 
peak integral file. 
• Exit will close QUANTIFY. 
 
Help 
 
• Manual will open the manual (this document). 
• About QUANTIFY will show the program version. 
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Panel 1: Peak Integrals 
As a first step, you have to choose a file where the integral values are stored. For 
information on the data format of the used files please see Section 4.1.1. Select 
Browse and choose the peak integral file. The file may be either an Excel .xls file, 
a tab stop separated .txt file or an AMIX Analytic Profiler .txt file. The file name 
including the path of the chosen file is shown in the field File name. The file type of 
the chosen file is shown in the field File type. 
 
Please note that Microsoft Excel is required to read Excel files. If Excel is not 
installed on your computer, please use .txt files instead. 
 
For Microsoft Excel files, you will have to enter the name of the spreadsheet 
containing the data (default is Integrals) in the field Sheet and the range where the 
values are stored (default is A2:B5000) in the field Range. Make sure not to 
include headlines in the given range. 
 
QUANTIFY can also read data from Bruker AMIX Analytic Profiler mprofile.txt 
output files. For details on the parameters to use in AMIX Analytic Profiler see 
Chapter 6. 
 
Example: Click Browse. A file selection window will pop up. Change the file type 
to Tab stop separated .txt and choose the file urine_control.txt in the folder 
QUANTIFY\Examples\Peak integral files. 
 
 
 
Panel 2: Peak Information 
In this panel you have to choose if you want to use additional peak information. 
This information is necessary for individual peak calibration and additional peak 
reliability checks. To use this additional information, check the Enable check mark. 
 
In this case, you will have to specify a file where the information is stored by 
selecting Browse. For the data format of the used file please see Section 4.1.2. 
The file may be either an Excel .xls file or a tab stop separated .txt file. The file 
name including the path of the chosen file is shown in the field File name. The file 
type of the chosen file is shown in the field File type. 
 
Please note that Microsoft Excel is required to read Excel files. If Excel is not 
installed on your computer, please use .txt files instead. 
 
When using Excel files, you will have to specify the spreadsheet name and the 
range where the values are stored in the fields Sheet and Range. Please make 
sure not to include any headlines in the area defined in the Range field. 
 
Example: Click on the check box Enable. Click Browse. A file selection window 
will pop up. Change the file type to Tab stop separated .txt and choose the file 
urine_peakinfo.txt in the folder QUANTIFY\Examples\Peak information and LLOQ 
files. 
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Panel 3: Lower Limits of Quantification 
Here you have to choose if you want to check if the calculated concentrations are 
above individually defined LLOQ’s. Check the Enable check box to activate this 
function. 
 
You will have to specify a file where the LLOQ’s are stored by selecting Browse. 
For the data format of the used files please see Section 4.1.2. The file may be 
either an Excel .xls file or a tab stop separated .txt file. The file name including the 
path of the chosen file is shown in the field File name. The file type of the chosen 
file is shown in the field File type. 
 
Please note that Microsoft Excel is required to read Excel files. If Excel is not 
installed on your computer, please use .txt files instead. 
 
When using Excel files, you will have to specify the spreadsheet name and the 
range where the values are stored in the fields Sheet and Range. Please make 
sure not to include any headlines in the area defined in the Range field. 
 
Example: Click on the check box Enable. Click Browse. A file selection window 
will pop up. Change the file type to Tab stop separated .txt and choose the file 
urine_LLOQs.txt in the folder QUANTIFY\Examples\Peak information and LLOQ 
files. 
 
 
 
Panel 4: Parameters 
These parameters control the outlier detection and reliability checking of the 
results, among others. The parameters are pre-filled with defaults that should yield 
good results. Anyway, you may change these parameters in order to optimize your 
results. 
 
Correction Factor 
Each concentration is multiplied by this factor before checking if the concentration 
is above the LLOQ. The value has to be positive (>0), default value is 1 (no 
correction). 
 
This factor is useful for example if your reference substance concentration is 
different in some of your spectrum sets, for example due to a change of supplier. 
The difference to the dilution factor described below is that the correction factor is 
applied before checking for the LLOQ’s, as a change in the reference substance 
concentration will result in false absolute concentrations in the first hand. 
 
Dilution Factor 
Each concentration is multiplied by this factor after checking if the concentration is 
above the LLOQ. The factor has to be positive (>0), default value is 1 (no 
correction).  
 
This may be used if all samples are diluted in the same way. The difference to the 
correction factor named above is that diluting the sample will not result in false 
absolute concentrations. Therefore, the dilution factor is applied after checking the 
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LLOQ’s. If each sample is diluted in a different way, you may use the individual 
Dilution Correction in Panel 5. 
 
Outlier Threshold 
This is a threshold for outlier detection. For compounds having more than one 
peak, the median of all peaks is calculated. Values that differ more than the outlier 
threshold from the median relatively are excluded as outliers. The outlier threshold 
has to be positive (>0), default value is 0.4. 
 
Peak Threshold 
This is a threshold for controlling the reliability of a result by checking how many of 
the peaks available for a molecule are present in a spectrum. The ratio of found 
peaks to total peaks has to exceed the peak threshold. The peak threshold has to 
be in the range of 0 to 1, default is 0.66. 
 
Example: Leave all parameters on their default settings. 
 
 
 
Panel 5: Options 
This panel controls additional functions of QUANTIFY. 
 
Scale To 
If this check box is enabled, all integral values of one spectrum will be divided by 
the value of the first valid peak of the reference substance specified in the 
corresponding text field. In case your peak integrals are already scaled to the 
reference substance signal, as in AMIX files, this check box does not need to be 
enabled. 
 
Reference Concentration 
Here you may enter the concentration of the references substance specified in the 
Scale to field. The Reference Concentration has to be positive (>0). It is important 
to use the concentration corrected to your sample amount. For example, if you add 
400 µL of sample to 50 µL of D2O containing 10 mmol/L tmsp, you have to enter 
1.25 as reference concentration, as 10 mmol/L * (50 µL / 400 µL) = 1.25 mmol/L. 
 
Normalize To 
If this check box is enabled, all concentrations will be divided by the concentration 
of the compound entered in the corresponding text field. For urine, this is usually 
done with the creatinine concentration, but you may choose any compound here. 
 
Dilution Correction 
If this check box is activated, individual Dilution Correction will be performed on all 
spectra. This may be used in case different sample amounts were used for the 
different spectra, or in case of tissue extracts, where different tissue amounts were 
employed. The individual dilution factor for each spectrum has to be provided in 
the peak integral file as part of the spectrum title. For details see Section 4.1.1. 
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Calculate Means for Replicates 
If this check box is activated, QUANTIFY will search for replicate spectra of the 
same sample, indicated by the spectrum title. For details see Section 4.1.1. 
 
Means and technical errors (TE’s) will be calculated in case replicates are found. 
For TE calculation only the first two replicate spectra are used. 
 
Example: Enable the check box Normalize to and enter creatinine in the 
corresponding text field. Disable the check boxes Scale to, Dilution correction and 
Calculate means for replicates. 
 
 
 
Panel 6: Perform Quantification 
After filling in all fields, the main window of QUANTIFY will look like Figure 4.2. 
 
 
 
 
 
 
 Figure 4.2. The main window of QUANTIFY after filling in all fields according to the example files. 
 
 
When the button Quantify! is selected, you are requested to choose an output file. 
This may either be a tab stop separated .txt file or a Microsoft Excel file. Please 
note that Microsoft Excel is required to write Excel files. If Excel is not installed on 
your computer, please use .txt output files instead. For Excel files, it will 
automatically be determined which Excel version is installed on the computer and 
the matching file format and file extension (.xls or .xlsx) will be chosen. 
 
Example: Click Quantify! A save as window will pop up. Select Save. 
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The status of the calculations is shown as a progress bar during the quantification. 
After successful quantification, the result file will be automatically opened. 
 
An example for an Excel result file is shown in Figure 4.3. Additional example 
result files can be found in the folder QUANTIFY\Examples. 
 
The compound concentration values will be stored in the spreadsheet Results. For 
each compound the mean, the standard deviation and the minimal and maximal 
values over all spectra will be shown at the lower end of the table. Additionally, the 
number of spectra containing this compound is added. 
 
All used parameters, file and folder names, additional information such as date 
and version numbers, user data, warnings and error messages will be stored in 
the spreadsheet Configuration. All factors will be extended with an underscore (_) 
to circumvent Excel to convert the variable type in an unwanted way. 
 
 
 
 
 
 
Figure 4.3. An Excel result file. The different spreadsheets of the file can be seen on the lower 
margin of the figure. 
 
 
Information about the number of used peaks for each compound of each spectrum 
will get stored in the spreadsheet Used peaks. For each metabolite, two entries 
are given, the left one containing the concentration from the Results spreadsheet, 
the right one indicating the ratio of used peaks to available peaks for this 
compound. For example, (6/6) would mean that all six peaks were used for the 
calculation of the mean value, indicating a low variance in peak intensities, as 
indicated by the lack of excluded outliers. This implies a high reliability of the 
result. In contrast, a value of (1/6) would mean that only one out of six values was 
used, indicating either a low number of visible peaks or a high variance that led to 
outlier exclusions. In such cases, a manual checking of the other peaks, for 
example in the Outliers spreadsheet, might be necessary. 
 
In case Dilution Correction was chosen in Panel 5, the dilution corrected 
concentrations are stored in the spreadsheet Dilution corrected in the output file. 
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In case Calculate Means for Replicates was chosen in Panel 5, means and TE’s 
will be written to the spreadsheet Mean in the output file. 
 
In case Normalize to was chosen in Panel 5, a spreadsheet named Normalized to 
compound name is created, e.g. Normalized to creatinine. This spreadsheet 
contains the normalized values. 
 
All original values (before checking for LLOQ’s and multiplying by correction and 
dilution factors) will be stored in the spreadsheet Original values. 
 
If you choose .txt files as output, up to eight .txt files will be generated containing 
these data. The files will have a fixed number of columns that are separated by a 
tabulator. The file names are derived from the entered file name by adding 
extensions, for example filename_results.txt. 
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4.3 Quick Start 
 
QUANTIFY is pre-configured to allow a quick start. In this mode, most 
implemented features are disabled. Still, this mode may allow a quick view on your 
data. Please note that quantification results from this mode are only semi-
quantitative. For accurate quantification, please refer to the step-by-step guide in 
Section 4.2. The main feature active in this mode is automatic outlier removal 
based on deviations from the median. 
 
For quantification, you need a file that contains the NMR peak integral values 
obtained for the different compounds you are interested in. For details on the 
format of the file see Section 4.1.1. 
 
Run the file quantify.exe. The main window will show up (Figure 4.4). 
 
 
 
 
Figure 4.4. The main window of QUANTIFY in quick start mode with default parameters 
 
 
Panel 1: Peak Integrals 
Select Browse and choose the file containing the peak integral values. 
 
 
Panels 2 - 4 
You do not need to change the pre-filled default values in these panels. 
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Panel 5: Options 
Activate the Scale to check box and enter the name of your reference substance. 
Enter the concentration of your reference substance in the field Reference 
concentration. 
 
 
Panel 6: Perform Quantification 
Select the button Quantify!. This will open a dialog where you can choose the 
output file name. Afterward, quantification is performed and the result file opened. 
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5 Troubleshooting 
 
• Starting QUANTIFY Fails 
 If QUANTIFY fails to open, please install the file MCRInstallerR2007b.exe. 
This file is available from the same source as quantify.zip, for example from 
the software section on http://genomics.uni-regensburg.de/site/institute. 
 
 
• Error: Subscripted assignment dimension mismatch 
• Error: Attempted to access ...; index out of bounds 
These error messages indicate problems while reading a peak integral 
value file. Make sure that for each spectrum in the peak integral file the 
number of compounds and corresponding peaks, and the order of 
compounds is identical. 
 
 
• Error: Data format not supported. No AMIX file? 
If you encounter this error message when reading peak integral values from 
a .txt file, most probably QUANTIFY tried to open a tab stop separated .txt 
file as an AMIX .txt file. In case you use AMIX .txt files, something seems to 
be wrong with the file format. Make sure you follow the steps in Chapter 6 
when creating AMIX .txt files. 
 
In case you use a tab stop separated .txt file, make sure you choose the 
matching entry from the file type menu when selecting the file using Browse 
in Panel 1 (see Figure 5.1).  
 
 
 
 
 
Figure 5.1. Choosing the integral value file type 
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6 Creating Peak Integrals Using AMIX 
 
In order to create peak integral files using AMIX Analytic Profiler (Bruker BioSpin, 
Rheinstetten, Germany), you should follow the steps described below to ensure 
that the files are readable for QUANTIFY. The procedure is described for AMIX 
version 3.9.3 and may differ for other versions. Parameters not explicitly named in 
this section should not affect the readability of the files and may therefore be 
chosen according to your preferences. 
 
You have to activate both identification and quantification in AMIX in order to get 
usable files. 
 
 
6.1 AMIX Peak Integrals from 1D Spectra 
 
To quantify compounds from 1D spectra, the .txt file may not contain any 2D 
HSQC data. To achieve this, you have to deactivate the buttons for 2D/HSQC 
identification and quantification. 
 
 
 
 
 
 
Figure 6.1. Perform identification and 1D have to be enabled 
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Figure 6.2. Perform 1D quantification has to be enabled 
 
 
 
 
Figure 6.3. Detailed and Report all results have to be enabled 
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6.2 AMIX Peak Integrals from 2D HSQC Spectra 
 
When quantifying from 2D HSQC spectra, 1D spectra have to be quantified as 
well, although this data will not be used later on. QUANTIFY will look for 2D HSQC 
data in the file and use these for quantification. 
 
 
 
 
 
 
Figure 6.4. Perform identification has to be enabled both for 1D and HSQC 
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Figure 6.5. Both Perform 1D quantification and Perform 2D quantification have to be enabled 
 
 
 
 
 
Figure 6.6. Detailed and Report all results have to be enabled 
